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Chapter 1: INTRODUCTION 
 
1.1 HISTORICAL IMPACT OF INFLUENZA VIRUS  
The Influenza A Virus (IAV) has caused several pandemics during the 20th century, and 
continues to cause annual epidemics and pandemics. Both pandemics and epidemics represent 
a significant economic burden owing to costs of prevention, treatment, absenteeism, and excess 
hospitalizations. Besides infection in humans, the IAV is also a pathogen in several animals, 
including pigs and birds. Wild aquatic birds like ducks, geese, terns or gulls (Anseriformes and 
Charadriiformes) are considered to be natural reservoirs of IAV. The transmission of IAV to 
poultry (e.g. Galliformes) results in two pathotypes: low pathogenicity IAV and Highly 
Pathogenic Influenza A Virus (HPAIV). To date, the HPAIV has been caused only by IAV 
viruses of the H5 and H7 subtypes, resulting in a severe and systemic infection, with close to 
100% of lethality in poultry. The first avian HPAIV fatal infections in humans were reported in 
Hong Kong in 1997 (Claas et al., 1998; Subbarao et al., 1998), where culling was an efficient 
strategy to control this outbreak. In 2003, the reports of HPAIV human cases resulted in an 
worldwide alert (60% of mortality rate) but fortunately, human-human transmission did not 
occurred or was extremely rare (Chotpitayasunondh et al., 2005). In 2009, outbreaks of 
respiratory illness caused by IAV were reported in Mexico (Fraser et al., 2009). Later the IAV 
identified was a novel swine-origin H1N1, followed by outbreaks globally and leading to an 
official declaration by the World Health Organization on June of 2009 of a pandemic IAV. 
Nevertheless, most of patients presented a mild infection and do not required hospitalization.  
These data and the fact that the pandemic H1N1 was a triple reassortant, from swine North 
American H3N2 and H1N2 with Eurasian avian-like H1N1 swine IAV (Garten et al., 2009), 
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highlighted the importance of zoonotic diseases preparedness. The pandemic swine H1N1 
became the first pandemic of this century and caused global alert, since presented a high 
transmissibility in humans, raising concern about further pathogenicity (Smith et al., 2009; 
Zimmer and Burke, 2009). Nevertheless, the pandemic H1N1 low lethality seems to be 
underestimated. From spring 2009 to summer 2010, the pandemic H1N1 death toll was 
estimated in 18 500, but recent reports contrast significantly, with an estimated 10 – 15 fold 
higher death toll, according to a recent report (WHO, Pandemic (H1N1) 2009–update 112, 
www.who.int/csr/don/2010_08_06/en/index.html), (Dawood et al., 2012), highlighting the lack of 
proper surveillance. 
The “Spanish Flu” pandemic during 1918-1919 caused the highest recorded death toll by any 
infectious disease in the history, with a conservative estimate of 50 million deaths (Johnson and 
Mueller, 2002). In the 21st century, the work by Taubenberger resulted in the sequence of the 
genome of the “Spanish Flu” virus that caused the 1918 pandemic (H1N1 A/Brevig 
Mission/1/1918) (Taubenberger et al., 1997; Taubenberger et al., 2005). Later it was revealed 
that 1918 pandemic IAV was closer to mammalian than to avian IAV (Taubenberger et al., 
2007). These studies resulted into the so called “resurrection” of the 1918 pandemic virus, one 
of the deathliest infectious agents in history, provoking public and governmental concern, 
demonstrating the profound effects of one single IAV pandemic in the society even after more 
than 80 years of occurrence. Three other IAV pandemics took place in the 20th century: the 
Asian flu (H2N2, 1957), the Hong Kong Flu (H3N2, 1968), and the Russian Flu (H1N1, 1977) 
(Kawaoka et al., 1989; Horimoto and Kawaoka, 2005; Tumpey et al., 2005). The Asian and 
Hong Kong pandemic IAV were genetically related to the descendants of the Spanish flu virus 
but had acquired avian genes by gene reassortment process. Such a reassortment is possible, 
i.e. by co-infection of avian and human IAV in one host (presumably a mammalian host that is 
susceptible to both human and avian IAV such as the pig), producing a virus with mixed viral 
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RNA segments of both IAV (Fang et al., 1981). This process generally yields a highly virulent 
virus to the reassortment host.  For example, the IAV of 1957 acquired avian PB1, HA and NA 
gene segments, and the virus of 1968, the HA and PB1 genes were also from avian origin. The 
process of reassortment is not the only factor contributing to the virulence of a pandemic IAV, it 
is suspected that the human to human transmissibility of the “Spanish Flu” 1918 virus was 
obtained by a mutations in the mutation in the HA gene (E190D and D225) (Glaser et al., 2005; 
Stevens et al., 2006). 
On the other hand, the seasonal IAV epidemics have widespread impacts, infecting 250-500 
million people each year, leading to 250.000-500.000 deaths, reaching a peak of morbidity 
during winter months in moderate climate zones (www.who.int. 
/mediacentre/factsheets/fs211/en/index.html). The elderly (over 65 years), the very young (less 
than 2 years) and the immuno-compromised patients are particularly susceptible to more severe 
respiratory disease and death due to IAV infection. A commercial vaccine formulation against 
the seasonal IAV is available in developed countries, but it is non-optimal and raises polemic 
about its sustainability. In addition, the possibility of contribution of the HPAIV to seasonal IAV 
epidemics remains a constant worldwide threat. 
 
1.2 CLASSIFICATION 
The influenza virus represents three of the six genera from the Orthomyxoviridae family, has a 
segmented, single-stranded, negative sense RNA genome (-ssRNA) complexed as vRNPs, 
encapsidated in a matrix shell that is enveloped by a lipid bilayer (see section 1.5), and is 
subdivided into three different genera: influenza A, B and C viruses (Bouvier and Palese, 2008). 
This classification is based on the identity of the major internal protein antigens such as 
Nucleoprotein (NP) and Matrix protein 1 M1 (Horimoto and Kawaoka, 2001). The IAV genera 
CONFIDENTIAL Page 11 
 
can be further classified into subtypes according to the serological reactivity of its major surface 
glycoproteins Neuraminidase (NA) and Hemagglutinin (HA). All different genetic subtypes of 
IAV, 16 for HA and 9 for NA, are maintained in a vast natural reservoir of wild waterfowls and 
shorebirds, from which they emerge to cause disease in domestic poultry, horses, pigs and 
humans (Fouchier et al., 2005). Although all subtypes are continuously replicating usually 
asymptomatically, in the intestines of their natural avian hosts, only four HA (H1, H2, H3 and 
rarely H5, H7 and H9) and two NA (N1 and N2) subtypes, and are known to cause human IAV 
infections, since the characterization of isolates in 1933 (Webster et al., 1978; Webster et al., 
1992).  
In contrast, influenza B and C viruses infect primarily humans, but there have been also 
examples of transmission to other hosts (influenza B viruses in seals) (Osterhaus et al., 2000; 
Steinhauer and Skehel, 2002). In contrast to influenza A viruses, influenza B and C viruses do 
not have a natural reservoir from which they can recruit novel surface antigens. As a 
consequence, they undergo only gradually antigenic variation. However, the genome of 
influenza B viruses mutates frequently enough, making long-lasting immunity following infection 
or vaccination impossible. In addition, strains of one of the two antigenically distinct lineages 
(Victoria and Yamagata lineage) are currently included in the formulation of influenza vaccines. 
Influenza C virus is the most stable and outbreaks are typically local and do not become large 
epidemics or global pandemics. In addition, a standard nomenclature is followed, in which the 
virus genus is described first, followed by the host species (omitted if human origin), the 
geographical origin, strain number and year of isolation. For the influenza A viruses, this is 
followed by the HA and NA subtype between brackets, i.e. A/crested eagle/Belgium/01/2004 
(H5N1).  
In humans, the IAV (H3N2 and H1N1) and B viruses are of epidemiological interest, since they 
cause recurrent seasonal influenza epidemics, and are therefore also the constituents of the 
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annual inactivated or live-attenuated influenza vaccines. For example the 2012 - 2013 
recommended influenza vaccine composition includes: A/California/7/2009 (H1N1), 
A/Victoria/361/2011 (H3N2) and B/Wisconsin/1/2010.  
 
1.3 GENOME 
The genome of IAV is composed of 8 negative sense single-stranded viral RNA (-ssRNA) 
segments comprising about 14 kb, which encodes 12 viral proteins, including a newly 
discovered overlapping protein encoded in the segment 3 of the genome, called PA-X (Jagger 
et al., 2012). The influenza genome segments contain cis-acting packaging signals that mediate 
the specific packaging of a full genome in an orderly fashion within the virus particle (Fujii et al., 
2003; Hutchinson et al., 2010). The numbering of the different genome segments is based on 
their decreasing length. These -ssRNAs are transcribed in 8 positive stranded messenger RNAs 
(mRNAs), which are translated in 12 proteins (Figure 1A) (Wise et al., 2009b). Each -ssRNA 
segment encodes one or two proteins, making use of alternative splicing or shifted reading 
frames (Steinhauer and Skehel, 2002). 
The viral RNA-dependent RNA-polymerase is error prone with a mutation rate of over 5 X 10-5 
average mutation rate per base pair per replication cycle, because it does not have proof-
reading activity to prevents replication errors (Drake, 1993). This relatively high mutation rate 
(almost one nucleotide exchange per genome per replication) leads to the accumulation of point 
mutations and subsequent amino acid replacements during the virus propagation in the host 
species. As a result of these mutations, a heterogeneous viral population is produced, and if a 
selective pressure (i.e. antiviral drugs) is present during the replication process, selection of 
escape-mutants can occur. For example, IAV escape-mutants can present insensitivity to an 
antiviral drug, antibody binding abolished, or no longer be recognized by cytotoxic CD8 T-cells. 
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The change of the antigenic properties of the membrane glycoproteins HA and/or NA, mainly 
due Ab pressure, is called Antigenic Drift (AD) (Ferguson et al., 2003). Therefore, changes in 
antigenic properties caused by AD are possible every replication cycle. During AD in HA, a 
number of AA sequence changes can take place close to the receptor-binding site, which may 
influence the binding affinity and specificity and lead to adaptation to a new host (Hensley et al., 
2009). Genetic recombination between different viral strains infecting the same host may also 
be a source for antigenic alteration. On the other hand, the replacement of complete RNA 
segments encoding for HA and NA between different subtypes influenza A viruses leads to 
abrupt changes in these antigenic determinants and is called Antigenic Shift (AS), resulting in 
reassortant virus (Rohde and Scholtissek, 1980; Rohm et al., 1996) (Webster and Hulse, 2004). 
The variation in antibody binding sites in HA and NA created by AD or even AS over time, 
permits virus evasion from the human immune system. One consequence of this process is the 
well-known yearly formulation of IAV vaccines for humans. Reassortment in the other six genes 
also plays a role in the evolution of the IAV, but less is known about their pathogenicity 
(Lindstrom et al., 1998). In contrast to AD, AS is relatively rare, but is important in the 
emergence of pandemics in human populations, being able to produce antigenically new viruses 
in the human population.  
The presence of AS in zoonotic human infections poses a potentially pandemic threat. It has 
been reported that mutations at the receptor-binding site of HA are necessary to cross the 
interspecies barrier between birds and humans. The human airway epithelium contains 
receptors for human and avian viruses, the first on non-ciliated cells and the latter on ciliated 
cells, localized in the upper and lower human respiratory tract, respectively (Matrosovich et al., 
2004b). The pigs are candidates to be a potential pandemic intermediate host, since the 
epithelial cells of pigs trachea co-express a2,3-linked SA and a2,6-linked SA on the epithelial 
cells of their trachea, making them susceptible to co-infection by avian and human IAV 
CONFIDENTIAL Page 14 
 
(Scholtissek et al., 1985; Ito et al., 1998; Kobasa et al., 1999; Van Reeth, 2007; Nidom et al., 
2010). As mentioned above, the recent pandemic H1N1 swine flu of 2009 evidences the role of 
animal host as a potential source of pandemic IAV. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Graphic representation of the Influenza virus protein coding sequences and the virion. A. The 
gray boxes depict the coding sequences for the 12 viral proteins, organized in 8 negative-sense single 
stranded RNA genomic segments. The numbers at the boxes flanks indicate: (left) the genome 
segment that encodes the protein; (right) the protein amino acid sequence length. B. The virion 
consists of a core with the RNP-complex, encapsided by a lipid bilayer with the embedded membrane 
proteins Hemagglutinin (HA, blue), the sialidase Neuraminidase (NA, red) and the ion channel M2 
protein (M2, magenta). The RNP-complex consists of the 8 genomic segments in complex with the 
proteins M1, PB1, PB2 and PA. (figure 1B taken from 
http://www.cdc.gov/media/subtopic/library/diseases.htm PHIL ID #11822). 
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1.4 INFLUENZA VIRUS PROTEINS 
The three integral membrane proteins are: the receptor binding Hemagglutinin (HA), the 
sialidase Neuraminidase (NA) and the Matrix ion channel protein 2 (M2). The most abundant 
membrane protein, HA, is a homotrimeric type I transmembrane glycoprotein and is important 
early in the viral infection cycle by binding to the N-acetylneuraminic acid or Sialic acid (Sia) 
residues on the host cell and facilitating fusion between the viral envelope and the endosomal 
membrane (Wilson et al., 1981). The NA is a homotetrameric type II transmembrane 
glycoprotein and is critical for the release of virus particles from the cell surface and the spread 
of the virus (Hogue and Nayak, 1994). The HA and NA proteins are the major antigenic 
determinants of the influenza viruses. The less abundant matrix M2 ion channel is a small 
homotetrameric type III transmembrane protein with proton channel activity, enabling activation 
of the membrane fusion function of HA and uncoating and disassembly of the virus during the 
initial stages of infection (Pinto et al., 1992). The cytoplasmic tail of the M2 protein also plays a 
role in virus assembly (Iwatsuki-Horimoto et al., 2006). The viral M1 supports the viral envelope 
and is the most abundant component of the virion and plays a pivotal role in the process of 
assembly and budding, and also envelops the viral RiboNucleoProtein-complex (vRNP). The 
Non Structural Protein 2 (NS2) mediates the export of newly synthesized vRNP from the 
nucleus, and is therefore also referred to as the Nuclear Export Protein (NEP) (Neumann et al., 
2000). The vRNP-complex consists of the arginin-rich NucleoProtein (NP) and a heterotrimeric 
RNA-dependent RNA polymerase complex (RdRp) consisting of three proteins: two Polymerase 
Basic (PB1 and PB2) proteins and one Polymerase Acidic (PA), which bind to the terminal 
helical hairpin of each viral -ssRNA segment (see figure 2D). The PA-PB1-PB2 polymerase 
complex is responsible for transcribing the mRNA and for synthesizing positive-sense 
antigenomic copy RNA (cRNA) from which the newly produced -ssRNAs are transcribed and 
incorporated into new progeny viruses. The rest of the -ssRNA segment is coated with NP, 
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which has an overall positive charge, enabling it to bind to the negative-charged phosphate 
backbone from the -ssRNA (Compans et al., 1972; Murti et al., 1988; Baudin et al., 1994). The 
NP is also necessary for the synthesis of cRNAs and -ssRNAs to be recognized as template for 
the viral polymerase (Steinhauer and Skehel, 2002). Finally, there are also non structural IAV 
proteins, involved in cell regulation. The -ssRNA segment encoding PB1 has a small 
overlapping ORF, that encodes the small non-structural protein PB1-F2 which has a pro-
apoptotic function, and the non-essential PB1-N40 protein, which may have an influence on 
virus replication and whose absence may be detrimental in some genetic backgrounds (Krug 
and Aramini, 2009; Wise et al., 2009a). The Non-Structural protein 1 (NS1) antagonizes 
interferon suppression and is abundantly present in the infected cell but is, together with PB1-
F2, not incorporated in the virion (Takasuka et al., 2002).  
 
1.5 REPLICATION CYCLE 
Human influenza is usually transmitted via air droplets produced by coughs or sneezes, 
followed by mucosal contamination of the respiratory tract of a new host. In humans, the primary 
targets for IAV are the epithelial cells from the respiratory tract, and NA promotes virus access 
to these target cells by mucus degradation in the respiratory tract (Matrosovich et al., 2004a). In 
addition, decoy receptors on mucins, cilia and the glycocalix of epithelium cells in human 
airways are removed by NA, hereby aiding virus invasion of the ciliated epithelium of human 
airways because these decoy receptors can no longer impede virus access to functional 
receptors on the surface membrane of target cells (Matrosovich et al., 2004a).  
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1.5.1 ENTRY 
The IAV binds via HA to a Sia residue on the target cell, resulting in the IAV virion entering the 
infected cell in an endosome via endocytosis (Figure 2A). After attachment, virus particles are 
internalized by receptor-mediated clathrin-dependent and -independent endocytosis (Rust et al., 
2004). After the endosome internalization and detachment of clathrin molecules, the tetrameric 
M2 ion channel pumps H+ ions from the acidic endosome into the interior of the virion, resulting 
in a pH of ca. 5.0 in the virion core. This causes dissociation of the -ssRNA from M1 by 
disruption of the low pH-sensitive interaction (Ciampor et al., 1992). This acidification leads to 
exposure of the buried, highly hydrophobic N-terminal fusion peptide of the HA2 subunit of each 
HA monomer. The fusion peptide inserts in the endosomal membrane, initiating fusion of viral 
and endosomal membranes, and the release of the viral RNPs (vRNPs) (Haque et al., 2005; 
Wagner et al., 2005) (Figure 2B). 
 
1.5.2 GENOME REPLICATION 
The vRNPs are released into the cytoplasm and are imported into the nucleus via Nuclear 
Localization Signals (NLS) into the NP protein, in importin α-β dependent pathway (Ozawa et 
al., 2007) (Figure 2C), where they are used as template for the production of cRNA and mRNA. 
Viral mRNA and cRNA synthesis occur by two distinct mechanisms (Nagata et al., 2008). 
Transcription of mRNA is dependent of a process called ‘cap-snatching’ from nuclear pre-
mRNAs. The viral mRNA synthesis requires capped RNA primers, which are obtained by a 
process called cap-snatching (Plotch et al., 1979; Plotch et al., 1981). The PB2 subunit of the 
polymerase is involved in binding to the m7GpppXm cap structures from the host cell 
polymerase II. The PA has a cap-dependent endonuclease activity and cleaves off cap 
structures from the host cell pre-mRNAs, and thereby shuts down the synthesis of most host 
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proteins (Yuen and Wong, 2005; Dias et al., 2009). The fragments consist of a cap plus 10-13 
extra nucleotides and serve as primers for the initiation of viral mRNA synthesis. Termination of 
mRNA synthesis occurs by iterative copy of stretch of U residues generating a poly (A) tail 
(Figure 2E). The viral mRNA shuttles back to the cytoplasm where it is translated into viral 
proteins. This requires NP to assure the switch from viral mRNA synthesis to cRNA replication 
(Newcomb et al., 2009). On the other hand, the cRNA in the nucleus serves as a template for 
the production of genomic –ssRNA. In contrast to viral mRNA synthesis, cRNA and -ssRNA 
replication is initiated without a primer (Figure 2E). The newly produced vRNP are recognized 
by the M1 protein, via M1-RNA and M1-NP interactions. The complex vRNP-M1 is recognized 
by the NLS-containing NEP protein. In a cellular export protein Crm1 (chromosome region 
maintenance 1) dependent pathway, the vRNP-M1-NEP complexes are transported to 
cytoplasm (Elton et al., 2001) (Figure 2F). The vRNP-M1 complexes are targeted to assembly 
sites, lipid rafts enriched by HA and NA proteins, in the cell membrane (Figure 2G). 
 
1.5.3 VIRION RELEASE 
The release of viruses from infected cells is promoted by NA, which cleaves the Sia residues 
from viral and cellular glycoconjugates, to which the newly formed viral particles are attached, 
thereby preventing HA-mediated self-aggregation and facilitating viral release (Air and Laver, 
1989) (Figure 2H). The release of newly produced virions occurs approximately eight hours 
post-infection, either into the airway to find another cell to infect, or by aerosol droplets (i.e. 
during coughing or sneezing), permitting person-to-person transmission. Virus shedding 
typically continues for up to one week, after which a virus-specific antibody clearing can be 
present (Carrat et al., 2008). 
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Figure 2. Replication cycle of influenza A viruses and role of HA and NA specific antibodies. A. IAV 
virus entry into the host cell through endocytosis mediated by the attachment of HA to sialyled 
receptors. B. Endosome acidification activates viral M2 ion channel allowing disruption of M1-vRNP 
interaction and subsequent virus uncoating. The pH dependent conformational rearrangement of HA 
permits endosomal membrane fusion, the releasing individual vRNPs into the cytoplasm. C. Viral 
genome segments are then transported into the nucleus via Nuclear Localization Signals (NLS) carried 
by NP protein and the importin alpha–beta mediated pathway. D. Schematic organization of vRNP is 
depicted in the inset. Viral genome consists of negative sense RNA (vRNA) existing as viral 
ribonucleoprotein (vRNP) complexes associating heterotrimeric RNA dependent RNA polymerase 
(RdRp, constituted by PB1, PB2, PA proteins) and many copies of nucleoprotein (NP). E. An initial 
round of transcription produces 5_ capped and 3_ poly (A) viral mRNA efficiently exported towards the 
cytoplasm to be translated (step a, red). Then vRNA templates are replicated into a perfect positive 
sense copy RNA (cRNA, step b). This replicative intermediate form is the template for neosynthesis of 
many copies of vRNA (step c). F. After the formation of vRNPs within the nucleus, M1, NEP (Nuclear 
Export Protein, primary referred to as NS2) and NP catalyze its transport to the cytoplasm via a CRM1-
dependent pathway. G. M1-vRNP complexes are directed to the virus assembly sites M1 interacts with 
cytoplasmic tails of H1 and NA, leading to assembly and budding of virions. H. Their final release from 
cell surface relies on the viral NA sialidase activity (Josset et al., 2008). I.  HA specific antibodies block 
virus attachment, resulting in the decrease of infected cells. J. NA-specific antibodies bind virus to the 
cell, preventing release of newly produced virions and inducing aggregation 
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1.6 HEMAGGLUTININ  
The two surface glycoproteins HA and NA are the major antigenic determinants of the influenza 
viruses, but the HA is naturally immunodominant. The HA is the major antigenic determinant, as 
mentioned above, because it has a key role in the initial stages of infection by its receptor 
binding and membrane fusion activities (Yoshida et al., 2009). As mentioned above, the HA has 
an important role in the endosomal membrane fusion during the IAV replication cycle. The HA 
protein is encoded by the fourth -ssRNA segment, and is synthesized as a single chain 
precursor (HA0) in the endoplasmic reticulum (ER), where is assembled as a homotrimer of the 
host cell by the help of chaperones and exported to the cell surface via the Golgi network 
(Webster et al., 1992). Once in the cell surface, the HA0 can be cleaved into two subunits (HA1 
and HA2) by specific host proteases (Kido et al., 1992). Structurally, each HA monomer has a 
globular head and stalk domain, conformed by two subunits HA1 and HA2. The HA1 domain of 
each monomer is built up by β-sheets, with a shallow depression conforming the Receptor 
Binding Domain (RBD), which is responsible for binding to the Sia receptors (Gamblin et al., 
2004). The RBD has three structural elements: a 190-helix (HA1 residues 188 – 190); the 130-
loop (HA1 residues 134 – 138) and the 220-loop (HA1 residues 221 – 228) (Figure 3B). The 
HA2 subunit is constituted by a membrane proximal α-helical stalk that functions as an anchor 
domain, and a fusion peptide, that is responsible for fusion between the viral and the endosomal 
membrane (Palese and Schulman, 1976) (Figure 3A). The RBD is localized at the membrane 
distal end of HA1 (Figure 3A-B), and binds to Sia receptors with low affinity (Sauter et al., 1992). 
Nevertheless, the high density of HA copies on the virion surface, increase the HA avidity to Sia 
receptors, by multivalent binding. The HA1 globular domain is a preferential target for HA 
neutralizing antibodies, that block viral attachment (Figure 2I), and contains antibody recognition 
sites, mapped close to the RBD (Figure 3B). For example, by escape mutants analysis using a 
CONFIDENTIAL Page 22 
 
H5-specific camelid single chain antibody, the mutations K154S/D and K189N/E  showed to be 
close to the RBD, and blocked the binding of a H5N1 virus to cells (Ibanez et al., 2011) (Figure 
3B). The avian IAV have preferential binding for α2-6 linked Sia in the intestinal tract, whereas 
the human-adapted IAV tend to bind to α2-3 linkage (Parrish and Kawaoka, 2005). The switch 
of specificity from α2-3 to α2-6 is a critical step in the adaptation of avian IAV to human host, 
and it seems to be an important factor in hindering the avian IAV (including H5) human to 
human transmission, after avian-human infection. The majority of the HAs have a restricted 
infection in the lung of the mammals, because of the specific cleavage site (Q/E-X-R) and 
narrow tissue distribution of relevant proteolytic enzymes. In contrast, the H5 and H7 subtypes 
have a polybasic sequence that has been associated with high virulence in birds, due enhanced 
cleavage susceptibility by a broader range of cellular proteases (Hulse et al., 2004). 
Consequently, H5 IAV present a tissue tropism not only restricted to the lungs, but extends to 
other organs, including the brain. The H5N1 HA1 C-terminal cleavage site comprises until the 
proline 324 (Pro324), not including the QRERRRKKR residues before the N- terminal glycine 1 
(Gly1) of the HA2. The HA2 N-terminus is stabilized by hydrogen bonds from its backbone 
amide groups to Asp11 and to Ser113 of the adjacent HA2 monomer (Figure 3C) (Stevens et 
al., 2006). The 17 serological different subtypes are divided into two major phylogenetic groups: 
group 1 (H1, H2, H5, H6, H8, H9, H11, H12, H13, and H16) and group 2 (H3, H4, H7, H10, H14, 
and H15). The available HA structures indicate that the two groups differ in their HA stalk region 
and in the regions that are required for membrane fusion (Steel et al., 2010). In contrast, the 
Sia-binding site is conserved in all HA subtypes of IAV, throughout antigenic variation 
(Watowich et al., 1994). 
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Figure 3. Diagrams of H5N1 HA structure and specific cleavage site. A. Side view of a NA trimeric 
molecule (PDB: 21BX, VN04N1, derived from A/Vietnam/1203/2004). Each monomer has a stalk and 
head domain (HA1 – HA3). For clarity reasons, each monomer has been colored differently. In one 
monomer, the HA1 (red) membrane distal receptor binding site (RBD) localization is depicted by the 
orange dotted line, while the membrane proximal polybasic cleavage site is in the black box. B. Top 
view of the HA trimer. The RCB of HA1 is also depicted in orange dotted line, constituted by the 130 
and 220-loops and the 190-helix. The HA1 K154S/D and K189N/E mutations are indicated in green. C. 
Amplification of the HA cleavage site. Cleavage of the polybasic site of HA1 c-terminus from the fusion 
peptide at the N-terminus of the HA2, which is stabilized by hydrogen bonds from AspB112 and SerF113, 
from adjacent monomers (figure 3C taken from Stevens et al., 2006). 
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1.7 NEURAMINIDASE  
There are nine serotypes of NA (N1-N9) that are subdivided into two phylogenetically distinct 
groups: with group 1 consisting of N1, N4, N5 and N8 and group 2 consisting of N2, N3, N6, N7 
and N9 (Thompson et al., 1994) (Figure 4A). Two pandemic H1N1s, the A/BrevigMission/1/1918 
(BM18N1) and the A/California/04/2009 (CA09N1) and the emergence of highly HPAIV H5N1 
A/Vietnam/1194/2004 (VN04N1), suggest that N1 NA is of major concern. Phylogenetic analysis 
of the N1 NA sequences reveals three different clusters, co-incident with their human, swine or 
avian origin (Figure 4B). The VN04N1 NA is a representative of HPAIV H5N1, which shared a 
high sequence homology (> 95 %) with the NA of A/Crested Eagle/Belgium/01/2004 (BE04N1) 
and  (TU05N1), two HPAIV H5N1 also used in this study. In addition, the VN04N1 and BE04N1 
belong to the H5N1 clade 1, separated from the TU05N1 in clade 2 (Figure 4C-D). Depending of 
the avian or mammal origin, NA substrate specificity varies. As a generality, the NA prefers to 
cleave α 2-3 linked Sia (3’Sia) (Kobasa et al., 1999). Interestingly, it has been reported that the 
preference of the NA towards α 2-6 Sia (6’Sia) may be associated with HA binding specificity 
from avian (3’Sia) to human (6’Sia) (Baum and Paulson, 1991). The preference of the N1 
towards 3’Sia over 6’Sia depends of the host, since it varies between species: human 5:1; pigs, 
20:1, birds, 50:1 (Mochalova et al., 2007). Several human IAV prefer 6’Sia cleavage more than 
avian IAV, but still there is a great preference of NA for 3’Sia.  
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The -ssRNA segment number 6 encodes the NA protein, a homotetrameric type II 
transmembrane glycoprotein. NA is the second major antigenic determinant and is essential in 
the spread of the virus by cleaving the SA receptors on the host cell and on the virus itself. 
Without functional NA-activity, the lack of removal of the Sia residues from the viral and infected 
cell surfaces resulted in aggregation of the newly produced virus particles on the surface of the 
infected cell. A major role in this aggregation is the interactions between HA-receptor binding 
sites and Sia, preventing the release and the spread of the IAV (Palese et al., 1974). The NA 
protein monomer has a square box-shaped head at the top of a long thin stalk, of variable 
length, followed by hydrophobic amino acids (AAs) to anchor the NA into the lipid membrane, 
the transmembrane domain (TMD), and a cytoplasmic domain (Cytd) at the N-terminal end 
(Figure 5 A-B) (Laver and Valentine, 1969; Wrigley et al., 1973; Steinhauer and Skehel, 2002). 
In the lipid bilayer of the virion, the NA is present as a tetramer composed of four identical NA 
monomers. Each monomer of the box-shaped fourfold symmetric head consists of six four-
stranded antiparallel β-sheets, arranged in a propeller fashion and the active site of the NA is 
located on top of each monomer, forming the catalytic cleft (Colman et al., 1983; Varghese et 
Figure 4. Phylogenetic analysis of representative neuraminidase genes and N1 proteins. A. The IAV 
neuraminidases genes are divided into group 1 (yellow) and groups 2 (blue), in green are the N1 NA: 
BM18N1, A/BrevigMission/1/1918 (H1N1); CA09N1, A/California/04/2009 (H1N1); VN04N1, 
A/Vietnam/1194/2004 (H5N1). B. Human, swine, and avian origin N1 genes are depicted in blue, 
yellow and green, respectively: WSN/33, A/WSN/1933 (H1N1); Brisbane/07, A/Brisbane/59/2007 
(H1N1); PR8/34, A/Puerto Rico/8/1934 (H1N1); Sw/Denmark/93, A/Swine/Denmark/WVL9/1993 
(H1N1);  Sw/Spain/03, A/Swine/Spain/50047/2003 (H1N1); Sw/Zhejiang/07, A/Swine/Zhejiang/1/2007 
(H1N1); Ck/India/06, A/Chicken/India/NIV33487/06 (H5N1); BHGoose/QH/05, A/Bar-headed 
Goose/Qinghai/1/2005 (H5N1). Bootstrapped neighbor-joining analysis (adapted from Li et al., 2010). 
C. Phylogenetic tree of 6 N1 proteins, 3 H1N1: two pandemic, BM18N1 (AAF77036) and CA09N1 
(ACP41107), the lab strain PR834N1 (ACF41837); and 3 HPAIV H5N1 analyzed in this project: 
BE04N1, A/Crested Eagle/Belgium/01/2004 (ABA70757), VN04N1 (ABP52007) and TU05N1, 
A/turkey/Turkey/&/2005 (ABQ58915). In parenthesis are the protein accession numbers. D. Pair 
distances analysis of the N1 protein sequences of C. Percent of similarity in upper triangle, percent of 
divergence in lower triangle. Alignment and homology analysis by Clustal W method.  
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al., 1983; Burmeister et al., 1992) (Figure 5B). The NA Cytd has a 6 residues consensus 
sequence (MNPKQK), and mutants of this domains present a significant decrease in virion 
budding. Nevertheless, neither the Cytd detailed functions nor its cytoplasmic interaction 
partners are known (Barman et al., 2004). TMD, varying in length from 7 to 29 residues, 
contains a signal peptide anchor that redirects the NA into the ER lumen and retains it in the 
infected cell membrane. Recent studies indicated that the NA tetramer’s proper folding and 
activity depends on the presence of the TMD. The stalk appears to contribute only marginally to 
NA tetramer formation since as few as 10 AA residues from the NA stalk are enough to allow 
folding. Nevertheless, TMD is not necessary for the synthesis and trafficking of the NA, but TMD 
absence compromises NA activity and results in improper folding. Interestingly, the TMD and 
stalk can be targeted to the ER, pass protein quality control and enter the Golgi complex, and 
can tetramerize without the head domain (da Silva et al., 2013), highlighting the importance of 
the role of the TMD during the NA tetramerization. It seems that the NA head domain alone can 
properly assemble on its own, but when a stalk domain is present, the head domain N-terminus 
must be stabilized by the TMD to prevent aggregation. The NA stalk domain length is very 
variable from 32 to 50 residues, and possesses cysteine residues that contribute to the NA 
stability by intermolecular disulphide bridges (S-S), and also canonical glycosylation sites (N-X-
S/T). Deletions in the NA stalk domain are associated with reduced accessibility to Sia complex 
substrates. Reduced length of the NA stalk is often found in HPAIV that transmitted from ducks 
to land-based poultry, such as chickens and turkeys (Munier et al., 2010). Unfortunately, only 
crystallographic structural data of the NA globular head domain are available (Figure 5A).  
The NA enzymatic activity was discovered in 1947 (Hirst, 1941), but only 15 years later the 
sialic acid was identified as its substrate (Figure 5C) (Gottschalk, 1956). The activity of the NA 
seems to depend on the tetrameric conformation, as it has been reported that protease-
extracted NA from crude virus preparations conserved 100 % of activity, suggesting that a 
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proper folding is necessary for NA activity, the monomeric forms being considered not active 
(Bucher and Kilbourne, 1972). Several factors are considered to contribute to the NA tetramer 
stability: i) optimal activity at pH 5.5 – 6.5; ii) head domain residue mutations, i.e. the mutation 
E119G results in the lack of a salt bridge of E119 with the E156 in a neighbouring monomer, 
disrupting the tetramer formation; iii) the difference of glycosylation patterns between the NA 
tetramer and monomers and dimers, suggests that tetramerization is favored in NA molecules 
with untrimmed mannose residues (Man5-9GlcNAc2); iv) the presence of Ca
2+ molecules in the 
NA structure, confirmed by crystallographic data, is an important factor for NA tetramerization 
stability (Lawrenz et al., 2010). The Michaelis constant (Km) reported for the NA with the small 
substrate 2’-4-Methylumbelliferyl-α-D-N acetylneuraminic acid (MUNANA) is in the range of 6 – 
520 µM; the Km for the 3’ Sia is 171 – 750 µM. The specific activity of the NA with MUNANA as 
a substrate is: 100 (N1) and 900 (N9) nmol / sec per mg (Wu et al., 2009; Schmidt et al., 2011). 
It has been observed that NA has a lower activity for cleaving complex glycoprotein substrates, 
compared with small substrates like MUNANA. Also the presence of glycans with O-acetylations 
resulted in lower NA activity, because the O-linked 3’Sia is less efficiently cleaved than the N-
linked one (Corfield et al., 1986). 
The NA AA residues that are responsible for the active site are highly conserved among the NA 
subtypes, and can be divided into 3 types for their analysis: residues that have direct contact 
with the Sia substrate at the catalytic site, active site framework residues, and 150-loop 
residues. The residues that have contact with Sia are polar and charged: R118, D151, R224, 
R292, R371 and Y406 (contacting the carboxylate moiety of the Sia), the R152 (contacting the 
acetamido group of Sia) and E276, which makes hydrogen bonds to the hydroxyl groups of the 
Sia (Figure 5C). The structure of the active site is stabilized by hydrogen bonds and salt bridges 
by the framework residues: E119, R156, W178, S179, D198, I222, E227, H274, E277, N294 
and E425 (Figure 5D). The group 1 NA 150-loop residues (G147, T148, V149, K150 and D151) 
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contribute to more extensive interactions with the Sia and the other NA substrates: (Figure 2E-
F). The first 3-dimensional structure of any NA solved by X-ray crystallography resulted from 
pronase-released N2 heads. This first structure was solved at 2.9 Å of resolution, and was a 
composite of two different Asian origin N2, representing H2N2 (A/RI/5+/57) or H3N2 
(A/Tokyo/3/67) (Varghese et al., 1983). Later, the crystal structures of 2 IAV NA (N2, N9), (Tulip 
et al., 1991; Varghese et al., 1992) and Influenza B NA (Burmeister et al., 1992), were reported. 
The 2 NA active site rigid structures have been used as an excellent target for drug design, i.e. 
oseltamivir or zanamivir. The first N1 crystal structure was reported by Russell (Russell et al., 
2006), from bromelain-extracted NA from crude H5N1 HPAIV preparations (derived from a 
VN04N1). This N1 structure revealed a main structural difference compared with the group 2 NA 
reported structures. In the N1, the loop comprising the 147 – 152 residues (called “150-loop”) 
was able to adopt a closed or open conformation. In addition, oseltamivir binding to the N1 
catalytic site occurred in the 150-loop open conformation, resulting in the N1 adopting a closed 
conformation. This conformational change suggested that the oseltamivir binding favours a 150-
loop closed conformation that requires less energy than the open conformation (Figure 2E-F). 
The NA of N1 and N2 bind oseltamivir with similar affinity suggesting that the difference in 
energy between the 150-loop open or closed conformations is not very large. The crystal 
structure of the pandemic 2009 H1N1 NA (09N1) surprisingly showed that the 150-loop was 
absent in the active site architecture (Li et al., 2010). The NA from CA09N1 was closely related 
to the NA of Eurasian swine isolates (Figure 4B). The root mean square deviations (rmsd) of the 
150-loop residues of the CA09N1 compared to the BM18N1 and a N2 NA was 2.184 and 0.261, 
respectively, showing the greater similarity of the CA09N1 150-loop residues to the NA of the 
group 2 than group 1. A possible explanation to this group 2 NA similarity of the CA09N1 is the 
shared isoleucine at position 149, while the NA of group 1 has a valine at the same position. 
The isoleucine possess an extra carbon compared with the valine and is oriented towards the 
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P347, suggesting that in CA09N1, like in some of the group 2 NA, the 430 loop coordinated the 
closed 150-loop conformation (Li et al., 2010).  
A second sialic acid binding site, different to the NA active site had been reported in N9 NA, and 
is composed of the residues N367, S370, N400, W403 and L432, being called hemadsortion 
site (HB) (Figure 5D). Notably, this second binding site is only present in NA of birds but not in 
humans. In avian IAV that infect humans, this HB site is lost. This loss might be necessary for 
the adaptation of the avian IAV to recognize 6’Sia present in humans, but its function is not 
completely known (Varghese et al., 1997). Interestingly, the Sia bound to the NA HB is in a boat 
conformation, in contrast to the Sia in chair conformation in the binding site of HA and NA active 
site. NA mutants with a +HB site have a higher NA activity than mutants –HB with complex 
substrates, suggesting that the HB site possibly contributes to stabilize the Sia substrate, or 
maybe by “feeding” the NA active site.  
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1.8 INFLUENZA ANTIVIRALS  
 Influenza A and B virus infections can cause local and systemic reactions, including sudden 
onset of high fever, head ache, chills, myalgia, coughing, sore throat, runny nose, diarrhoea, 
primary pneumonitis and occasionally secondary bacterial infections (Hubert et al., 1992). The 
severe morbidity that is often associated with HPAIV infection in humans can be attributed to a 
high replication rate and a broad cellular tropism that can lead to a systemic spread (see section 
1.6). During severe infections, a deregulated induction of pro-inflammatory cytokines and 
chemokines (sometimes called “cytokine storm”) is associated with HPAIV infections, and can 
result into an excessive immunological response and autoimmune symptoms (de Jong et al., 
2006). The treatments reported and available against HPAIV are far from optimal: treatment 
Figure 5. Diagrams of NA structure and its substrate. A. Side view of a membrane bound NA tetramer. Each 
monomer is composed of 4 parts, from N- to C- terminal: a cytoplasmic domain (Cytd, purple), a 
transmembrane domain (TMD, yellow), a stalk domain (light green) and the catalytic globular head domain 
(green) in ribbon representation (PDB: 2HTY, VN04N1 derived from A/Vietnam/1194/2004). In one of the 
monomers, the catalytic cleft is in surface and colour presentation: residues that make direct contact with the 
Sia substrate (red), catalytic site framework (yellow) and the D149 and R150 (blue) as part of the “150 loop”. 
B. Top view of the NA tetramer of A. derived from C. The NA natural substrate is the sialic acid (Sia) (carbon 
atoms coloured in green) with an acetamido and carboxylate groups at carbons 4 and 6, respectively. D. 
Amplification of one N9 monomer structure, where the catalytic site and a second Sia-binding domain (HB) 
are depicted. The NA catalytic site is a cleft that harbours a Sia molecule (red dotted lines), with highly 
conserved residues in both NA groups. As in B, the residues that have direct contact with Sia are in red 
(R118, R224, E276, R292, R371 and Y406); the framework residues in yellow (E119, R156, W178, S179, 
D198, I222, E227, H274, E277, N294 and E425). The residues D151 and R152 also make direct contact 
with the Sia and are represented in blue, as reference residues for the “150-loop” (G147, T148, V149, K150 
and D151). The residues of the HB site (present in avian origin IAV) that make contact with a second Sia are 
in orange (S367, S370, S372, N400, W403 and K432). (PDB: 1MWE; N9 derived from 
Tern/Australia/G70c/75). E. The N1 catalytic site has an extra 150 cavity. A representative 150 cavity of 
VN04N1 is depicted. The cavity results from the 150-loop adopting an open conformation, and upon 
substrate binding, the cavity provides extra surface and contacts to NA substrates. F. The lack of the 150 
cavity in the pandemic CA09N1, resembling the group 2 NA 150-loop in closed conformation (CA09N1 150-
loop similar to D), had been subject of recent polemic, and it seems that both conformations can exist in 
CA09N1 (PDB: 3NSS). 
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with convalescent plasma for influenza A H5N1 infected patients has been shown to be 
protective (Zhou et al., 2007); a risky combination of antiviral drugs and immunomodulators can 
control severe HPAIV infections (White et al., 2009). In addition, bacterial secondary infections 
are associated with IAV infections that complicate the clinical outcome (Rameix-Welti et al., 
2009). 
There are two types of antivirals that are licensed for the treatment of human influenza. These 
drugs target only two viral proteins: the transmembrane domain (TM) of M2, targeted by 
amantadine and rimantadine; and the inhibitors of the catalytic activity of NA, i.e. oseltamivir, 
zanamivir and peramivir. These drugs are most often used against seasonal influenza and have 
been applied to try to control disease in patients caused by H5N1 and H7N7 infection. These 
antivirals drugs present several advantages compared to vaccines: i) administration when the 
circulating influenza strains do not match the available vaccines; ii) efficient therapeutic effect to 
reduce morbidity and length of disease; iii) immediately effective and available, can be 
stockpiled in advance; iiii) effective against a broad range of IAV strains. Unfortunately, the use 
of IAV antiviral drugs is characterized by long term treatment and high concentrations used in 
clinical cases, causing selective pressure and the appearance of reported and emerging 
resistant mutants.   
The adamantanes, amantadine and rimantadine, are synthetic amines that block the M2 ion 
channel. The adamantanes are the first generation of IAV antiviral drugs and are effective in 
both prophylaxis and treatment reducing the duration of illness in healthy individuals by 
approximately 1 day (Jefferson et al., 1999). These drugs are orally administered, inexpensive, 
stable and easily stockpiled by their long shelf life (at least two decades). However, 
adamantanes treatment is frequently complicated by gastrointestinal and central nervous 
system side effects which significantly limits its wide-scale use (Tominack and Hayden, 1987). 
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Next to this, M2 inhibitors are effective against IAV while they do not bind to the M2 ion channel 
of Influenza B viruses. The adamantanes are also limited in their clinical use by the widespread 
drug resistance (Wenzel, 2000).  
The second group of licensed antiviral drugs against influenza are the NA inhibitors, which 
primarily act by inhibiting viral spread.  Inhibition of the viral NA affects several stages of the IAV 
replicative cycle: i) hindering the passage of the virus through the mucus of the respiratory tract 
and suppressing infection before virus entry into cells, by a NA-dependent HA-mediated binding 
to its cellular receptor (Matrosovich et al., 2004a); ii) inhibition of the release of progeny virus on 
the surface of infected cells, slowing down the spread of the virus. 
Analysis of the three-dimensional X-ray structure of the catalytic cleft of the IAV N2 NA has led 
to the design of the NA inhibitors: zanamivir (Relenza) and oseltamivir (Tamiflu) (Vonitzstein et 
al., 1993; Kim et al., 1997). These drugs (introduced in 1999 and 2000, respectively) are 
designed to interfere with the normal function of IAV NA by mimicking Sia (Figure.6A). Although 
the AA sequence homology between NA from type A and type B virus is only 30%, their NA 
have a similar topology with a highly conserved active site pocket of the enzyme (Colman et al., 
1984; Air et al., 1990). As a consequence, the NA inhibitors are active against both influenza A 
and B viruses. The first NA inhibitor, zanamivir, is a Sia derivate in which the 4-hydroxyl group 
of sialic acid is replaced with a guanidinyl group which binds to NA with high affinity (Krug and 
Aramini, 2009) (Figure 6B). The use of zanamivir is limited by its poor bioavailability, due to a 
positively charged guanidine group in its structure. Therefore it has to be administered topically 
as a dry powder by an oral inhalator (Monto et al., 1999). The impractical way of administration 
of zanamivir, as well as the shortage of supply, limits its wide-scale use.  
The other anti-NA drug, oseltamivir is currently the most used available drug for IAV treatment 
and can be orally administered because of the presence of a lipophilic side chain (Mendel et al., 
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1998) (Figure 6B). The oseltamivir oral form is an inactive pro-drug that requires ester-
hydrolysis by hepatic esterases for its conversion into its active form, oseltamivir carboxylate. 
The NA inhibitors reduce the duration of influenza symptoms in average-risk patients by 
approximately one day, and in high-risk and older patients by 2,5 days (Hayden et al., 1997; 
1998; Hayden et al., 1999; Matsumoto et al., 1999; Monto et al., 1999; Treanor et al., 2000; 
Lalezari et al., 2001). Compared to the M2 inhibitors, the NA inhibitors have the advantage of 
having lower induction of adverse secondary effects. However, resistant mutants against 
oseltamivir, and to a lesser extent against zanamivir, have been reported in vitro, in vivo and 
also in clinical specimens. In addition, recent polemic has been seen by reports challenging the 
efficacy of oseltamivir treatment, in biased clinical trials of children and adults IAV infected 
patients (Jefferson et al., 2012; Wang et al., 2012). The persistent treat of oseltamivir resistant 
mutants and its efficacy in human patients are pieces of evidences that highlight the necessity 
of antiviral alternatives for IAV.  
 Dependent on the specific mutation, a virus can become resistant against oseltamivir but 
remain sensitive for zanamivir (Carr et al., 2002; Moscona, 2005a, b, 2008). Since both 
inhibitors bind to the catalytic site of NA, cross-resistance mutations are also found with different 
drug resistance profiles (Oakley et al., 2010). In addition, some drug-resistant IAV strains permit 
binding of the drug to the NA, while the fitness is compensated by mutations in or near the HA 
receptor-binding site, leading to HA reduced binding efficiency to Sia-containing receptors 
(Gubareva et al., 2000). Since the before mentioned NA inhibitors are based on crystal 
structures of group 2 NA, there is special interest to design new anti-IAV drugs based on more 
recently reported N1 NA crystallographic structures (Collins et al., 2008; Li et al., 2010). Among 
the several oseltamivir-resistance mutations, the H274Y and the R292K (N2 numbering) binding 
dynamics had been studied in detail (Russell et al., 2006). The H274Y mutation in NA has been 
isolated in oseltamivir treated human volunteers, but HA mutations in the residues 137 and 225 
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were reported to affect the fitness of the virus in vitro and in vivo, by adopting a α2-6 Sia linkage 
preference in human respiratory tract (Gubareva et al., 2001). Two factors contributed for the 
mutant N1 H274Y inability to bind oseltamivir: i) the tyrosine residue at 274 results in a partially 
displaced E276. The bulkier tyrosine residue in the H274Y mutant pushes the neighbouring 
E276 carboxylate group into the active site cavity, resulting in the displacement of 2.0 Å of the 
oseltamivir pentyloxy group, compared to the wild-type NA (Figure 6C). In contrast, the 
zanamivir glycerol group hydrogen bonds formed by its 8 – 9 hydroxyls with the side chain of 
the E276 are not affected, conserving hydrogen bonds present (Wang et al., 2002b) (Figure 
6D); ii) the group 1 NA, the H274Y mutation cannot accommodate oseltamivir in the active site, 
due displacement of a bulky and conserved tyrosine residue Y252 just beneath the 274 residue, 
whereas in group 2 NA, the smaller threonine in the 252 position allows oseltamivir binding in 
the active site. This observation renders an explanation of why the H274Y mutation in group 1 
NA gives resistance to the oseltamivir, but not in the group 2 NA.  
In the N294S mutant, the extra hydrogen bond between the S294 with the E276 results in a 
displacement of the Y347 residue, flipping out from is normal position and being no longer 
coordinated by a Ca2+ molecule (Figure 6E). The appearance of this extra hydrogen bond alters 
the hydrophobic make up of the N1 substrate-binding site, resulting in weakening the hydrogen 
bond with the carboxylate of the oseltamivir. On the other hand, the R292K is an oseltamivir-
resistance mutation in the group 2 N2, and also results in lack of a hydrogen bond with the 
carboxylate group of oseltamivir. In the group 1 N1, the tyrosine in the 347 position can 
compensate the absence of this hydrogen bond, but the N347 in N2 cannot (Mishin et al., 
2005). The structures of NA from HPAIV N1 in complex with oseltamivir and zanamivir were 
solved (Collins et al., 2008), and suggested that the more similar the NA inhibitors to the Sia, 
the less chances of escape mutant to appear. The in vitro enzymatic analysis of H274Y and the 
N294S mutants showed that the oseltamivir inhibition of the NA activity in the 2 mutants was 
CONFIDENTIAL Page 37 
 
negatively affected, by increasing the inhibitory constant (KI) of the H274Y and the N294S, 285 
and 81 fold, respectively (Collins et al, 2008) (Figure 6F). On the contrary, the mutation Y252H, 
that was reported in human cases in Asia but not associated with oseltamivir treatment 
(McKimm-Breschkin et al., 2007), decreased the oseltamivir sensitivity by 10 fold. The NA 
activity (Vm) of these mutants was similar to the N1 WT, suggesting that mutations outside of the 
residues that make direct contact with the Sia do not affect NA activity. In contrast, none of 
these mutations affect the zanamivir binding to the NA. The H274Y NA increase in KI, or 
sensitivity to oseltamivir, can be explained by an association rate constant (Kon) 10 fold smaller 
than the NA WT, but a dissociation rate constant (Koff) 25 fold higher. 
There are contradictory reports about the compromised fitness of the H274Y mutant IAV. On 
one hand, the first reports about this mutation point out severely impaired fitness in vivo and in 
vitro posing the H274Y as a not clinically significant threat to human (Ives et al., 2002). On the 
other hand, later reports showed a not compromised replication efficiency of the H274Y and 
N294S in vitro (only 10X less viable than WT), showed only a slight decreases in morbidity of 
infected animals (Le et al., 2005; Yen et al., 2007), and most importantly, the H274Y mutation 
was found viable in human infections (Lackenby et al., 2008; van der Vries et al., 2008). 
Compensatory mutations had been proposed to play a major role into the rescue of fitness of 
the H274Y mutation (Collins et al., 2009; Bloom et al., 2010). For example, the mutation I223R 
(isolated from an immunosuppressed child) conferred resistance to the oseltamivir and 
zanamivir (Nguyen et al., 2010). In the pandemic H1N1, the double mutant I223R/H274Y double 
mutant gives a higher resistance to oseltamivir, and is does not compromise the replicative 
capacity and transmissibility of the IAV in ferrets (van der Vries et al., 2011). The crystal 
structure showed the existence of a “223 pocket” within the active site of the WT NA, but in the 
I223R pocket NA this pocket is absent. In the I223R the pocket harbours 2 water molecules and 
is occupied by the side chain of the arginine 223, which makes a hydrogen bond with the S247, 
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which results in a turning of the S247 to make and extra hydrogen bond with E277. These 
conformational rearrangements resulted in shrinkage of the NA active site, reducing the space 
that normally accommodates the pentoxyl group of the oseltamivir (Amaro et al., 2011). The 
mutations S247N also is linked to oseltamivir resistance, and is maybe involved in the shrinkage 
of the hydrophobic pocket in the NA active site, above mentioned. The double mutant 
S247N/H274Y fitness is not compromised in ferret models suggesting a normal NA activity 
(Amaro et al., 2011). 
In addition, it has been reported that the mutation H274Y reduced fitness can be rescued by 
secondary mutations, which are not localized close to the NA active site. In a H1N1 H274Y 
mutant background, the mutations V234M and R222Q restored the NA protein levels in infected 
cells to wild-type levels. This findings suggest that IAV that accumulates permissive mutations 
(like V234M and R222Q), and then acquired the H274Y mutations, can be oseltamivir-resistant, 
maintaining high level of fitness in the absence of the drug (Bloom et al., 2010).  
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1.9 ANTIBODIES 
1.9.1 CONVENTIONAL ANTIBODIES 
Recombinant Antibodies (Ab) are widely regarded as one of the main, if not the most promising 
tools against cancer and auto-immune, inflammatory, neurodegenerative and infectious 
diseases (Stiehm et al., 2008). Conventional Abs are relatively complex molecules consisting of 
pairs of heavy and light chains, whose N-terminal domain is more variable than the rest of the 
protein sequence. The Ab Heavy chain consists of three Constant domains (CH1, CH2 and CH3) 
and a Variable domain (VH). The Light chain has only two domains, the Constant domain (CL) 
and the Variable domain (VL). Important glycosylations on the CH2 domain are necessary for Ab 
effector functions, such as Antibody-Dependent Cellular Cytotoxicity (ADCC) and Complement–
Dependent Cytolysis (CDC), and for regulating antibody half-time in serum (Figure 4A). Ab 
binding is determined by the 3 hypervariable Complementary Determining Regions (CDR1, 
CDR2 and CDR3) present in both the VH and VL domains. These regions are located in 
juxtaposed loops, creating a continuous surface of ~ 1000 Å2 that specifically binds to the 
Figure 6. Structure of the N1 neuraminidase complexes. A. Sialic acid (blue) docked into the active site 
of wild-type VN04N1 (yellow) ribbons, from superposition of Sia complex of N2 (Varghese et al., 1992) 
(PDB: 2BAT). The positions of some key binding residues are shown with carbons coloured yellow, 
nitrogens blue and oxygens in red. The side chains of three mutations conferring oseltamivir-resistance 
to IAV: Y252H (Tyr 252), H274Y (His 274) and N294S (Asn 294), are shown as wild type residues 
depicted with green carbons. B. The structures of Sia, zanamivir and oseltamivir with carbons colored 
in blue, grey and yellow, respectively, are shown in similar orientation with selected carbon atoms 
numbered. C – E. The overlaid structures of the active sites of wild-type (yellow) and mutants N1 NA 
(green) are shown with bound inhibitors colored similarly; relevant portions of electron density maps are 
shown. C. H274Y in complex with oseltamivir and D, with zanamivir.  E. N294S in complex with 
oseltamivir. Dashed lines indicate selected hydrogen bonds. F. The conformation of oseltamivir and Glu 
276 from three complexes is shown after superimposition using protein atoms only; the carbon atoms of 
the inhibitor from the N1 wild-type are colored yellow, the H274Y in dark green and the N294S in light 
green. The affinities (KI) oseltamivir to the three NA are given in parenthesis. Modified from Collins et 
al., 2008. 
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epitope of an antigen. Although all CDRs can potentially make contact with the antigen, CDR3 
contacts with the epitope are generally more extensive. The structural diversity of the antigen-
binding sites of a conventional Ab depends on the size of the CDR3 in the VH and the 
conjunction with the VL at different angles and distances. These are grouped in 3 different 
classes, according to the size and type of an antigen: cavities (fitting haptens), grooves (fitting 
peptides) and planar sites (fitting surface patches of proteins) (Johnson et al., 2010). 
 
1.9.2 SINGLE VARIABLE DOMAIN OF THE HEAVY CHAIN ANTIBODIES  
In 1993 a surprising observation was reported for antibodies of the Artiodactyl Tylopoda family 
(Camelidae). Next to conventional Immunoglobulin G Ab (IgG), camelids also naturally produce 
Heavy Chain Ab (HCAb) that lacks the light chain (Hamers-Casterman et al., 1993). Two years 
later, similar single chain antibodies were discovered in cartilaginous fish (sharks) (Greenberg et 
al., 1995). Although the CH2 and CH3 of the HCAb and the conventional Ab are highly 
homologous, there is no CH1 domain in the camelid HCAb. The HCAb Heavy chain single 
Variable domain (VHH) is the only domain of HCAb that makes contact with the antigen. 
Surprisingly, although the VHH have only three CDR regions, their affinity for antigens reaches 
the low nanomolar to even picomolar range, matching the best affinities of conventional Ab. 
When expressed as single domains (soluble VHH), the VHH retain their strong epitope 
specificity and affinity, a feature that might be explained by the VHH architecture (Figure 4B). 
Just like the VH of conventional Ab, the AA sequence of VHH is organised in CDR1, CDR2 and 
CDR3, separated by four Framework Regions (FR1-FR4) (Muyldermans et al., 1994). As the AA 
sequence of the VHH FR is highly similar to those of conventional VH, it was not surprising that 
the overall architecture of the VHH closely resembles that of VH (Muyldermans et al., 1994). 
Both VHH and VH domains fold into two β-sheets with the three CDRs that link these two 
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sheets at one end of the barrel (or domain) (Desmyter et al., 1996; De Genst et al., 2006) 
(Figure 4C, 4E).  However, there are striking structural differences between VHH and 
conventional VH. Evidently, VHH lack an interacting VL domain. Associated with this lack, the 
hydrophobic AA present at the VH surface that is normally interacting with the VL, are 
substituted by hydrophilic AA (Figure 4D). This enhances the solubility of VHH single domain 
proteins that usually have an enhanced solubility compared to engineered VH single domain 
proteins.  
Structural features likely compensate the absence of the additional CDR in VHH. First, the 
CDR3 regions of camelid VHH are generally longer (13-17 AA) than the CDR3 regions of 
mouse and human VH (9-12 and 9-17 AA, respectively) (Wu et al., 1993). In contrast to 
conventional Ab, in which the antigen binding surface is often a flat surface, a cavity or a 
groove, the long CDR3 loop may extend from the antigen binding surface (Desmyter et al., 
1996). This enlarges the paratope surface and hence the potential affinity and repertoire of 
camelid HCAb. In addition, especially in dromedaries, the CDR1 and CDR3 regions contain a 
cysteine, which allows formation of a second disulfide bridge next to the single disulfide bridge 
in conventional VH (Muyldermans et al., 1994). This extra bridge likely stabilizes the CDR loops, 
thereby reducing their flexibility. This probably also contributes to the affinity (less entropy is lost 
upon antigen binding) and structural diversity of VHH. Long extending CDR3 loops that are 
stabilized by an extra disulfide bridge can explain the tendency of VHH to bind to clefts and 
concave surfaces more readily than conventional Ab do (Figure 4F) (De Genst et al., 2006). 
Indeed comparison of multiple structures of hen egg white lysozyme interacting with either 
several conventional human Ab or several camelid VHH clearly illustrated that VHH tends to 
bind to the concave substrate-binding pocket, whereas conventional antibodies favour epitopes 
on the “flat” surface of the antigen (Figure 4C). In addition, whereas each of the three CDRs of 
conventional VH contributes considerably to the interaction with antigen, VHH depended mainly 
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on the CDR 3 loop for this interaction. Other antigens that are hard to target by conventional 
antibodies, but can be targeted by camelid VHH are ion channels, GPCRs, haptens and 
enzymatic sites (Lauwereys et al., 1998; Rasmussen et al., 2011). 
Next to an extended CDR3, the AA sequence of the H1 loop that precedes and comprises 
CDR1 appears to be particularly more variable in camelid VHH than in conventional VH. This 
might be interpreted as an extension of the VHH CDR1 (Vu et al., 1997). Associated with this 
high variability in camelid VHH, CH1 loops adopt conformations that deviate from the canonical 
H1 structures of conventional VH (Barre et al., 1994) (Decanniere et al., 1999; Decanniere et al., 
2000). Camelid VHH CH1 loops appear to fold into a more diverse repertoire of structures. The 
high variability in the AA sequence and conformations of the CH1 loop contribute to the VHH 
paratope size (850-1150 Å2), which approaches that of conventional antibodies (VH + VL) 
(Desmyter et al., 2002). Clearly, different biochemical and structural features of camelid VHH 
compensate for the lack of a VL domain and allow a broad repertoire of specific high affinity 
antigen interactions. In addition, due to their small size and typical extruding CDR3 regions, 
camelid VHH tend to bind in cavities that are not readily accessible for conventional Ab. Next to 
these particular features, VHH single domain protein is exceptionally stable and soluble, even in 
stringent conditions. As VHH are small and naturally monomeric, they can be easily formatted. 
In addition, the small size of VHH allows them to penetrate deeper into tissue (i.e. tumor tissue) 
and to occasionally cross the blood-brain barrier. On the down side, the small size of single 
domain VHH contributes to their rapid clearance from circulation. 
Using display technologies, it is possible to select VHH from large, synthetic or naive libraries 
(Verheesen et al., 2006). Nevertheless, the phage display generated from an immune VHH 
repertoire is the most widely and powerful technique used nowadays to rapidly select VHH with 
the desired specificity (Arbabi Ghahroudi et al., 1997). VHH are easily produced in bacterial or 
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yeast systems in milligram quantities per litre of culture. The VHH stability, solubility, ease of 
production and small size make them excellent candidates for multivalent formatting. Tailor-
made constructions using VHH as building blocks enhance the avidity of the molecule even in a 
3-log scale, and several constructions are being tested in clinical trials (Els Conrath et al., 2001; 
Hmila et al., 2010). The VHH high potential as therapeutics had prompted the creation in 
Belgium of the biotechnological company Ablynx in 2001. Because of the publicity surrounding 
nanotechnology and the small size of the VHH, Ablynx named the VHH as “Nanobody”, and 
retains full intellectual property rights of the use of VHH in therapeutics and diagnosis. In the 
field of therapy nowadays only one monoclonal antibody is used against infectious disease 
(Synagis) (Groothuis and Simoes, 1993).  
Several examples of successful VHH treatment against viral infection in vitro and in laboratory 
mice have been reported (Hultberg et al., 2011; Ibanez et al., 2011; Schepens et al., 2011). 
These studies were mainly based on the use of VHH (monovalent or bivalent) molecules with 
virus-neutralizing activity i.e. that could prevent viral binding to the host cell in vitro. Another 
report mentioned the use of a VHH directed against M2 that could suppress replication of 
amantadine sensitive and resistant IAV strains and protected mice from lethal IAV challenge, 
and also showed cross-protective potential (Wei et al., 2011). These reports indicate that the 
VHH cannot only have antiviral capacity by blocking the binding of the IAV virion, but also can 
be used in other strategies to prevent virus spread. Effective anti-IAV alternatives are needed 
for the HPAIV treatment, and among them, the VHH technology is a promising tool. 
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Figure 7. Representative diagrams of a conventional Ab, an HCAb, and a VHH. A. A conventional Ab is a 
dimeric molecule, and each monomer comprising a heavy chain and a light chain. The heavy chain consists 
of the constant domains (CH1, CH2 and CH3) and the variable domain (VH). The light chain has only one 
conserved domain (CL) and a variable domain (VL). Important glycosylation sites (orange stars) are present 
in CH2, which is responsible for effector functions and the flexibility of the molecule. B. The HCAb is devoid 
of the light chain, and the CH1 is the paratope represent only in the single variable domain (VHH). C. The VHH 
can be expressed as a prolate-shaped, soluble molecule of ~15 kDa, with. The yellow square shows the 
antigen-binding site. D. The VHH sequence is made of four Framework Regions (FR1, light gray; FR2, cyan; 
FR3, magenta and FR4, yellow), and three Complementary Determining Regions (CDR1, green; CDR2, blue 
and CDR3, red). Residues F37, E44, G47and R45 (orange) are located in the FR2 and mask a hydrophobic 
patch. The dotted red line represents a disulfide bond between the FR2 and the CDR3; this bond stabilizes 
the molecule. E. A three-dimensional structure of an anti-lysozyme VHH, showing the typical Ig folding of β 
sheets, five strands in the front (roman numerals: I – V) and four strands in the back (VI – IX). The enlarged 
yellow square shows the antigen-binding site; formed by juxtaposition of three CDR. F. The VHH shown in G, 
is represented in complex with lysozyme (light blue). A protruding paratope consisting mainly of CDR3 (red) 
recognizes and binds the catalytic cleft of lysozyme, inhibiting its activity. C-, carboxy - terminal. -N, amino -
terminal. 
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1.9.3 NEURAMINIDASE-SPECIFIC ANTIBODIES  
The principal anti-IAV strategy is to induce protective humoral immunity against IAV 
immunogens by seasonal vaccination, which in turn is mainly based on neutralising Abs against 
HA. The level of protection against IAV depends on several factors: the composition and 
formulation of the seasonal vaccine, the circulating IAV in the population, and the level of pre-
existing Abs induced by previous vaccination or virus exposure. Antibodies targeting HA can 
neutralize IAV infectivity, because HA Abs can impede the HA binding into its cellular receptor, 
resulting in the absence of replication, also known as sterile immunity. Several HA Abs with 
prophylactic and therapeutic potential have been reported, but until recently the majority of the 
Abs only conferred protection to homologous or closely related IAV infection. 
Besides conventional Abs, also camelid VHH targeting HA were able to inhibit HPAIV infection 
and rescue challenged mice (Ibanez et al., 2011). In this study, the binding of the VHH close to 
the receptor-binding domain in the HA membrane distal part, contributed to the binding inhibition 
properties. However, the continuous antigenic drift of the HA from previous and current IAV 
vaccine compositions poses a serious challenge towards achieving reliable cross-protection 
(Carrat and Flahault, 2007). Recent reports had showed the capacity of broadly neutralizing HA 
antibodies to protect mice and ferrets, posing the importance of antibodies targeting conserved 
regions in IAV glycoproteins (Corti et al., 2011; Lingwood et al., 2012) 
NA-specific Abs are not expected to prevent infection by neutralising the virus, but instead can 
likely reduce the efficient release of virus from infected cells by blocking the cleavage of the Sia 
residues to which the newly formed viruses are attached, provided that such Ab have NA 
inhibition activity (Johansson et al., 1989). Consequently, anti-NA Abs can decrease virus 
shedding and hence reduce the severity of the IAV infection.  
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 M2e-based vaccination in mice has been found to induce Ab response against the conserved 
M2e region, offering protection against challenge with different IAV subtypes (Neirynck et al., 
1999; Tompkins et al., 2007). In addition, clinical phase I studies with M2e-vaccine candidates 
have been completed and demonstrated their safety and immunogenicity in humans (Schotsaert 
et al., 2009). In addition, a humoral response following infection is also raised against the NP 
and M1 proteins. However, due to the internal location of these components, the protection 
conferred has not been proven to be significant (Brugh et al., 1979; Webster et al., 1991). Abs 
against internal antigens are non-neutralizing and disappear more rapidly. Besides the 
neutralisation of infectivity or blocking of the release of virus (i.e. Abs against HA or NA), Ab can 
also induce immunological responses like CDC or ADCC.  
Nevertheless the NA content in the vaccine formulation is low and variable. In the recent years, 
the inclusion of the NA into the seasonal formulation of the IAV vaccines had been proposed, in 
order to increase the immunity of the vaccines and enhance cross-protection (Johansson and 
Brett, 2008; Bright et al., 2009). The NA Ab response can be easily monitored by NA inhibition 
assays. Nevertheless, a suitable substrate that can be used effectively is still missing, due to the 
variant capacity of elicited Ab to inhibit the NA activity using fluorogenic and chromogenic 
substrates (Sandbulte et al., 2009). The NA had been mutating faster than the HA recently, 
enforcing the importance of including NA in vaccines. The fact that the NA substrate specificity 
is not the same as HA specificity, suggested HA-NA substrate affinity mismatch (Gulati et al., 
2005).  
How could NA-specific Abs suppress influenza virus infectivity?, Abs raised against the NA does 
not interfere with the IAV binding to the host cell, but it does decrease the release of newly 
produced virus from infected cells, resulting in plaque size reduction (Kilbourne et al, 1968). 
Structure determination of antibody-antigen complexes by X-ray crystallography remains the 
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only definitive way to learn how an Ab recognizes and binds to the surface of its antigen. 
Specific NA Abs targeting regions close to or in the rim of the catalytic site (Figure 5A) can 
result in inhibition of the NA catalytic activity. The relevance of the inhibition of the NA catalytic 
activity in the NA-Ab protection is highlighted by the fact that only Abs with NA inhibitory 
capacity had been able to select antigenic variants or escape-mutants in vitro. Several NA 
mAbs had been reported, most of them targeting NAs belonging to group 2 (Table 1). In the Ab-
antigen complex there is clear shape and biochemical complementarity, hydrogen bonds, van 
der Waals interactions, salt links or water molecules trapped at the interface, all contribute to the 
overall binding energy. Surprisingly, despite the growing importance of the NA contribution to 
the Ab response, only three NA-Ab complexes had been resolved by X- ray, all of them from 
group 2 N9 (see references in table 1). The information of the location of the NA epitope and a 
detailed interface structure had played a significant role in the understanding of the NA antigenic 
drift and catalytic site.   
One of the first reports of NA inhibitory Ab, was the panel of 8 mAbs reported by Jackson and 
Webster (Jackson and Webster, 1982), raised against a H2N2 virus, A/Tokyo/3/67. Seven of 
these mAbs were able to inhibit the activity of the NA of purified virus, using a macromolecular 
substrate, such as fetuin (50 kDa) (Table 1). Remarkably, four of those mAbs (23/9, 25/4, S25/3 
and S32/3) were able to inhibit the NA activity using the small substrate N-acetylneuraminyl 
lactose (NAL) (600 Da). Unfortunately, the inhibitory effect of these mAbs was not further 
characterized, neither an inhibitory concentration (IC50) were reported. Interestingly, it was also 
reported that a HA Ab (mAb 123/4) partially inhibited the NA activity, suggesting that the binding 
of a HA Ab can affect the NA access to substrate by steric hindrance (Table 1) (Jackson and 
Webster, 1982). A much bigger panel of mAbs was used by Webster  for the antigenic and 
biological characterization of a H2N2 NA (R1/5+/57) (Webster et al., 1984). The panel of mAbs 
was used to map 4 putative overlapping antigenic regions in the pronase-released N2, 
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according to NA inhibition assays and competitive radioimmunoassay. The putative antigenic 
regions 1 and 4 appeared far from the NA catalytic site, but different between each other, since 
region-specific mAb competition was absent. Nevertheless, the mAbs targeting the antigenic 
regions 1 and 4 failed to inhibit the NA activity using fetuin or NAL substrates. In contrast, the 
mAbs recognizing the antigenic regions 2 and 3 inhibit the NA activity, using the fetuin 
substrate. In addition, the mAbs targeting the antigenic region 2 were also subdivided in 4 
subgroups, or 4 overlapping epitopes within the region 2, and these mAbs were also able to 
inhibit the growth of IAV in chick embryos and allowed selection of antigenic variants. 
Surprisingly, only 2 mAbs recognizing antigenic region 2 (subgroup 2D, 266/4 and 509/3) were 
able to inhibit 50 – 80 % of the NA activity using NAL as substrate (Table 1). These results 
suggested that the subgroup 2D epitope is in close proximity to the catalytic site of the NA. An 
interesting observation in this study was the fact that several NA mAbs inhibited the 
hemagglutination of crude virus, possibly by proximity of HA and NA protein spikes on the virion, 
allowing steric inhibition of the HA binding with Abs to NA and vice versa. 
 
1.9.4 N9 mAb NC41 AND NC10 
The mAb NC41 was originally part of a panel of 35 mAbs raised against a pronase-released N9 
(H11N9, derived from A/tern/Australia/G70c/75), and were used to determine N9 antigenic 
structure by selection of antigenic variants. The N9-NC41 complex was analyzed because NA 
yielded large protein crystals that were X-ray diffraction quality, and the three-dimensional 
structure of this complex was obtained (Colman et al., 1987; Colman et al., 1989). The contact 
residues in N9 responsible for the surface binding in the complex N9-NC41 are: 323 – 350, 368 
– 370, 400 – 403, and 430 – 434 (N2 numbering) (Figure 8A) (Tulip et al., 1992). Nineteen AA 
residues on the N9 are in contact with 17 on the NC41 mAb. The surface areas buried in the 
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antigen and antibody complex formation are each 800 Å2, comprising 12 hydrogen bonds and 
three ion pairs in the interface (Table 1). Several mAbs of the panel were able to inhibit the N9 
activity using fetuin and NAL as substrates. Nevertheless, the 3-D structure of this complex 
showed that the Fab fragments of the NC41 were not blocking the access of the NAL substrate 
to the N9 catalytic site. This suggested that the low N9 catalytic activity derives from the 
displacement of its residue R371, which in the complex N9-NC41, points out directly into the 
catalytic site (Colman et al., 1987). In addition, the mutation R371K resulted in the loss of 90 % - 
95% of NA catalytic activity. The N9-NC41 complex solving was an example of dynamics into 
antigen-antibody complex formation, due local perturbations of the antigen in the centre of the 
N9 epitope, challenging the rigid “lock-key” model (Colman et al., 1987). Interestingly, the 
N329D and I368R mutation in the N9 did not affect greatly the NC41 binding. The structure of 
the N9 of both mutants with NC41, showed local relaxation of both the Ab and antigen 
structures (compared to the wild type N9 – NC41 complex) around the mutation, suggesting 
what was called “promiscuous” aspect of immune surveillance. Mutations within the NC41 
binding site had little or no effect in N9 affinity, which could be supported by the flexibility of the 
VL-VH interface in the Fv fragment of the Ab. In addition, the NC-41 studies showed that the 
loss of hemagglutination activity in N9 (substitutions in the residues 367, 369, 370, and 372) did 
not affected the NA activity, leading to propose that the hemagglutination site of the N9 was 
separated from its catalytic site (Webster et al., 1987). 
In similar way that the NC41, the NC10 was also part of a panel of mAbs against a N9, and the 
N9 -NC10 complex X-ray structure was reported by Malby (Malby et al., 1994; Tulip et al., 1994; 
Malby et al., 1998). The NC41 and NC10 antigenic epitopes overlap, having approximately 70% 
of surface residues in common, but different residues were found to make the most critical 
contributions to the NC41 and NC10 complex stabilities. Compared with NC41 epitope, the 
NC10 epitope has different energy calculations when complexed with N9, like lower ΔG values 
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than the NC41 epitope and the major contributions are made by K432, N329 and mannose 
200F. Interestingly, the “shape complementarity” (Lawrence and Colman, 1993) measure of the 
complexes of N9 with NC10 and NC41, is 0.65 or 0.66, respectively (Malby et al., 1994), very 
similar, suggesting there are another factors to contribute to the differences within the complex 
interface. On the contrary to the NC41 complex, the NC10 complex posses several water 
molecules in the interphase, where they increase the surface buried within the complex as well 
as increasing the shape complementarity. The water molecules in this complex not only help 
filling the cavity and enhance surface complementarity, but they also serve to bridge hydrogen 
bonds between the two proteins, therefore acting as adaptors. The role that water molecules 
play in shaping complementarity may explain why the N9 - NC10 interaction is not mediated by 
just a subset of critical contacts, as seen in the N9 - NC41 complex, were water is excluded 
(Lee and Air, 2002, Novotny et al., 1994) (Table 1). It is thus possible, for two different Abs, to 
recognize the same protein surface in strikingly different ways.  
 
1.9.5 N2 mAb Mem5 
The mAb Mem5 recognizes an antigenic site in N2 that is subject to antigenic variation. The 
Mem5 binds to loops surrounding the N2 active site cavity. In contrast, the Mem5 epitope is in 
the opposite site to the region bound by the mAbs NC10 and NC41 to N9, which is away from 
the active site. The Mem5 can inhibit NA activity upon the cleavage of macromolecular 
substrates (fetuin), but it was only capable of inhibiting the activity of NA small substrates by 40 
% (Table 1) (Gulati et al., 2002). The Mem5 CDRs have canonical structures, and 6 CDR are in 
contact with N2, while only 4 and 5 CDRs are involved in the N9 contact with NC10 and NC41, 
respectively. The contact surface of the N2 and the Mem5 is 2622 Å, bigger than the N9 
complexed with NC10 and NC41 (1413 and 1815 Å, respectively). The epitope of the Mem5 in 
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the N2 consisted of 4 loops in N2: 146-157 195-202, 216-231 and 243-251 (Figure 8B) (Lee and 
Air, 2006). This binding of Mem5 partially occludes the N2 active site. The Mem5-N2 contact 
surface is also contributed by the N200 carbohydrate moiety, which is also important in the N9-
NC10 complex, and its lack results in a decreased NA activity probably by misfolding of the NA. 
There are 33 direct contacts between Mem5 and N2, including 3 salt bridges (D147, H150 and 
E199), 14 hydrogen bonds and 16 van der Waals interactions. In a similar way that NC41, the 
N2-Mem5 complex have residues  with major contribution to the binding, R249, K221, E199, 
H150, all of them accounting for the 30 % of the binding surface. In addition, substitutions in the 
residues 198, 199, 220 and 221 had been identified in Mem5 escape-mutants. This structure 
also showed a higher level of hydratation in the contact surface, (the N9-NC10 complex did not 
contain any water molecules and the N9-NC41 contained only 3) the N2-Mem5 contains 58 
water molecules in the surface (Venkatramani et al., 2006). The water molecules are important 
because they fill up the gaps where the surfaces do not have shape complementarity, but this is 
not the case for the Mem5-N9 interface complex. Nevertheless, the residue E199, which 
contributes greatly to the contact surface and is mutation is present in several escape-mutants 
but is surrounding in a dry island without any water molecule. 
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Figure 8. Crystallographic structures of the N9-NC10 and N2-Mem5 complexes. The NA monomers (green 
ribbons) have the catalytic site in surface representation, sharing the residue colour code of figure 2. The 
MAb heavy and light chain are in magenta and cyan, respectively. A. The N9-NC10 complex. The AA 
residues in N9 that make contact with NC10 are in orange and are not close to the N9 catalytic site (PDB: 
1NMC). B. The N2-Mem5 complex. Compared to the NC10, the Mem5 epitope is within the rim of the 
catalytic site, with several residues of the “150-loop” part of the epitope (PDB: 2AEP). 
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Table 1. Comparison of NA-specific mAbs 
mAb 23/9 * 509/3 * NC41 NC10 N8-4 N8-10 Mem5 
IAV  H2N2 
Tokyo/3
/67 
H2N2  
R1/5+/57 
H11N9 
Tern/Australia/
G70c/75 
H11N9 
Tern/Aus
tralia/G70
c/75 
H1N8 
WS/duck/U
kraine/1/63 
H1N8 
WS/duc
k/Ukrain
e/1/63 
H3N2 
Memphi
s/31/98 
NA 
epitope  
ND ND 323 – 350, 368–
370, 400-403, 
430–434 
328-332, 
341-344, 
366-370, 
400-403 
ND ND 146-157, 
195-202, 
216-231, 
243-251 
Escape 
mut. 
sites &  
221, 253, 
344, 368, 
370, 403 
150, 329, 
334, 344, 
368, 370, 
403 
220, 329, 367, 
368, 369, 370, 
372, 400, 432 
§
 
 150, 199, 
284, 344, 
346, 367, 
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CHAPTER 2: AIMS 
 
2.1 SCOPE 
The huge economical and animal welfare impact as well as the pandemic threat associated with 
highly pathogenic avian Influenza A virus (HPAIV) H5N1 outbreaks remain a major concern. An 
enormous economic and social burden was seen in Asiatic countries during 1997 – 2005, where 
the poultry industry has been devastated, due to the high lethality of HPAIV in chickens and as 
a result of massive culling of HPAIV infected birds, the prime containment strategy. Moreover, in 
Hong Kong, in 1997 the first human casualties directly attributed to avian HPAIV were reported 
(de Jong et al., 1997). Since 2003, more than 600-laboratory confirmed cases of H5N1-infected 
humans have been reported in 15 countries 
(www.who/int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/index.ht
ml), where a mortality rate of 60% was seen. Compared with seasonal influenza infections, 
human HPAIV infection are more severe, presenting a higher replication rate, broader cellular 
tropism, systemic spread resulting in high levels of circulating proinflammatory cytokines and 
chemokine (de Jong et al., 2006; Gu et al., 2007; Baskin et al., 2009). Specific antiviral 
treatment options of hospitalized H5N1-infected patients are largely limited to the NA inhibitor 
oseltamivir. However, high doses appear to be required for a systemic treatment, and very often 
drug-resistant viruses emerge in the course of such treatments (Gooskens et al., 2009). In 
addition, two recent reports provided experimental evidence that H5N1 viruses can likely evolve 
into variants with human-to-human transmission. Although these studies were performed in 
ferrets and demonstrated that  HPAIV H5N1 viruses can be selected that acquired airborne 
transmission between ferrets, the findings renewed the concerns of public health care officials  
that H5N1 viruses may eventually become human-to-human transmissible (Herfst et al., 2012; 
Imai et al., 2012). Today, the fastest measure against such a pandemic influenza virus outbreak 
CONFIDENTIAL Page 57 
 
is still the use of antivirals such as oseltamivir and Relenza to mitigate disease in infected 
patients.  
However, the clinical benefit of the use of e.g. oseltamivir is modest at best and based on meta-
analysis of reported clinical trials even uncertain (Jefferson et al., 2012; Wang et al., 2012).  
Furthermore, to implement small compound drugs such as the NA-inhibitors oseltamivir or 
Relenza on a vast scale (global population, use in poultry) is unrealistic and too expensive. 
Despite these short comings, even today, oseltamivir (Tamiflu) as a treatment for seasonal 
influenza represents a blockbuster for Roche. 
For this PhD project, the aim was to generate and evaluate a novel strategy to try to control 
H5N1 virus infections in vitro and in vivo, the latter in experimental mouse model. First, our aim 
was to target NA because it is an enzyme that is very important in the viral life cycle. In addition, 
NA is targeted by the human humoral immune system and is subjected to antigenic drift and 
shift. Antibodies directed against NA have antiviral activity, which has been best documented for 
antibodies that block NA activity. Based on this rational, we proposed a strategy that takes 
advantage of the potential of camel single chain antibodies (VHH). Our aim was to select VHH 
antibodies that inhibit NA activity. Ideally the binding of such VHH molecules to NA would 
involve essential contacts with the conserved residues that make up the catalytic cleft of the 
enzyme; VHH appear to be uniquely capable of recognizing catalytic clefts in enzymes (De 
Genst et al., 2006). NA-specific VHH with antiviral potential could possibly also recognize 
conserved epitopes on the surface of NA. Finally, our aim was to take advantage of two robust 
expression platforms for these VHH molecules: E. coli, allowing the expression of VHH in simple 
mono- and dimeric format and an Arabidopsis thaliana seed-directed expression platform that 
allows the expression of high amounts of Fc-tailed dimeric VHH-based biologicals. Ultimately, 
and beyond the scope of this thesis, a seed-based expression system for recombinant NA-
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targeting VHH could be explored further as an economical production platform for oral delivery 
of the antiviral as a crude extract or even as intact seeds, to domesticated birds. 
 
2.2 OBJECTIVES 
The first step of the project was to produce recombinant H5N1 Neuraminidase for camelid 
immunization. NA is a membrane bound tetrameric glycoprotein. NA is enzymatically active as a 
tetramer. As an immunogen we decided to use soluble recombinant N1 NA, named N1rec, 
which was engineered as a soluble protein, where the NA cytoplasmic, transmembrane and 
stalk domains were substituted for a type I secretion signal followed by a yeast-derived 
tetramerization domain GCN4. A Baculovirus platform was chosen to produce a soluble 
tetrameric N1rec in insect cells, because is an efficient platform for the production of complex 
proteins, including mammalian or avian-origin proteins. Purified N1rec, derived from A/crested 
eagle/Belgium/01/2004, was then used to immunize an alpaca. N1rec-binding VHH (N1-VHH) 
were selected from an immune phage library by panning with the antigen. The N1-VHH 
candidates would then be produced in bacteria (Escherichia coli) as soluble monovalent 
proteins for further characterization (N1-VHHm). The inhibitory capacity of the N1-VHH against 
N1rec was assessed and correlated with antiviral activity in H5N1 infected cells in vitro. The N1-
VHH that showed the most potent antiviral activity were then formatted as bivalent molecules in 
order to increase affinity by introduction of avidity, in two different production platforms. As a first 
approach, the selected N1-VHH genes would be designed in an expression cassette comprising 
2 VHH genes in tandem, fused by a flexible linker and produced in bacteria (N1-VHHb). In the 
second approach, more complex bivalent molecules would be plant-produced, and targeted as 
seed storage proteins in Arabidopsis thaliana. The selected N1-VHH genes would be fused to a 
mouse IgG2a Fc sequence, resulting in two N1-VHH molecules fused by their Fc moiety (N1-
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VHH-Fc). All the bivalent formats of the N1rec-binding VHH were first evaluated in vitro and 
subsequently in vivo, in a mouse model of H5N1. Both a clade 1 and a clade 2 H5N1 virus 
would be used as well as an oseltamivir-resistant virus. 
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ABSTRACT 
Although the influenza virus neuraminidase (NA) is the target of several antiviral drugs (e.g. 
oseltamivir) and has a major immunogenic potential, the inclusion of NA in vaccine formulations 
has been largely neglected. We immunized an alpaca with H5N1 NA recombinant protein, 
derived from the highly pathogenic influenza virus A/crested eagle/Belgium/09/2004. An 
immune phage library was constructed and H5N1 NA-binding single chain camelid (N1-VHH) 
was isolated by panning. Two monovalent N1-VHHs (N1-3-VHHm and N1-5-VHHm) showed 
strong inhibition of the NA activity, and also antiviral activity in cell-based assays, against clade 
1 and 2 H5N1 virus. We introduced bivalency into the N1-3-VHH and N1-5-VHH in two bivalent 
formats: the bacteria-produced N1-VHHb (two N1-VHH moieties fused by flexible linker); and 
the plant-produced N1-VHH-Fc (N1-VHH moiety fused to a mouse IgG2a Fc). The in vitro 
antiviral potency of both bivalent formats was increased 10– to 100-fold, compared to their 
monovalent counterparts. Using a murine model, we assessed the in vivo antiviral potential 
using a single-dose of N1-VHH treatment at 24 hours before a lethal challenge of H5N1 virus. 
Sixty µg treatment with N1-3-VHHb or N1-5-VHHb rescued Balb/c mice, with a survival of 100%. 
The plant-produced formats showed an increased protection in mice. The single-dose N1-3-
VHH-Fc and N1-5-VHH-Fc treatment of 17 or 3.5 µg, respectively, also rescued 100% of H5N1 
challenged mice. The N1-5-VHH-Fc treatment in mice presented a less severe morbidity, 
compared with N1-3-VHH-Fc, and was dose-dependent. Next, we used a mutant H5N1 virus, 
carrying the H274Y substitution in the NA (H5N1 H274Y), to assess the antiviral potential of the 
N1-VHH in an oseltamivir-resistant virus. The single dose treatment N1-3-VHHb and N1-3-VHH-
Fc (60 and 84 µg, respectively) rescued 100% of H5N1 H274Y challenged mice, but the 
morbidity was severe. We did not observe antiviral effects of the N1-5-VHH in any format 
against the H5N1 H274Y. These pieces of evidence highlight our N1-VHH as a promising 
alternative to influenza virus treatment, with veterinary and clinical potential. 
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INTRODUCTION 
Zoonotic influenza A virus (IAV) infections are a persistent threat because their pandemic 
potential. In particular, highly pathogenic avian influenza viruses (HPAIV) of the H5N1 and 
H7N7 subtypes occasionally cross the species barrier between domesticated birds and human. 
Whether these viruses could become transmissible between humans through reassortment with 
circulating swine or human IAV or by gradually accumulating mutations, remains very difficult to 
predict (Carrat and Flahault, 2007). In the last decade, two zoonotic outbreaks had a major 
impact on public health: the HPAIV H5N1 (Tran et al., 2004) and the swine flu (H1N1) or 
“Mexican flu” outbreak in 2009, confirmed the lack of preparedness against pandemic influenza 
(Ilyushina et al., 2010). 
HPAIV H5N1 influenza virus infection in humans leads to an unusual high mortality, reaching a 
60% mortality rate (Chotpitayasunondh et al., 2005). The high pathogenicity of HPAIV H5N1 in 
humans can be attributed to a high replication rate and a broad cellular tropism that can lead to 
a systemic spread. A deregulated induction of proinflammatory cytokines and chemokines 
(sometimes called “cytokine storm”) is associated with severe HPAIV H5N1 infections, and can 
result into an excessive immunological response (de Jong et al., 2006). The treatments reported 
and available against HPAIV H5N1 are far from been optimal: treatment with convalescent 
plasma for influenza A (H5N1) infected patients had been shown to be protective (Zhou et al., 
2007) as well as a risky combination of antiviral drugs and immunomodulators (White et al., 
2009). 
Effective anti-influenza alternatives are needed for the HPAIV H5N1 treatment, and among 
them, the single chain monoclonal antibody technology is a promising tool. Naturally occurring 
single chain antibodies had been found in sharks (Greenberg et al., 1995; Dooley et al., 2003) 
and camelids (Hamers-Casterman et al., 1993). The camelid single domain antibodies 
CONFIDENTIAL Page 62 
 
represent a new promising alternative in the monoclonal antibody repertoire (Muyldermans et 
al., 1994). The variable domains of the functional heavy-chain antibodies (VHH) discovered in 
camels are related to the human VH subgroup III (Nguyen et al., 1998). Their specificity, 
robustness, ease of production and flexibility had prompted a long lasting research as binding or 
stabilizing moieties, or building blocks for therapeutics (Coppieters et al., 2006). The VHH tends 
to target epitopes with concave topology, in contrast with the planar epitopes recognized by 
“classical” light and heavy chain antibodies (De Genst et al., 2006). The protruding paratope in 
the Complementary Determining Region 3 (CDR3) had been reported to be a major contributor 
to the binding contact surface. The VHH small and robust format permits the design of tailor 
made VHH, boosted by the identification of stable “frameworks” in the VHH structure that allows 
CDR grafting (Saerens et al., 2005). Some of the most promising described properties of the 
VHH are inhibitors for several enzymes, and stabilizing moieties for membrane bound proteins 
that permit their crystallization (Lauwereys et al., 1998; Decanniere et al., 1999; Decanniere et 
al., 2000; Desmyter et al., 2002; Rasmussen et al., 2011). It has also been reported that the 
VHH showed an affinity to its antigen even in the nanomolar to picomolar range (Ward et al., 
1989), matching the best affinity ever reported into the “classical” antibodies. The reported high 
affinity and inhibitory properties of the VHH make them an attractive tool against influenza 
proteins. In addition, several examples of successful VHH treatment against viral diseases have 
been reported (Hultberg et al., 2011; Ibanez et al., 2011; Schepens et al., 2011). Also, a VHH 
against M2 resulted in the inhibition of the replication of amantadine-sensitive and -resistant 
influenza virus strains and protected mice from lethal influenza challenges, with cross protective 
potential (Wei et al., 2011). All these pieces of evidence indicate that VHH can not only have 
antiviral efficiency by blocking the binding of the influenza virion (VHH against HA), but also can 
be used in other ways to prevent virus spread. Here we report on the isolation and 
characterization of VHH directed against NA from an HPAIV H5N1 virus. We demonstrate the in 
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vitro and in vivo antiviral potential of NA-binding VHH (N1-VHH) against oseltamivir-sensitive 
and -resistant strains. 
 
MATERIALS AND METHODS 
H5N1 INFLUENZA VIRUS 
H5N1 IAV strains NIBRG-14 and NIBRG-23 were obtained from the UK National Institute for 
Biological Standards and Control, a center of the Health Protection Agency. NIBRG-14 and 
NIBRG-23 are 2:6 reverse genetics–derived reassortant of NA and HA derived from 
A/Vietnam/1194/2004 (H5N1) or A\turkey\Turkey\2005 (H5N1), respectively, and A/PR/8/34 
(H1N1) viruses. The H5N1 H274Y is a 1:1:6 reverse genetics-derived reassortant with the NA 
derived from A/crested eagle/Belgium/09/2004 (Van Borm et al., 2005) (with the H274Y 
mutation introduced by site-specific mutagenesis), the HA from A/Vietnam/1194/2004 and the 
remaining six genome segments from A/PR/8/34. All of the HA segments of these H5N1 viruses 
lack the coding information for the polybasic cleavage site, hence making them acceptable for 
use in BioSafety Level (BSL-2) facilities. Following adaptation to Balb/c mice, the HA and NA-
coding regions of the mouse-adapted NIBRG-14 (NIBRG-14 ma) and H5N1 H274Y (H5N1 
H274Yma) were sequenced and found to be identical to those of the parental viruses. The 
median Tissue Culture Infectious Dose (TCID50) and median Lethal Dose (LD50) of NIBRG-14 
ma and H5N1 H274Yma virus were determined using the method of Reed and Muench. All 
H5N1 IAV experiments above described, were performed in BSL-2 rooms with negative 
pressure relative to adjoining rooms.  
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BACULOVIRUS-BASED PRODUCTION OF RECOMBINANT SOLUBLE TETRAMERIC NA 
We produced enzymatically active, soluble tetrameric NA (N1rec) derived from A/crested 
eagle/Belgium/01/2004 (H5N1) using proprietary technology (WO 2002/074795). N1rec was 
produced using a recombinant baculovirus expression system in Sf9 cells. The N1rec 
expression cassette (n1rec) consisted of: the secretion signal of IAV HA type 1 (ssHA, 16 
residues), the leucine zipper, derived from Saccharomyces cerevisiae, transcription factor 
GCN4 (tGCN4, 32 residues) (Harbury et al., 1993) (De Filette et al., 2008) and the extracellular 
part of the H5N1 NA derived from A/crested eagle/Belgium/09/2004 (53–449 amino acid 
residues) (Van Borm et al., 2005) (Figure 2). This expression cassette was cloned into a 
pAcMP2 Baculovirus transfer vector (BD Biosciences®), resulting in the pAcMP2n1rec vector. 
Recombinant baculovirus was generated by co-transfection of pAcMP2n1rec with linearized 
Autografa californica Nuclear Poliedrosis Virus (AcNPV) DNA, BaculoGold (BD Biosciences®), 
into Sf9 insect cells (derived from Spodoptera frugiperda), using the ESCORT IV Transfection 
Reagent (Sigma®). The resulting recombinant AcNPVN1rec virus was used for infection of Sf9 
cells. Sf9 cells were incubated at 28 °C in rolling bottles in TC-100 medium (Invitrogen®), 
supplemented with 10% FCS and penicillin/streptomycin. Four days after infection, the 
supernatant was harvested and clarified by centrifugation (1 hr at 50,000 g). 
NEURAMINIDASE ACTIVITY ASSAY  
NA activity was quantified by determining the rate of cleavage of the fluorogenic substrate 4-
MUNANA (2’-4-Methylumbelliferyl-α-D-N-acetylneuraminic acid, sodium salt hydrate, 50 mM, 
dissolved in deionized water, Sigma-Aldrich®) into 4-methylumbelliferone. The NA activity 
reaction was performed in 200 mM NaAc, 2 mM CaCl2, 1 % butanol and 1 mM 4-MUNANA and 
measured in a kinetic mode, with excitation at 365 nm and emission at 450 nm in an Optima 
Fluorostar®. A standard curve of increasing concentrations of soluble 4-methylumbelliferone 
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was included to correlate the fluorescence intensity with the molar amount of 4-
methylumbelliferone. One NA activity unit is defined as 1 nmol of 4-methylumbelliferone / min.  
RECOMBINANT NEURAMINIDASE PURIFICATION 
Two parts (v:v) of n-butanol were added to 3 parts of cleared AcNPVN1rec infected Sf9 cells 
supernatant and the resulting mixture was shaken vigorously for 5 minutes. The aqueous 
phase, containing the soluble N1rec, was separated from the organic phase, and was 2.5 times 
diluted in 5 mM KH2PO4 pH 6.6 and 0.22 µm filtered. The diluted aqueous phase was 
subsequently applied to a HA Ultrogel® Hydroxyapatite Chromatography Sorbent (Pall®) 
packed XK26\70 column (GE Healthcare®), and eluted with a gradient of 5 – 400 mM KH2PO4 
pH 6.6, 4 % butanol. Eluted fractions with NA activity were pooled and loaded onto a Blue 
Sepharose (Sigma-Aldrich®) column, and equilibrated with 50 mM MES pH 6.6, 5 % glycerol, 8 
mM CaCl2. Bound proteins were eluted by a single step elution with 50 mM MES pH 6.6, 5 % 
glycerol, 8 mM CaCl2, 1.5 M NaCl. Eluted fraction with NA-activity were subsequently loaded on 
a HiLoad 16/60 Superdex 200 (GE Healthcare®) gel filtration column that was equilibrated with 
50 mM MES pH 6.6, 5 % glycerol, 8 mM CaCl2, 150 mM NaCl. Peak fractions containing NA 
activity were pooled, aliquoted and stored at -80ºC for further use. All the chromatography steps 
were performed using an Akta purification station (GE Healthcare®). 
CAMELID IMMUNIZATION AND PHAGE LIBRARY CONSTRUCTION  
An alpaca (Vicugna pacos) was weekly injected subcutaneously with 125 µg of N1rec during 35 
days, in the presence of incomplete Freund’s adjuvant emulsions. On day 39, anticoagulated 
blood was collected for the preparation of lymphocytes. Lymphocytes were isolated using a 
UNI-SEP density gradient separation kit (NOVAmed®), and total RNA was extracted. cDNA was 
prepared using oligo (dT) primers, and the VH and VHH genes were amplified with: primer call 
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01 (GTCCTGGCTGCTCTTCTACAAGG) and primer call 02 
(GGTACGTGCTGTTGAACTGTTCC). PstI and NotI restriction sites were inserted into the 
amplified sequences using the primers: A6E (GAT GTG CAG CTG CAG GAG TCT GGR GGA 
GG) and 38 (GGA CTA GTG CGG CCG CTG GAG ACG GTG ACC TGG GT). The resulting 
PCR product (550 bp) and the vector pHEN4 were PstI and NotI digested and ligated (Arbabi 
Ghahroudi et al., 1997) and transformed into electrocompetent TGI E. coli cells. Transformants 
were grown in 2xTY medium, (supplemented with 100 µg/ml ampicillin and 1% glucose) into the 
exponential phase, and the helper phage M13K07 was added. The resulting VHH phage display 
library was subjected to 4 consecutive rounds of panning, performed with solid-phase coated 
N1rec. This bio-panning resulted in the isolation of 13 individual N1rec-binding candidates: N1-
1-VHH, N1-2-VHH, N1-3-VHH, N1-4-VHH, N1-5-VHH, N1-6-VHH, N1-7-VHH, N1-8-VHH, N1-9-
VHH, N1-10-VHH, N1-11-VHH, N1-12-VHH and N1-13-VHH. 
N1-VHHm PRODUCTION AND PURIFICATION  
The VHH coding information of the selected N1rec-binding phages was amplified by PCR with 
the primers A6E and 38. A 400 bp PCR product and the pHEN6c vector were PstI and BstEII 
digested, ligated and used to transform E. coli WK6 strain. In the pHEN6c vector, the coding 
information for the N1rec-binding VHH candidates were cloned downstream of an N-terminal 
PelB secretion signal sequences and the cloning strategy introduced a carboxyterminal 
hexahistidine tag (Figure 1). For production and purification of soluble VHH, pHEN6c-
transformed WK6 cells were grown in TB medium supplemented with: ampicillin (100 µg/ml), 2 
mM CaCl2 and 0.1% glucose. After 16 hours, VHH production was induced with 1 mM of IPTG, 
and the periplasmic fraction was extracted by osmotic shock using TES (0.2 M Tris pH 8.0, 0.5 
mM EDTA and 0.5 M sucrose). Periplasmic extracts were centrifuged at 8000 rpm at 4 °C and 
the supernatant was applied to a His Select Nickel Affinity gel (Sigma®). Following loading, the 
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column was washed with PBS and the soluble VHH was eluted with 0.5 M imidazole and 
dialyzed at 4 °C against PBS. Monomeric N1-VHH (N1-VHHm) was concentrated with a 
Vivaspin 5000 MW cutoff filter (Vivascience®). Total protein concentration was determined with 
BCA protein Assay kit (Thermo Scientific). 
ELISA ASSAYS 
Ten µg/ml of N1rec or M2e-tGCN4 (De Filette et al., 2008) were coated O/N in 96 well Maxisorp 
(Nunc®) plates. Dilution series of the 13 N1-VHH candidates (from 10 µM – 0.1 nM) were 
incubated in the coated plates for 2 hrs at 37 °C, and VHH excess was washed 3X with PBS. 
The binding of the N1-VHHm to the tGCN4 moiety or to the N1rec NA globular head was 
assessed by a mouse α-His-tag fused with Horse Radish peroxidase HRP (1:5000). After 3X 
PBS wash, 100 µl of TMB substrate (Pharmigen BD) was added and absorbance at 565 nm 
was obtained. 
N1-VHHm STRUCTURE PREDICTION AND NA MODELLING 
The AA sequences of the 13 N1-VHH were loaded into the ESyPred3D Web Server 1.0 
Molecular Biology Research Unit, The University of Namur, Belgium 
(http://www.fundp.ac.be/sciences/biologie/urbm/bioinfo/esypred/), and retrieved as PDB files. 
The structures of the 13 N1-VHH were modelled with DeepView/Swiss-PdbViewer 
(http://spdbv.vital-it.ch/), and the NA modelling was done using PyMOL Molecular Graphics 
System (DeLano Scientific). 
N1-VHHm SURFACE PLASMON RESONANCE ANALYSIS  
The affinity of the monovalent N1-3-VHHm, N1-5-VHHm and N1-7-VHHm directed against 
N1rec was determined by Surface Plasmon Resonance (SPR) on a Biacore3000 platform. 
N1rec antigen was first immobilized (2000 RU) into a Series S sensor chip CM5 (GE 
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Healthcare®) (coupling in 10 mM NaAc pH 4.5), with regeneration in 0.02% SDS. Subsequently, 
each monovalent N1-VHHm was diluted in HBS buffer (0.01 M HEPES, 0.15 M NaCl, 0.005% 
Tween 20, pH 6.4) to obtain a N1-VHH gradient between 1.95 and 1000 nM. The different N1-
VHHs were injected over the CM5 chip to record their binding kinetics with the N1rec. Binding 
sensograms were used to calculate the kon and koff values, the equilibrium dissociation constant 
(KD) and to perform epitope competition analysis, using the Biacore T100 evaluation software. 
CONSTRUCTION OF THE BIVALENT N1-VHH  
The coding information of N1-3-VHHm and N1-5-VHHm was amplified with primers MH 
(CATGCCATGGGAGCTTTGGGAGCTTTGGAGCTGGGGGTCTTCGCTGTGGTGCGCTGAGG
AGACGGTGACCTGGGT) and A4short 
(CATGCCATGATCCGCGGCCCAGCCGGCCATGGCTGATGTGCAGCTGGTGGAGTCT) to 
introduce an NcoI restriction enzyme site at both extremities of the amplified fragment. The MH 
primer also added the hinge sequence of llama γ2c (Ala-His-His-Ser-Glu-Asp-Pro-Ser-Ser-Lys-
Ala-Pro-Lys-Ala-Pro-Met-Ala) (Hmila et al., 2010) to the 3′ end of the N1-VHH. PCR-amplicons 
were cloned into pHEN6c plasmid containing the n1-3-vhh or the n1-5-vhh genes, in order to 
generate the homo-bivalent N1-3-VHHb and N1-5-VHHb expression constructs (Figure 1). 
These bivalent constructs were expressed and purified as outlined above. 
ARABIDOPSIS-BASED EXPRESSION OF N1-VHH-Fc FUSIONS 
The n1-vhh-fc expression cassette was designed as follows: from 5’ to 3’: LB (left border of T-
DNA); 3’ ocs (3’ end of the octopine synthase gene); npt II (neomycin phosphotransferase II 
open reading frame); Pnos (nophaline synthase gene promoter); Pphas (β-phaseolin gene 
promoter); 5’ utr (5’ UTR of arc5-I gene); SS (signal peptide of the Arabidopsis thaliana 2S2 
seed storage protein gene); KDEL (ER retention signal); n1-3-vhh (coding sequence of the N1-
3-VHH); 3’ arc (3’ flanking regulatory sequences of the arc5-I gene); n1-3-vhh (coding sequence 
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of the N1-3-VHH fused to the mouse CH2 and CH3 IgG2a hinge sequence); RB, T-DNA right 
border (Figure 1) (De Jaeger et al., 2002) (Van Droogenbroeck et al., 2007). The N1-3-VHH-Fc 
genetic fusion was synthesized commercially (GenScript®), and cloned into a pPhasGW binary 
T-DNA vector, resulting in the pPhasGWn1-vhh-fc vector. The N1-3-VHH coding information 
was removed from the N1-3-VHH-Fc construction, and replaced with the N1-5-VHH and N1-7-
VHH coding information, using BstEII and PstI enzymes. Ligation mixtures were transformed 
into WK6 strain. A plant-produced Coronavirus-Fc fusion protein (GP4) fused to a mouse IgG2a 
Fc moiety, and was used as an irrelevant control. The GP4-Fc was kindly provided by Robin 
Piron, from the Gene regulation laboratory, from the Department of Plant Systems Biology, VIB, 
Technologiepark 927, Ghent University. 
PRODUCTION AND PURIFICATION OF N1-VHH-Fc 
The pPhasGWn1-vhh-fc constructs were used for transformation of Agrobacterium C58C1RifR 
(pMP90). This Agrobacterium strain was grown on YEB medium supplemented with rifampicin 
(100 mg/L), gentamycin (40 mg/L), spectinomycin (100 mg/L) and streptomycin (300 mg/L). 
Arabidopsis transformants were subsequently obtained by Agrobacterium-mediated floral dip 
transformation (Clough and Bent, 1998). Seeds from T1 segregating plants were used as the 
starting material for the isolation of the plant-produced N1-VHH-Fc proteins. One gram of seeds 
was crushed for total protein extraction in 25 ml of 50 mM Tris-HCl, pH 8.0, 200 mM NaCl, 5 
mM EDTA, 0.1% (v/v) of Tween 20 and Complete® protease inhibitor tablets (Roche®). The 
seed extracts were clarified by centrifugation and applied to a protein G sepharose column (GE 
Healthcare®). N1-VHH-Fc proteins were eluted with a single step of 0.1 M glycine pH 3.0. 
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H5N1 PLAQUE ASSAY  
Monolayers of MDCK cells were grown in DMEM supplemented with 10% Fetal Bovine Serum, 
1 % penicillin/streptomycin, 1 % glutamine; at 37 °C with 5% CO2. MDCK TMPRSS2 (kindly 
provided by Dr. Wolgang Garten, Philipps-Universität Marburg, Germany) (Bottcher et al., 2009) 
were cultured in DMEM supplemented with geneticin (0.3 mg/ml) and puromycin (2 µg/ml) and 
the expression of TMPRSS2 was induced with doxycycline (0.5 µg/ml). At 70% of confluence, 
the MCDK cells were infected with a moi of 10 with NIBRG-14, NIBRG-23 or H5N1 H274Y, as 
indicated. Samples containing N1-VHHm, N1-VHHb, N1-VHH-Fc or oseltamivir were mixed with 
0.8% of Avicel RC-591™ as overlay (Matrosovich et al., 2006). After 2-4 days of incubation, the 
cells were fixed with 4% paraformaldehyde in PBS for 30 min. The cells were permeabilized 
with 20 mM glycine, 0.5% (v/v) Triton X-100. After blocking, the cells were incubated for 2 hrs 
with polyclonal α-NIBRG-14 (1:1000) or α-M2e monoclonal antibody (1:5000). After washing, α-
Figure 1.  Schematic representation of the expression cassettes of the two bivalent N1rec-binding VHH.  A. 
Bacteria-produced N1-VHHb, fused by a flexible linker (IgG2c hinge) and a hexahistidine tag. B. The plant-
produced N1-VHH-Fc, targeted as a seed storage protein. 
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mouse IgG-HRP conjugated was used to visualize plaques using the substrate TrueBlue™ 
Peroxidase Substrate (KPL®).  
IMMUNOFLUORESCENSE  
Sixty percent confluent MDCK TMPRSS2 cells monolayers were infected with NIBRG-14 at a 
moi of 10, in serum free medium (SFM). After 2 hrs of adsorption at 37 °C, 5 % CO2, the 
inoculum was removed from the monolayer, followed by washes with SFM, and refreshing with 
DMEM for TMPRSS2 culture (see above). After 8 hrs infection; the cells were fixed, 
permeabilized and blocked. The cells were incubated for 2 hrs with house-made polyclonal α-
H5N1 NA recombinant protein (1:1000), washed and incubated for one hour with goat α-mouse 
IgG-ALEXA Fluor 633 (Invitrogen®), at 1:5000, mounted in glass slides and analysed. 
NA SEQUENCE ALIGNMENT  
The phylogenetic tree and amino acid substitutions of the aligned sequences of the H5N1 NA 
of: A/crested eagle/Belgium/01/2004 (accession number: ABP52007), A/Vietnam/1194/2004 
(ABA70757) and A/turkey/Turkey/01/2005 (ABQ58915), were obtained by the Clustal W 
method, using in the MegAlign software (DNASTAR®). 
MICE EXPERIMENTS 
Specific-pathogen–free female Balb/c mice, 7–9 weeks old, were purchased from Charles River 
(Germany) and used for all experiments. Mice were housed in ventilated cages with high-
efficiency particulate air filters in temperature-controlled, air-conditioned facilities and had food 
and water ad libitum. Mice were anesthetized by intraperitoneal injection of xylazine (10 μg/g) 
and ketamine (100 μg/g) before intranasal administration of N1-VHHm, N1-VHHb or N1-VHH-
Fc. Mice were challenged 4 hours later with 1 or 4 LD50 of the indicated virus (50 μL, divided 
equally between the nostrils). The N1-VHH in any format were diluted in endotoxin-free 
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phosphate-buffered saline (PBS) with 1% (wt/vol) bovine serum albumin and dosing ranged 
from 5 – 0.25 mg/kg, as indicated in the figure legends. To determine the effect of intranasal N1-
VHH delivery on lung virus titer production, mice were challenged with 4 LD50 of NIBRG-14 ma 
IAV. Lung homogenates were prepared in PBS, cleared by centrifugation at 4°C, and used for 
virus titration. Monolayers of MDCK cells were infected with 50 μL of serial 1:10 dilutions of the 
lung homogenates, in a 96-well plate in serum-free Dulbecco's modified Eagle medium 
(Invitrogen®) supplemented with penicillin and streptomycin. After 1 h, the inoculum was 
replaced by medium containing 2 μg/ml of L-(tosylamido-2-phenyl) ethyl chloromethyl ketone–
treated trypsin (Sigma®). End-point virus titers were determined by hemagglutination of chicken 
red blood cells and expressed as TCID50 per milliliter. IAV RNA levels were determined by 
quantitative RT-PCR. RNA was isolated from 150 μL of cleared lung homogenate using the 
Nucleospin RNA virus kit (Machery-Nagel®). The relative amount of NIBRG-14 ma genomic 
RNA was determined by preparing viral cDNA and performing quantitative PCR with M-genomic 
segment primers (CGAAAGGAACAGCAGAGT and CCAGCTCTATGCTGACAAAATG) and 
probe (GGATGCTG) (probe no. 89; Universal ProbeLibrary, Roche®) and the LightCycler 480 
Real-Time PCR System (Roche®). To determine the degree of protection against mortality, 
mice were challenged with 4 LD50 of NIBRG-14 ma virus and subsequently monitored for 14 
days. A 30% loss in body weight was the end point at which moribund mice were euthanized. All 
animal procedures were approved by the Institutional Ethics Committee on Experimental 
Animals. 
MICE EXPERIMENTS STATISTICAL ANALYSIS 
Graphpad (Graphpad Prism®, version 5) was used for statistical analysis. Differences between 
groups were tested using the 2-way ANOVA. When this test demonstrated a significant 
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difference between groups (P < .05), t tests were used to compare 2 groups. Kaplan-Meier 
survival curves were plotted and evaluated.  
SELECTION AND CHARACTERIZATION OF H5N1 N1-VHHm ESCAPE MUTANT VIRUSES 
NIBRG-14 ma escape viruses were isolated independently by selection with N1-3-VHHm and 
N1-5-VHHm in vitro. NIBRG-14 ma virus was serially diluted and used to infect MDCK cells in 
the presence of N1-3-VHHm or H5-VHHb (using a 4.2 or 3.7 µM concentration, respectively, 
corresponding to 10-fold the median inhibitory concentration NA inhibition assay using N1rec, 
IC50). Escape mutants were screened by induction of cytopathic effect, and after 12 passages in 
the presence of N1-VHHm, escape viruses were plaque purified by growth on MDCK cells 
overlaid with 0.6% low-melting agarose in the presence of N1-3-VHHm or N1-5-VHHm. Only six 
escape virus isolates obtained by selection with N1-5-VHHm, and were amplified on MDCK 
cells, still in the presence of the 10-fold IC50 of N1-5-VHHm. Total RNA was extracted from the 
supernatant and used to clone the cDNA corresponding to the NA viral RNA (vRNA) segment 
(Stech et al., 2008). Deduced amino acid substitutions in the NA sequence of escape viruses 
were modeled with PyMOL Molecular Graphics System (W. L. DeLano, 2002; DeLano 
Scientific) using the H5N1 NA structure from A/Vietnam/1194/2004 (PDB code 2HTY). 
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RESULTS 
PRODUCTION OF RECOMBINANT TETRAMERIC NEURAMINIDASE  
A Baculovirus Expression Vector System was used to produce a recombinant soluble tetrameric 
and enzymatically active H5N1 NA derived from A/crested eagle/Belgium/09/2004 (N1rec). The 
N1rec expression cassette gene (n1rec) (Figure 2) was cloned into a pAcMP2 expression vector 
(pAcMP2n1rec), under the control of the AcNPV basic protein promoter, which is an infectious 
cycle late phase promoter preferred for the production of proteins with post-translational 
modifications. Infection of Spodoptera frugiperda (Sf9) cells with the recombinant baculovirus 
AcNPVN1rec (containing the N1rec expression cassette) resulted in sialidase activity in the cell 
supernatant, suggesting that the N1rec product was a soluble and enzymatically active 
tetrameric NA (Figure 2B). A house-made polyclonal mouse antibody against a recombinant 
H5N1 NA was used for detection of NA in H5N1 MDCK TMPRSS2 infected cells and further 
N1rec characterization (Figure 2C). The infected Sf9 SuperNatant (SN) was the starting material 
for the N1rec protein purification by chromatography. First, the SN was butanol-extracted, 
separating the SN in an organic phase (fatty acids content) and an aqueous phase, which 
contained the NA-activity. The aqueous phase was diluted and applied to a hydroxyapatite 
packed column (Figure 2D). The UV profile of the hydroxyapatite eluted fractions, showed a 
peak of high protein content, between eluted fractions 20 – 45, corresponding to high NA activity 
according to a NA activity assay, using the small fluorogenic substrate MUNANA (MW. 469 Da). 
The hydroxyapatite eluted fractions that scored positive in the NA activity assay and 
immunoblotting, were pooled and further purified using a Blue Sepharose packed column 
(Figure 3A-B, 4A). Following a final size exclusion chromatography step by Superdex 200, the 
tetrameric N1rec containing fractions were eluted after 150 – 180 ml, and the NA activity and 
immunoblot assays confirmed the catalytic activity of these fractions (Figure 5A-B). On the other 
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hand, the UV peaks that elute after ca. 190 ml possibly corresponded to N1rec in tri-, di- or 
monomeric forms, but the NA activity assay confirmed the absence of any NA activity (Figure 
5A-B). The N1rec eluted from gel filtration was ca. 90% pure N1rec (Figure 6C-D and Table 1). 
The theoretical molecular weight of N1rec is 49.5 kDa, but the relative electrophoretic mobility in 
SDS-PAGE suggested a size of approximately 60 kDa (Figure 6D), presumably due to the 
presence of glycosylations; there are three N-glycosylation and two O-glycosylation sequences 
in the N1rec. The purified protein had a specific activity of 56850.9 NA units/mg of total protein 
and the progressive enrichment of the N1rec production process is depicted in the Table 1. 
 
 
 
 
 
 
 
 
 
 
 
CONFIDENTIAL Page 76 
 
Table 1. Progressive enrichment of eluted fractions of N1 NA through the 
purification process 
 Volume (ml) Total NA units\mg 
total protein 
a
 
Relative purity 
AcNPVN1rec infected 
Sf9 supernatant 
1650 20605.92 ND b 
Butanol extracted 
aqueous phase  
1450 13115.45 ND 
Hydroxyapatite 
Elution  
555 12080.01 35% 
Blue sepharose 
Elution  
15 21801.24 80% 
Superdex 200 Elution  11 56850.90 90% 
a Based in a NA inhibition assay, using the substrate 2’-(4-methylumbelliferyl)-a-D-N 
acetylneuraminic acid (MUNANA), expressed in NA units  (1 unit neuraminidase = nmoles 
4-methylumbelliferone/min).  
b  ND, Not determined 
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Figure 2. Design and initial steps of production of recombinant N1. Soluble recombinant NA (N1rec) 
derived from H5N1 A/crested eagle/Belgium/01/2004 was produced in Sf9 cells using the Baculovirus 
expression platform. A. Diagram of the n1rec expression cassette in the pACMP2 vector: promoter, 
Baculovirus basic protein promoter; ssHA, secretion signal of HA; tGCN4, tetramerizing leucine zipper; 
H5N1 NA, extracellular domain of the N1rec. B. Neuraminidase activity in crude cleared culture 
supernatant (SN) of infected Sf9 cells. Supernatants of different amounts of AcNPVN1rec infected cells or 
mock infected cells were measured in a NA activity assay (MUNANA substrate). C. MDCK TMPRSS2 
cells were mock or NIBRG-14 infected, fixed and stained against NA, using a house-made mouse 
polyclonal α-NA. There is a specific signal in the cell membrane corresponding to NA expression in 
NIBRG-14 infected cells, which is not present in mock infected cells. The scale in the right lower corner 
represents 20 µm. D.  Immunoblot of the initial purification process of N1rec is depicted, before 
chromatography and using a mouse polyclonal Ab against a recombinant H5N1 NA. SN, crude cleared 
culture supernatant of infected SF9; BE, butanol-extracted SN; 2.5X, 2.5 times dilution of BE before the 
first chromatography step. The numbers 1 and 2 denote two different batches produced. The theoretical 
molecular weight of monomeric N1rec is 49.5 kDa, but migrates close to 60 kDa, due to possible 
glycosylations.  
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Figure 3. Representative hydroxyapatite elution profile and NA activity characterization of eluted 
N1rec-containing fractions. A. The butanol-extracted and 2.5X diluted SN was applied to a 
hydroxyapatite column, and the eluted F20 – F45 showed a major protein content peak, according to 
their UV profile. Eluted fractions (red); SN injection (magenta arrow); mAU, UV 280 nm (blue); 
Conductivity (brown); pH (grey); ml, eluted volume in milliliters. B. NA activity analysis of all the eluted 
fractions of A. The F20 – F 45 UV peak corresponds with the highest NA activity fractions (dotted red 
lines). RFU, relative fluorescence units. 
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Figure 4.  A representative N1rec second chromatographic purification step by Blue Sepharose. A. The 
elution from the Blue Sepharose column resulted in concentrated N1rec fractions (F2 – F5), with a single UV 
peak. Eluted fractions (red); Hydroxyapatite eluted pooled fractions injection (magenta arrow) mAU, UV 280 
nm (blue); Conductivity (brown); pH (grey), ml, eluted volume in milliliters. B. NA activity analysis of the 
eluted fractions of A.  The F2 – F 5 protein content peak corresponds with the highest NA activity fractions 
(dotted red lines). RFU, relative fluorescence units. 
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Figure 5. Representative N1rec purification final gel filtration process. A. The eluted pooled fractions after 
Blue Sepharose purification from figure 4 (magenta arrow) were applied to a Superdex 200 column. After 
ca. 150- 190 ml (F20 – F30) of eluted volume, a major UV peak corresponded to the size of tetrameric 
N1rec, while the following minor UV peaks possibly represent N1rec trimers, dimers or monomers. Eluted 
fractions (red); mAU, UV 280 nm (blue); Conductivity (brown); pH (grey), ml, eluted volume in milliliters. B. 
The NA activity revealed that the major UV peak (F20 – F30) corresponded with the fractions with NA 
activity (red dotted lines). In contrast the other minor peaks did not present any NA activity, suggesting that 
only the N1rec in tetrameric form is active. RFU, relative fluorescence units. 
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IMMUNIZATION AND VHH PHAGE LIBRARY CONSTRUCTION  
Next, N1rec was used as an antigen for the generation and selection of NA-specific VHH.  An 
alpaca (Llama alpacos) was immunized at day 0 with 125 µg of N1rec, followed by 6 weekly 
boosts (Figure 7A). One week after the last immunization, blood was collected and peripheral 
blood lymphocytes were isolated (Figure 7B). From the lymphocytes, total RNA was extracted 
and used as template for cDNA synthesis (Figure 7C). The VH and VHH genes were amplified 
by PCR, and the VHH genes were isolated and cloned into the phagemid vector pHEN4 (Figure 
7D-E, 8A) (Arbabi Ghahroudi et al., 1997). We obtained a VHH phage library of 2 X 108 
independent transformants. Fifty-seven percent of these transformants harbored a pHEN4 with 
a VHH cDNA insert of the correct size (550 bp) (Figure 7F-G). The VHH phage display library 
Figure 6. Analysis of the N1rec during and after the chromatography purification. Sequential N1rec 
purification and enrichment of the eluted fractions of the 3 different N1rec chromatography purification 
processes, by immunobloting: A, Hydroxyapatite; B, Blue Sepharose; and C, Superdex 200. In the 
Superdex 200, 9 µl of F19 – F26 were loaded per lane. All the blots were obtained using a mouse 
polyclonal Ab, against H5N1 NA recombinant protein. D. Coomasie stained reducing SDS-PAGE of the 
Superdex 200 eluted fraction F19 - F26 of C (18 µl of each fraction were resolved). BSA, Bovine Serum 
Albumin protein standards.  
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was then subjected to four consecutive rounds of panning, performed on solid-phase coated 
N1rec antigen (Figure 7H-I). Seventy-eight positive clones were selected and isolated from the 
eluted phages and were sequenced (Figure 7J). Subsequent restriction fragment length 
polyphorphism analysis narrowed down the N1rec-binding VHH candidates to 24 colonies, 
encoding 13 unique and different VHH sequences. These sequences were cloned into the 
bacterial expression vector pHEN6 (pHEN6n1-vhh) under the control of a lac promoter, for 
expression and purifications purposes (Figure 7K, 8B) (Kang et al., 1991).  
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Figure 7. Flow chart of the phage library production and panning process of the N1rec-binding VHH 
production. A. Purified N1rec was used to immunize an alpaca (Llama alpacos). B. Eight weeks after 
immunization, peripheral blood was extracted and the lymphocytes were isolated by a sucrose gradient. 
C. cDNA was obtained from total RNA extracted from isolated lymphocytes. D. VH and VHH genes were 
amplified from cDNA, and the VHH genes were isolated and purified. E. The VHH genes were cloned 
and inserted into the pHEN4 vector, where the VHH gene is fused to the phage protein III gene, resulting 
into a phagemid. F. TG1 competent cells were co-transformed with the phagemid and the helper phage 
M13, in order to produce viable and infective phages. G. A library of ca. 107 transformants was 
generated; an insert of 597 bp (VHH gene) was present in approximately 57% of the transformants. H. 
Purified phages from the library were used for panning N1rec-binding phages using N1rec as bait. A 
representative panning enrichment is depicted, showing specific enrichment through a dilution series, 
measured by the growing of bacteria infected with eluted phages from panning (conferring an antibiotic 
resistance gene, + Elution), compared with the negative control (- Elution). I. After 4 rounds of panning 
enrichment, eluted phages were isolated, and J. sequenced. K. The VHH genes of the selected 
sequenced phages were cloned into the vector pHEN6c, resulting into the VHH expression cassette (5’-
pelB-VHH gene-hexahistidine-3’) in order to produce soluble VHH. 
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Figure 8. Schematic diagrams of the phagemid vector pHEN4 and the production vector pHEN6. A. The 
VHH genes from the phage library were cloned into the pHEN4 vector (4527 bp), resulting in an 
expression cassette encoding the VHH gene (red dotted lines) fused to the phage gene III, resulting in a 
phagemid. Plac operator, lacUV5 promoter; Univ, universal primer recognition site; pelB, signal peptide for 
periplasmic targeting; HA tag, hemagglutinin tag for screening purposes (dark red box); GIII, GII primer 
recognition site; fd gene III, phage protein III gene; f1 origin; AmpR, ampicilin resistance gene; rep pMB1; 
origin of replication starts at 4347 bp (+/- 1). B. The selected VHH genes were cloned for soluble protein 
production into the vector pHEN6 (3288 bp). In this vector, the VHH gene is fused to a hexahistidine tag 
(His-tag, dark red box), that substituted the HA tag and the phage protein III gene. 
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PRODUCTION AND CHARACTERIZATION OF SOLUBLE MONOMERIC N1-VHH 
The sequences of the 13 N1rec-specific candidates are shown in Figure 9, containing four 
framework regions (FR1-FR4) and three complementary determining regions (CDR1-CDR3). 
The transformation of amber suppressor E. coli strain WK6 with the pHEN6n1-vhh vector 
resulted in the production a monomeric soluble N1rec-binding VHH (N1-VHHm) that is targeted 
to the periplasm and C-terminally tagged with hexahistidine. Following osmotic shock, 
periplasmic extracts were prepared and loaded into a nickel sepharose column, to purify each of 
the 13 different N1-VHHm proteins (Figure 10A-C). In silico structure prediction of the 13 N1-
VHHm showed a typical VHH structure, and interestingly, the CDR3 of N1-1-VHHm, N1-3-
VHHm, N1-4-VHHm, N1-5-VHHm and N1-6-VHHm presented an electronegative protruding 
paratope, not present in the rest of the N1-VHHm (Figure 11). The binding of the 13 N1-VHHm 
proteins to the NA moiety of N1rec, but not to its tGCN4 moiety was assessed by ELISA assay. 
The majority of the N1-VHHm did not present significant binding to a recombinant M2e-tGCN4 
protein, which contains the same tetramerizing leucine zipper (Figure 12).  We next assessed 
the capacity of the N1-VHHm candidates to inhibit the enzymatic activity of N1rec, by using a 
small MUNANA substrate. Interestingly, four candidates, N1-1-VHHm, N1-3-VHHm, N1-5-
VHHm and N1-6-VHHm, could inhibit the N1rec catalytic activity (Figure 13; Table 2). N1-3-
VHHm and the N1-5-VHHm were the most potent inhibitors of the N1rec catalytic activity (Table 
3), and together with N1-7-VHHm, were analyzed by SPR using immobilized N1rec. The N1-7-
VHHm protein was included in this analysis as a binding but non-inhibitory N1-VHHm control. 
Both N1-3-VHHm and N1-5-VHHm presented a high affinity for N1rec, with equilibrium 
dissociation constant (KD) in the low nanomolar (N1-5-VHHm) to picomolar (N1-3-VHHm) range. 
N1-7-VHHm showed an approximately 10- to 100-fold lower affinity KD than N1-5-VHHm and 
N1-3-VHHm, respectively (Table 2). These binding affinities of N1-3-VHHm and N1-5-VHHm for 
N1rec are comparable to affinities reported for an enzymatic monomeric VHH that inhibits the 
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activity of lysozyme (De Genst et al., 2006). Competitive SPR analysis also showed that prior 
binding of N1-3-VHHm to N1rec abolished subsequent binding of N1-5-VHHm and vice versa. 
On the other hand, N1-7-VHHm binding to N1rec was not affected by prior binding of N1-3-
VHHm or N1-5-VHHm to N1rec (Figure 14). This observation suggests that N1-3-VHHm and 
N1-5-VHHm bind an overlapping epitope in N1rec, while N1-7-VHHm targets a different epitope. 
We next analyzed the antiviral potential of the N1rec inhibitory VHH N1-3-VHHm and N1-5-
VHHm. Therefore, we used the IAV laboratory strain NIBRG-14, generated by reverse genetics 
and containing NA and HA (lacking the polybasic maturation sequence) segments derived from 
A/Vietnam/1194/2004. The sequences of the NA of NIBRG-14 and the NA derived from the 
A/crested eagle/Belgium/09/2004 (used for the alpaca immunization) are highly homologous, 
with only 13 AA differences. In the presence of N1-3-VHHm or N1-5-VHHm the size of NIBRG-
14 plaques in monolayers of infected MDCK cells was reduced in a concentration dependent 
manner (Table 3, Figure 16A). In contrast, N1-7-VHHm did not affect the size or number of 
NIBRG-14 plaques in this assay (Table 3). These results suggest that the in vitro antiviral 
potential of N1-3-VHHm and N1-5-VHHm depends on their NA-inhibitory activity.  
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Figure 9. Sequence of the13 N1rec-binding VHH candidates.  Alignment of the amino acid sequences of the 
13 N1-VHH, isolated by panning, from the phage library generated from an N1rec-immunized alpaca. Four 
framework sequences are separated by 3 diverse Complementary Determining Regions (CDR1, CDR2 and 
CDR3). The VHH CDR3 is the most variable region in the VHH candidate’s sequences. The colored 
histogram denotes the homology between the sequences: red, 100 %; orange 60 – 80%; green 40 – 60 %; 
light blue 20 – 40 %, dark blue < 20%. 
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Figure 10.  Production of soluble monomeric N1-VHH (N1-VHHm). A. Anti-hexahistidine immunoblot of the 
sequential purification and enrichment process of N1-VHHm production. Periplasmic Extracts (PE), His-
select column FLow through (FL1, FL2), Washes (W1, W2), eluted Fractions (F1, F2, F3), Dialyzed eluted 
pooled fractions (D), and His-select resin incubated OverNight after elution (O/N). B. Elution profile of the 
dialyzed eluted pooled fractions from A (magenta arrow), were gel filtrated by Superdex 200 column. The 
eluted fractions F14 - F17 single UV peak corresponded to a single band of ca. 15 kDa (red dotted lines), 
resolved by Coomasie stained reducing SDS-PAGE. Eluted fractions (pink, x axis); mAU, UV 280 nm (blue, 
y axis); Conductivity (brown).C. Coomassie-blue stained reducing SDS-PAGE of the 13 purified E. coli-
produced soluble N1-VHHm candidates. Twenty µg of monomeric SA-VHH was loaded as a non N1rec-
binding control VHH. The VHH size ranges from 14 – 15 kDa. Purified BSA standards were loaded for 
quantification and comparison. BSA, Bovine serum Albumin. SA-VHH, Seed Albumin binding VHH . 
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Figure 11. In silico prediction of the 3D-structure of the monomeric N1rec-VHH (N1-VHHm). The N1-
VHHm surface depicts the positive and negative electro-potential, as blue and red clouds, 
respectively. The VHH CDR3 is represented in a white ribbon structure. Note that N1-1-VHH, N1-3-
VHH, N1-4-VHH, N1-5-VHH and N1-6-VHH CDR3 present an electronegative protruding topology. 
The asterisk (*) and circle (°) indicate N1-VHHm from the same clonal family. 
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Figure 12. Binding capacity of the 13 N1-VHHm candidates to the N1rec protein by ELISA. Ten µg/ml of 
N1rec (N1rec-tGCN4.) or IAV recombinant protein M2 (M2-tGCN4) was used for coating O/N 96-well plate. 
Dilution series of the 13 N1-VHHm were incubated in the N1rec coated plates, and a mouse α-His-tag-
HRP was used to measure the binding between both proteins. All the 13 N1-VHHm showed binding to the 
N1rec in a dose dependent-manner, but the binding to the M2 coated plates was minor or absent. In the 
N1-1-VHHm, N-11-VHHm and N1-13-VHHm, the M2 binding was more than 0.2 units (OD495 nm) in the 
lowest dilutions. Interestingly, the binding of the N1-3-VHHm and N1-5-VHHm appeared not be affected by 
the dilution series. 
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Figure 13. N1rec inhibitory potential of the 13 N1-VHHm. From each N1-VHH, dilution series were 
incubated with 160 ng of N1rec at 37 °C, in the presence of 1 mM of MUNANA substrate. Readings at 
365 nm (excitation) and 450 nm (emission) were taken every 2 min. Only the N1-1-VHHm, N1-3-VHHm, 
N1-5-VHHm and N1-6-VHHm presented inhibition of the N1rec catalytic activity. The N1-3-VHHm and 
the N1-5-VHHm seemed to be the most potent NA inhibitors. 
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Figure 14.  Sensogram of the N1-VHHm binding to the N1rec, by SPR analysis. In the “x” axis is the 
time (seconds), and in the “y” axis is Resonance Units (RU), that reflects the increase in mass into the 
N1rec covalently linked into the circuit. The binding of N1-3-VHHm to the N1rec abolished the 
subsequent binding of the N1-1-VHHm, N1-5-VHHm and N1-6-VHHm, but did not avoid the N1-7-VHHm 
binding. In this last case, an increase of RU corresponded with an increase of mass into the bound 
complex, indicating N1-7-VHHm binding to N1rec. 
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Table 2. Binding and affinities of the N1-VHHm to N1rec by ELISA and Surface Plasmon 
Resonance  
N1-VHHm Binding to 
N1rec 
a
 
Inhibition of 
N1rec 
Kon (M
-1- s-1)
 b
 Koff (s
-1) 
c
 KD (M) 
d
 
1 + + ND 
e
 ND ND 
2 + - ND ND ND 
3 + + 3.6 E+6 1.3 E-3 3.7 E-10 
4 + - ND ND ND 
5 + + 1.2 E+5 5.8 E-4 4.7 E-9 
6 + + ND ND ND 
7 + - 4.4 E+4 2.8 E-3 6.3 E-8 
8 + - ND ND ND 
9 + - ND ND ND 
10 + - ND ND ND 
11 + - ND ND ND 
12 + - ND ND ND 
13 + - ND ND ND 
a  N1rec, tetrameric recombinant N1 Neuraminidase  
b Equilibrium dissociation constant KD (koff/kon),  
c
 Association rate constant kon  
d
 Dissociation constant koff,
  e
 ND, not determined  
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ENHANCED INHIBITORY AND ANTIVIRAL POTENTIAL OF BIVALENT N1-VHH FORMATS 
It has been reported that multivalent formats of VHH increase their affinity, by introducing avidity 
for their viral target antigen (Hultberg et al., 2011; Ibanez et al., 2011; Schepens et al., 2011). 
For example, the introduction of avidity drastically decreased the dissociation constant (Koff) of 
the VHH molecules directed against lysozyme, and significantly improved their enzyme 
inhibitory activity as compared to their monovalent counterparts format (Els Conrath et al., 2001) 
(Hmila et al., 2010). To increase the avidity of the N1-VHHm, two different bivalent formats were 
produced.  
BACTERIA-PRODUCED N1-VHHb 
As a first approach to obtain bivalent VHH, we used the llama IgG2c hinge (17 AA residues) as 
a flexible linker to fuse two identical N1-VHHm moieties in a tandem configuration, resulting in 
the bivalent N1-3-VHHb and N1-5-VHHb (Figure 15A, C and D). The complete sequence of the 
N1-VHHb is shown in Table 4. N1-3-VHHb and N1-5-VHHb were expressed and purified from 
E. coli in the same way as N1-VHHm. The in vitro N1-VHHb NA-inhibitory and antiviral activities 
were compared with those of their monovalent counterparts. We found that N1-3-VHHb and N1-
5-VHHb displayed a 500- and 2000-fold enhanced N1rec inhibition activity as compared with the 
corresponding monovalent N1-3-VHHm and N1-5-VHHm format (Table 3). Surprisingly, in a 
plaque assay using NIBRG-14 virus infected MDCK cells, both N1-3-VHHb and N1-5-VHHb had 
an antiviral activity that was comparable to the levels of their monovalent counterparts. We 
reasoned that the integrity of the bivalent format is necessary to present enhanced antiviral 
potency in both N1-VHHb. However, in the plaque assay with H5N1 infected MDCK cells, 
exogenous trypsin is used to facilitate maturation of HA in newly produced virions to allow 
multicycle replication of the recombinant NIBRG-14 virus. We found that the dimerizing llama 
IgG2c hinge linker in the N1-VHHb was sensitive to trypsin cleavage (Figure 15D). Therefore, in 
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the presence of trypsin (< 10 μg/ml), N1-3-VHHb and N1-5-VHHb were effectively severed into 
monovalent VHH. To circumvent the use of exogenously added trypsin we took advantage of 
the TMPRSS2 MDCK cells, which are transformed with the doxycycline-inducible serine 
protease TMPRSS2 and allow multicycle replication of IAV in the absence of trypsin (Bottcher et 
al., 2009). Using monolayers of TMPRSS2 MDCK cells for infection with NIBRG-14, the antiviral 
effect of N1-3-VHHb and N1-5-VHHb was 240- and 58-fold increased, respectively, compared 
with their monovalent format (Table 3). These results obtained with N1-VHHb indicate that: (i) 
there is a significantly enhanced NA-inhibitory and antiviral activity of both N1-VHHb compared 
with the N1-VHHm format; and (ii) the 10-fold difference between the increase of the N1rec 
inhibition compared to the plaque assay, suggests than there are other factors that account for 
the in vitro antiviral effect of the N1-VHHb than just their NA inhibitory potential (i.e. NA 
enhanced aggregation in the infected cell membrane). 
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Table 3. N1-3-VHH and N1-5-VHH formats inhibition of the catalytic N1 NA activity (IC50, 
nM) 
a
 and plaque size reduction in H5N1 virus infected cells (PIC50, nM) 
b  
                   Enzymatic  assay                    Plaque size reduction assay (cell-based) 
VHH 
format 
N1rec 
c
 Fold 
d
 NIBRG-14 
e
 Fold H5N1 H274Y 
f
 Fold NIBRG-23 
g
 Fold 
N1-3-
VHHm 
425,2 
+/- 149,4 
- 1844  
+/- 344,3 
- 6440  
+/- 1247,0 
- 4295  
+/- 2835,4 
- 
N1-5-
VHHm 
374,9 
+/- 118,5 
- 848,5  
+/- 380,2 
- >26500 - 3492  
+/- 2967,6 
- 
N1-7-
VHHm 
>15448 - >32896 - >32896 - >32896 - 
N1-3-
VHHb 
0,157 
+/- 0,206 
2708 7,6  
+/- 3,0 
240 52,2  
+/- 36,8 
123 24,6  
+/- 31,9 
174 
N1-5-
VHHb 
0,69 
+/- 0,231 
543 14,5  
+/- 11,1 
58 >707.5 - 23,6  
+/- 3,8 
148 
N1-3-
VHH-Fc 
1.31 
+/- 0.605 
324 23,08 h 79 89,4  
+/- 7,8 
71 24,2  
+/- 3,7 
177 
N1-5-
VHH-Fc 
1.49 
+/- 0.746 
251 28,14 h 30 >17083 - 27,03 129 
N1-7-
VHH-Fc 
>7900 - >5260 - >5260 - >5260 - 
Oselta
mivir 
586.1 
+/- 120.5 
- 15030  
+/- 10039 
- >243000 - 73000 h - 
         
a 
 Mean IC50 of NA inhibition assay using the substrate 2’-(4-methylumbelliferyl)-a-D-N acetylneuraminic acid 
(MUNANA), using 160 ng of N1rec, in 3 independent experiments. 
b  
 Mean PIC50 of duplicates plaque assays, in which VHH concentration reduced the 50 % of plaque size, 
compared to control VHH (at least 2 independent experiments.)  
C N1rec, tetrameric recombinant N1 Neuraminidase. 
d Fold increase inhibitory potency of the bivalent format compared to the monovalent format. 
e H5N1 NIBRG-14.  
f
 H5N1 H274Y. 
g H5N1 NIBRG-23. 
h
 Mean of single experiment. 
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TRANSGENIC PLANT-PRODUCED N1-VHH-Fc  
The previously described N1-VHH monovalent or bivalent molecules are relatively simple 
molecules that are stable and small sized, feasible for production in prokaryotic systems. 
Nevertheless, for more complex protein molecules, other production platforms were available 
and considered. We used a plant-based approach, with reported promising high-end yield 
results for recombinant antibodies (Van Droogenbroeck et al., 2007). By targeting the N1-VHH-
Fc as a seed storage protein, we were able to produce a second bivalent N1-VHH format. For 
this, the n1-3-vhh, n1-5-vhh and the n1-7-vhh genes were fused to the sequence encoding the 
hinge and Fc tail of a mouse IgG2a (n1-vhh-fc). The resulting protein, N1-VHH-Fc consists of 
two identical N1-VHH-Fc moieties linked by a disulphide bridge (Figure 15B, Table 4). These 
n1-vhh-fc constructs were cloned into the binary vector pPhas as a T-DNA expression cassette 
(Figure 15B, C and E). Subsequently, transgenic Arabidopsis thaliana plants were generated by 
Agrobacterium-mediated floral dip transformation. Seed extracts of segregating T3 Arabidopsis 
transformants were screened for the best expressors of the recombinant dimeric protein N1-
VHH-Fc. We also found a good correlation between a high expression of N1-VHH-Fc and NA 
inhibitory activity in crude seed extracts from different T3 transformants. N1-3-VHH-Fc, N1-5-
VHH-Fc and N1-7-VHH-Fc were purified from seed extracts by protein G affinity 
chromatography, and Coomassie stained reducing SDS-PAGE analysis showed that the N1-
VHH-Fc monomers migrated at ca. 42 kDa (Figure 15E). We found a clear enhancement of the 
N1rec inhibition and in vitro antiviral activity of N1-3-VHH-Fc and N1-5-VHH-Fc compared with 
the monovalent N1-3-VHHm and N1-5-VHHm (Table 3). The inhibition of replication of NIBRG-
14 virus by either N1-3-VHH-Fc or N1-5-VHH-Fc was 80- and 30-fold stronger compared with 
their monovalent counterparts (Table 3). These results indicated that the in vitro NA inhibition 
and antiviral activity against NIBRG-14 virus is enhanced 1 - 2 log fold in the N1-VHHb and N1-
VHH-Fc formats, compared with N1-VHHm. 
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Figure 15. Bivalent formats of the N1-3-VHH and N1-5-VHH. A. PCR amplification of the n1-vhhm (357 
bp) and the n1-vhhb (763 bp) genes inserted in the pHEN6c vector, resolved in agarose 1%. B. BamHI 
digested empty (E) or n1-vhh-fc gene inserted pPhasGW.arc vector. The 1066 bp band indicates an n1-
vhh-fc gene insert. C. Cartoon representation of the two N1-VHH bivalent formats. The bacteria-produced 
N1-VHHb consists of two moieties in tandem of N1-VHHm linked by a llama IgG2c hinge of 17 amino acid 
residues. The plant-produced bivalent N1-VHH-Fc comprises two N1-VHH-Fc moieties, each consist of 
one N1-VHHm fused to a mouse IgG2a Fc, dimerized through a disulphide bond (red line). D. The llama 
IgG2c-derived hinge is sensitive to trypsin. Coomassie stained reducing SDS-PAGE of purified N1-3-
VHHm, N1-5-VHHm, N1-3-VHHHb and N1-5-VHHb incubated for 60 min at 37 ºC in the presence or 
absence of 1 μg/ml or 10 μg/ml trypsin. The N1-VHHb molecules migrate at ca. 32 kDa, and the N1-VHHm 
and the cleavage products of N1-VHHb migrate as bands of ca. 17 kDa (arrows). E. Coomasie stained 
reducing SDS-PAGE of the eluted fractions from a protein G column purification step using seed extracts 
of pPhas transformed A. thaliana T3 plants. The N1-VHH-Fc constructs migrate at ca. 42 kDa (arrow). A 
degradation product (*) of ca. 28 kDa corresponds to the Fc moiety only, as was confirmed by 
immunobloting. 
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Table 4. Sequences of the N1-VHH bivalent formats 
Bivalent 
Molecule  
Amino acid sequence  
N1-3-VHHb  LQESGGGLVQPGGSLRLSCAASGSIFSIHDMGWYRRAPGKQRELVAAITSGGSTNYADSVKGRFTISRDNAK
NTVSLQMNSLKPEDTAVYYCNAWGEDYGLGEYDSWGQGTQVTVSSAHHSEDPSSKAPKAPMAQVQLQESG
GGLVQPGGSLRLSCAASGSIFSIHDMGWYRRAPGKQRELVAAITSGGSTNYADSVKGRFTISRDNAKNTVSLQ
MNSLKPEDTAVYYCNAWGEDYGLGEYDSWGQGTQVTVSSHHHHHH  
N1-5-VHHb  LQESGGGLVQPGGSLRLSCAASGSDISIYEMGWYRQAPGKQRELVAAITSGGTTNYADSVKGRFTISRDNAK
NTVYLQMNSLKPEDTAVYYCNAADFDLWEYDYWGQGTQVTVSSAHHSEDPSSKAPKAPMALQESGGGLVQP
GGSLRLSCAASGSDISIYEMGWYRQAPGKQRELVAAITSGGTTNYADSVKGRFTISRDNAKNTVYLQMNSLKP
EDTAVYYCNAADFDLWEYDYWGQGTQVTVSSHHHHH  
N1-3-VHH-Fc  LQESGGGLVQPGGSLRLSCAASGSIFSIHDMGWYRRRPGKQRELVAAITSGGSTNYADSVKGRFTISRDNAK
NTVSLQMNSLKPEDTAVYYCNAWGEDYGLGEYDSWGQGTQVTVSSPRGPTIKPCPPCKCPAPNLLGGPSVFI
FPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGK
EFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYK
NTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGKKDEL  
N1-5-VHH-Fc  LQESGGGLVQPGGSLRLSCAASGSDISIYEMGWYRQAPGKQRELVAAITSGGTTNYADSVKGRFTISRDNAK
NTVYLQMNSLKPEDTAVYYCNAADFDLWEYDYWGQGTQVTVSSPRGPTIKPCPPCKCPAPNLLGGPSVFIFPP
KIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFK
CKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTE
PVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGKKDEL  
N1-7-VHH-Fc  LQESGGGLVQPGGSLRLSCAASGSRFSRYDMGWYRQAPGKQRELVATITSGGITNYADSVKGRFTISRDNTK
NTVYLQMNSLKPEDTAVYYCNAEDPLRAIQLGSLTYEYWGQGTQVTVSSPRGPTIKPCPPCKCPAPNLLGGPS
VFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMS
GKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTEL
NYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGKKDEL  
Bold: N1-VHHm sequence 
Underlined: linker or tag 
Italics: IgGa mouse Fc  
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IN VITRO ANTIVIRAL ACTIVITY OF N1-VHH AGAINST H5N1 CLADE 2.2 AND 
OSELTAMIVIR-RESISTANT IAV 
The N1rec NA is derived from the A/crested eagle/Belgium/01/2004 and belongs to the clade 1 
of the H5N1 NAs, as well as the NA of the NIBRG-14 (derived from A/Vietnam/1194/2004). In 
contrast, the H5N1 virus NIBRG-23 NA is derived from A/turkey/Turkey/01/2005, belonging to 
the clade 2.2. These three different NA used in this study, shared a high amino acid sequence 
homology (> 95%). Although the number of laboratory-confirmed human cases of H5N1 virus 
infection remain limited, it appears that clade 2 H5N1 viruses comprise a majority of these 
zoonotic infections with HPAIV (Poland et al., 2007). We therefore evaluated the antiviral 
potential of N1-3-VHH and N1-5-VHH in the three formats available (i.e. monovalent, bivalent 
without and with Fc) against the clade 2.2 virus NIBRG-23 (Table 3, Figure 16B). Monovalent 
N1-3-VHHm and N1-5-VHHm reduced in vitro growth of NIBRG-23 virus on MDCK with an IC50 
in the low micromolar range (Table 3). Both bivalent formats of these NA-inhibitory VHHs (N1-3-
VHHb, N1-5-VHHb, N1-3-VHH-Fc and N1-5-VHH-Fc) displayed an approximately 150-fold 
higher in vitro antiviral activity against this clade 2 virus, as judged by a plaque size reduction 
assay. Based on these findings, we conclude that the two NA-inhibitory VHHs can inhibit 
representative H5N1 IAV from clade 1 and 2, with a comparable efficiency in vitro, suggesting 
that they target a common epitope of the NA of these viruses.  
Oseltamivir-resistant IAV frequently emerge and spread in the human population. Several 
mutations have been reported to contribute to oseltamivir-resistance but among these, the 
H274Y mutation (N2 numbering) is the most commonly found in oseltamivir-resistant viruses 
(Wang et al., 2002a). We used reverse genetics (Hoffmann et al., 2000) to generate a clade 1 
H5N1 virus harboring the H274Y mutation in NA derived from A/crested eagle/Belgium/09/2004 
(the HA segment from NIBRG-14 and the remaining 6 segments from PR/8), resulting in the 
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H5N1 H274Y virus used in this study. Next, we determined if our N1-3-VHHm, N1-5-VHHm, N1-
3-VHHb, N1-5-VHHHb, N1-3-VHH-Fc and N1-5-VHH-Fc would be active against this 
oseltamivir-resistant H5N1 virus that carries the H274Y mutation. Given that all of our formats of 
N1-3-VHH and N1-5-VHH performed similar in biochemical and in vitro antiviral activity assays, 
we were surprised to observe that only the N1-3-VHH in monovalent and both bivalent formats, 
but not any format of N1-5-VHH, reduced the growth of oseltamivir-resistant H5N1 H274Y virus 
(Table 3, Figure 16C). Compared to NIBRG-14 as a target, the H5N1 H274Y IC50 values were 
3- to 7-fold higher, but still in the low nM range. Even though the competitive SPR analysis 
suggested that the N1-3-VHHm and N1-5-VHHm epitopes in NA overlap, the contact residues 
necessary for their binding are probably not the same. The H274Y mutation seems to be 
sufficient to abolish the in vitro antiviral effect of the N1-5-VHH formats during the infection with 
the H5N1 H274Y mutant virus used in this study. We conclude that N1-3-VHHm, N1-3-VHHb 
and N1-3-VHH-Fc can inhibit growth of H5N1 viruses in vitro, and that their antiviral protection is 
enhanced in both bivalent formats.  
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Figure 16.  Comparative antiviral effect of the monovalent and bivalent formats of the N1-VHH in 
representative plaque assays. Dilution series of VHH (Dilution left column) were incubated 1 hr at 37 °C 
with the indicated virus, and then TMPRSS2 MDCK cells were infected with A. NIBRG-14, B. NIBRG-23 
or C. H5N1 H274Y. After 1 hr of adsorption, fresh medium containing the corresponding diluted VHH was 
added to the washed cells. The infected cells were incubated for 24 hrs and immunostained against M2 
protein. The antiviral effect was dose-dependent as indicated in the dilution series. D. Representative 
sizes of the average plaque sizes (amplified 10X, compared with plaques in A, B and C) visualized by 
immunostaining.  –VHH, absence of N1-VHH treatment; Oseltamivir, Os. 
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N1-3-VHHm AND N1-5-VHHm TREATMENT REDUCES MORBIDITY IN H5N1-
CHALLENGED MICE 
We next evaluated the in vivo antiviral effect of N1-3-VHHm and N1-5-VHHm. In a first 
experiment we administered intranasally 100 µg of N1-3-VHHm, N1-5-VHHm, and N1-7-VHHm 
to Balb/c mice at 4 hours before challenge with 4 LD50 of mouse-adapted NIBRG-14 virus 
(NIBRG-14 ma). As positive controls we included a group of mice that received 30 µg of H5-
VHHb, a bivalent NIBRG-14 ma HA neutralizing VHH (Ibanez et al., 2011), as well as daily oral 
administration of oseltamivir at a high dose of (45 mg/kg/day). The body weight was followed 
daily, and the groups treated with the inhibitory N1-3-VHHm or N1-5-VHHm showed a 
significant difference in morbidity at 72 and 96 hours after infection, compared with the groups 
treated with the N1-7-VHHm and PBS (P < 0.001) (Figure 17A). Four days after infection, the 
mice were sacrificed to determine lung virus titers. Assessment of the lung virus load by 
endpoint dilution in a TCID50 assay revealed that all mice had a high virus load between -4.75 
to -6.48 TCID50/ml approximately in the lung homogenates (including the oseltamivir-treated 
group), except for the H5-VHHb treated group, which had lung virus titres below detection level 
(Figure 17B). We therefore decided to quantify the amount of viral RNA in the lung 
homogenates using a genome strand-specific RT-qPCR method. Except for the samples 
derived from the H5-VHHb treated mice, all the N1-VHH treated groups showed high viral RNA 
levels at 96 h after infection, comparable to those in the PBS-treated group, even so for the high 
oseltamivir-treated mice, although this group differed significantly from the single dose N1-
VHHm treated animals (P < 0.05) (Figure 17C). We conclude that intranasal administration of 
N1-3-VHHm and N1-5-VHHm prevents body weight loss after challenge with NIBR-14 ma virus 
during the early stage of infection. 
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BIVALENT N1-VHH PROTECTION AGAINST H5N1 CHALLENGE  
The in vitro results indicated that the bivalent formats of the inhibitory N1-VHHs increased their 
potency against the tested H5N1 viruses between 30- to 240-fold compared to their monovalent 
counterparts (Table 3). We therefore assessed if this increased antiviral effect would also be 
reflected in an in vivo challenge experiment. We first determined the protective potential during 
the early stages of viral infection. Four hours prior to challenge with 4 LD50 of NIBRG-14 ma, 
groups of Balb/c mice were intranasally given 60 µg of N1-3-VHHb, 60 µg of N1-5-VHHb, 60 µg 
of BL-VHHb (a bivalent VHH directed against the irrelevant bacterial target β-lactamase), 84 µg 
of N1-3-VHH-Fc, 84 µg of N1-5-VHH-Fc or 84 µg of GP4-Fc (a plant-produced Coronavirus-Fc 
fusion protein with an IgG2a Fc moiety, used here as an irrelevant control). Treatment with N1-
Figure 17. Single intranasal administration of N1-3-VHHm, N1-5-VHHm, N1-3-VHHb and N1-5-VHHb 
decrease the morbidity during the first four days after challenge with H5N1 virus. A. Groups of 6-8 week-
old Balb/c mice were given 100 µg of indicated VHH, administered intranasally at 4 hours before 
challenge with 4 LD50 of NIBRG-14ma virus. Thirty µg of intranasal administered H5-VHHb and daily oral 
administration of oseltamivir (45/kg/day, from 4 hrs before challenge) were included as positive controls. 
Body weight was monitored daily after challenge and expressed as the percentage of initial body weight. 
The groups of mice treated with N1-3-VHHm and N1-5-VHHm displayed significantly less morbidity than 
the groups treated with PBS (P < 0.001), N1-7-VHHm (P < 0.001) at 72 and 96 hours post infection. Mice 
were sacrificed on day 4 after challenge and lung homogenates were prepared. B. Assessment of the 
lung virus load by endpoint dilution of the NIBRG-14 infected mice treated with N1-VHH (TCID50/ml). C. 
A viral genome specific RT-qPCR was used as readout for the viral load. The obtained Ct values for the 
individual mice are plotted and a horizontal line indicates the mean. The Ct value H5-VHHb group was 
significantly different (indicative for lower virus load), compared to all other groups (***: P < 0.001). The 
oseltamivir-treated group was only slightly different from the groups treated with the N1-3-VHHm, N1-5-
VHHm and N1-7-VHHm (*: P < 0.05). D. The bivalent format of the N1-3-VHH and N1-5-VHH increases 
the potency to reduce the morbidity in H5N1-challenged mice. Four hours before challenge with 4 LD50 of 
NIBRG-14 ma, groups of Balb/c mice were treated intranasally with 60 µg of VHHb (N1-3-VHHb, N1-5-
VHHb or BL-VHHb), 84 µg of VHH-Fc (N1-3-VHH-Fc, N1-5-VHH-Fc or GP4-Fc). Mice treated with 
neutralizing H5-VHHb (30 µg) or oseltamivir (45 mg/kg/day, daily by gavage) were included as positive 
controls. The groups treated with both bivalent formats of the N1-3-VHH and N1-5-VHH were significantly 
different compared with groups treated with: BL-VHHb and GP4-Fc at 60 hpi (P < 0.05), 72 and 96 hpi (P 
< 0.001); PBS, 36 and 60 hpi (P < 0.05), and at 72 and 96 hpi (P < 0.001). 
CONFIDENTIAL Page 111 
 
3-VHHb or N1-3-VHH-Fc significantly improved morbidity at 72 and 96 hours after infection (hpi) 
compared with the negative control groups GP4-Fc and PBS (P < 0.001). The protection against 
weight loss was comparable to that observed with the positive controls (H5-VHHb and 
oseltamivir, the latter given daily at 45 mg/kg/day, by gavage) (Figure 17D). Treatment with the 
bivalent formats of N1-5-VHH resulted in a decrease in morbidity that was significant at 60, 72 
and 96 hpi compared with the negative controls (P < 0.001) (Figure 17D). Determination of the 
lung virus load on the fourth day after challenge by a TCID50-based assay using lung 
homogenates from sacrificed mice revealed that all challenged groups, except the H5-VHHb-
treated mice (no virus detectable), had a comparable lung virus load (Figure 17B). Taken 
together, both bivalent formats (tandem repeats and Fc-mediated) of N1-inhibitory N1-3-VHH 
and N1-5-VHH improve protection during the first four days following NIBRG-14 ma challenge, 
but did not decrease significantly the viral load in H5N1-infected mice lungs. 
 
BIVALENT N1-VHH PROTECTION AGAINST A LETHAL CHALLENGE WITH H5N1 VIRUS 
IS DOSE-DEPENDENT  
In order to see if mice that have been challenged with 4 LD50 of NIBRG-14 ma virus can be 
rescued by prior administration of N1-3-VHHb, N1-3-VHH-Fc, N1-5-VHHb or N1-5-VHH-Fc, we 
followed the morbidity and mortality over a 2-week period. For this, we focussed on the bivalent 
formats and first assessed their protective efficacy in a dose-response experiment. Groups of 
four Balb/c mice were treated intranasally with 60, 12, 2.5 or 0.5 µg of N1-3-VHHb or N1-5-
VHHb. In parallel, another group was treated by oral administration of oseltamivir (45 
mg/kg/day). Negative control groups were treated with 60 µg of BL-VHHb or with PBS prior to 
challenge. In this experiment, mice that had received 60 µg of N1-3-VHHb, N1-5-VHHb or BL-
VHHb prior to the challenge received a second intranasal dose with 60 µg of the same bivalent 
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VHH at day 6 after the challenge. All mice from the PBS and BL-VHHb treatment groups 
succumbed at 9 -10 days after the challenge. In contrast, oseltamivir and intranasal high dose 
N1-3-VHHb or N1-5-VHHb (60 µg) treatment displayed clear body weight loss following 
challenge (Figure 18A and C), but protected the mice against lethality (Figure 18B and D). The 
surviving N1-3-VHHb 60 µg treated group, but not the N1-5-VHHb 60 µg treated group, 
displayed a significant delay in recovery from weight loss after the challenge compared with the 
oseltamivir treated group (Figure 18A and C). A single intranasal dose of 12 µg or 2.5 µg of 
either N1-3-VHHb or N1-5-VHHb provided partial protection against mortality but failed to 
reduce morbidity (Figure 18A-D). 
We next evaluated protection against a potentially lethal NIBRG-14 ma challenge by prior single 
intranasal administration of the plant-produced N1-3-VHH-Fc and N1-5-VHH-Fc formats. Eighty-
four and 17 µg of N1-3-VHH-Fc as well as oseltamivir treatment provided full protection against 
NIBRG-14 ma challenge and the survival of the mice treated with 3.5 and 0.7 µg was dose-
dependent (Figure 19B and D). Nevertheless this protection was associated with significant 
body weight loss for all dosages used, including the oseltamivir group (Figure 19A and C). All 
PBS and GP4-Fc treated animals died at day 9 after the challenge. On the other hand, the body 
weight loss was less severe in all N1-5-VHH-Fc treated groups, and only in the group treated 
with 0.7 µg some of the mice died (Figure 19B and D). Finally, when comparing the protective 
efficacy of the two bivalent formats of N1-3-VHH and N1-5-VHH, it appears that the Fc moiety in 
the N1-VHH-Fc formats provides an extra protective effect against morbidity and mortality 
following NIBRG-14 ma challenge. Taken together, we conclude that bivalent formats of N1-3-
VHH and N1-5-VHH can protect mice against a potentially lethal challenge with an H5N1 virus, 
although this protection does not completely eliminate morbidity. 
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Figure 18.  The bacteria-produced N1-VHHb formats protect against morbidity and mortality in a dose-
dependent way in H5N1-challenged mice. Unless is stated, groups of 4 Balb/c mice were given the 
indicated amount of N1-VHH and administered 24 hours before challenge with 4 LD50 of NIBRG-14ma 
virus. One group of mice was treated with one dose of oseltamivir (45 mg/day/kg) as positive control at 
24 hrs before challenge, followed by daily boost from 6-14 days after challenge. A boost of N1-VHHb 
was given at 6 dpi only to the highest doses of each treatment.  A. The group of mice treated with 60 µg 
of N1-3-VHHb presented significant increase in morbidity compared to the oseltamivir group at: 10 – 11 
dpi (P < 0.001), 12-13 dpi (P < 0.01) and 14 dpi (P < 0.05). The difference of the morbidity between the 
different N1-3-VHHb treated groups was not significant (P > 0.05).  B. The survival of the N1-3-VHHb 
60 µg group was 100 %, being highly significant compared to the control groups BL-VHHb 60µg and 
PBS (***, P < 0.001). The group N1-3-VHHb 12 µg survival was of 50%, but still significant compared to 
the PBS groups (**, P < 0.01). The survival of the groups treated with N1-3-VHHb 2.5 µg (25 %) and 
0.5 µg (0 %) was not different to the control groups (P > 0.05). C. The morbidity of the N1-5-VHHb 60 
µg treated group was different to the N1-5-VHHb 12, 2.5 and 0.5 µg groups at days 10 – 14 (P < 
0.001), but not different to the oseltamivir group (P > 0.05). D. The survival and significance of the N1-
5-VHHb treated groups was the same as the N1-3-VHHb treatment in C. dpi, days post infection.  
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N1-3-VHHB AND N1-3-VHH-FC PROTECT AGAINST A CHALLENGE WITH AN 
OSELTAMIVIR-RESISTANT H5N1 VIRUS 
In vitro analysis demonstrated that N1-3-VHH, but not N1-5-VHH, in monovalent or bivalent 
format could reduce the growth of oseltamivir-resistant H5N1 H274Y virus (Table 3). To try to 
extrapolate these findings to an in vivo challenge model, groups of six Balb/c mice received 30 
µg of N1-3-VHHb, N1-5-VHHb or BL-VHHb, by intranasal administration 24 hours before the 
challenge with 4 LD50 of either NIBRG-14 ma or H5N1 H274Y virus. A PBS recipient group was 
included as negative control. In parallel, a group was treated by daily oral administration of 
oseltamivir (1 mg/kg/day), a dose that has been reported to protect laboratory mice against a 
challenge with an H5N1 virus (Govorkova et al., 2001). All N1-3-VHHb, N1-5-VHHb and 
oseltamivir treated mice survived the challenge with NIBRG-14 ma virus whereas PBS and BL-
VHHb recipient mice succumbed (Figure 20A and B). This result demonstrates that a single 
intranasal administration of N1-3-VHHb of N1-5-VHHb is sufficient to protect against a 
subsequent (24 h later) potentially lethal challenge with an H5N1 virus that has an antigenically 
matching NA. Again all surviving mice suffered from substantial but transient weight loss after 
Figure 19.  The plant-produced N1-VHH-Fc treatment gave better protection against morbidity and 
lethality than the N1-VHHb treatment in H5N1-challenged mice. Groups of Balb/c mice were given the 
indicated amount of N1-VHH-Fc and administered 24 hours before challenge with 4 LD50 of NIBRG-
14ma virus. One group of mice was treated with one dose of oseltamivir (45 mg/day/kg) as positive 
control at 24 hrs before challenge, followed by daily boost from 6-14 days after challenge. A boost of 
N1-VHH-Fc was given at 6 dpi only to the highest doses of each treatment, including the oseltamivir.  A. 
Groups of 6 Balb/c mice were treated with different amounts of N1-3-VHH-Fc, but the difference in 
morbidity was not significant between them or compared with the oseltamivir treated group (P > 0.05). 
B. The survival of the N1-3-VHH-Fc treated groups is dose-dependent, and is significant compared to 
the control groups PBS and GP4-Fc 84 µg: N1-3-VHH-Fc 84 µg and 17 µg, 100% (both ***, P < 0.001); 
N1-3-VHH-Fc 3.5 µg, 66.6 % (**, P < 0.01); 0.7 µg, 33.3 % (PBS only *, P < 0.05, ). C. The morbidity of 
the groups treated with N1-5-VHH-Fc was not significant different between them and to the oseltamivir-
treated group. D. The survival of the groups treated with N1-5-VHH-Fc 84, 17 and 3.5 µg was 100%, 
being highly significant compared with the groups GP4-Fc 84 µg and PBS (both ***, P < 0.001). The 
treatment with N1-5-VHH-Fc 0.7 µg resulted in a survival of 75 %, different from the groups GP4-Fc 84 
µg and PBS (**, P < 0.01). 
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the challenge (Figure 20A). From the mice that had been similarly treated as above but 
challenged with H5N1 H274Y virus, only those that had received N1-3-VHHb prior to the 
challenge survived. All other groups, including those that had been treated with an oseltamivir 
dose that fully protected against a NIBRG-14 ma challenge, died following the challenge with 
the H5N1 H274Y virus (Figure 20C and D). 
Finally, we evaluated the effect of prior intranasal instillation of N1-3-VHH-Fc, N1-5-VHH-Fc, 
including also N1-7-VHH-Fc in our lethal challenge model. We again included PBS and 
oseltamivir treatment groups as well as GP4-Fc recipients. Following challenge with 4 LD50 of 
NIBRG-14 ma, all mice except one in the PBS and one in the GP4-Fc group died. In the N1-7-
VHH-Fc group, only one of the six mice died after challenge. In contrast, all mice in the N1-3-
VHH-Fc, N1-5-VHH-Fc and oseltamivir groups survived this challenge, all displaying significant 
body weight loss, except for the mice that had received N1-5-VHH-Fc appearing to be fully 
protected from morbidity following the NIBRG-14 ma challenge (Figure 21A and B). A challenge 
with H5N1 H274Y virus proved lethal to all mice except for those that had been treated in 
advance with N1-3-VHH-Fc (all mice survived) or N1-7-VHH-Fc (4 out of 6 mice survived) 
although all animals suffered from substantial body weight loss (Figure 21C and D). We 
conclude that bivalent NA-specific VHH can protect against a potentially lethal challenge with 
oseltamivir-resistant H5N1 virus. 
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Figure 20. Single-dose treatment with N1-3-VHHb, but not with N1-5-VHHb, rescued mice from a H5N1 
H274Y lethal challenge. Twenty-four hours before challenge with 4 LD50 of NIBRG-14 ma or 1 LD50 
H274Y H5N1 virus, groups of 6 Balb/c were given: 60 µg of N1-3-VHHb, N1-5-VHHb or BL-VHHb. A 
group of 6 mice was treated with oseltamivir (1 mg/day/kg) as positive control. A. There was no 
significant difference in the morbidity between the groups treated with N1-3-VHHb and N1-5-VHHb, or 
compared to the oseltamivir group during the NIBRG-14 infection (P > 0.05). In contrast there was an 
increased morbidity in the irrelevant bivalent VHH BL-VHHb and the PBS treated groups until 9 day post 
infection. B. In NIBRG-14 ma infected mice, the N1-3-VHHb, N1-5-VHHb and oseltamivir-treated groups 
showed a survival of 100%, being significantly different from the control groups BL-VHHb and PBS (***, 
P < 0.001), where all the mice were dead at 10 days post infection. C. The morbidity of H5N1 H274Y 
treated group was severe and only slightly delayed compared with all other groups. The maximal body 
weight loss of all groups was close to 70 % at 9 days post infection, but only the N1-3-VHHb treated 
group showed an increase of body weight at and after 10 dpi. D. The treatment with N1-3-VHHb rescued 
all the H5N1 H274Y infected mice (survival of 100 %), with high significance compared with the rest of 
the groups (***, P < 0.001). The N1-5-VHHb, oseltamivir, BL-VHHb and PBS treatments failed to rescue 
H5N1 H274Y infected mice.  
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DISCUSSION 
As commented in the introduction, for several years the vaccine-induced Ab efficacy has been 
focused rather on HA immunogenicity than NA. NA Abs exert their effects further downstream in 
the IAV infection process, cannot neutralize the viral infectivity, but they can sharply inhibit 
replication efficiency and reduce the disease severity upon infection (Schulman et al., 1968; 
Johansson et al., 1987). There is evidence that the NA Ab response during vaccination can be 
correlated with the NA activity, which is in turn dependent on the NA amount present in the 
vaccine formulation. Elderly subjects, immunized with trivalent inactivated vaccines containing 
H1N1 or H3N2 IAV, presented high titers of NA Ab, after a high dose of vaccine. Ab titers 
against N1 or N2 had been associated with high NA enzymatic activity in the vaccine 
preparation, suggesting that the NA content and activity in IAV vaccines is a predictive marker 
for immunogenicity (Cate et al., 2010). Nevertheless, the HA immunodominancy over NA, and 
the low NA antigen content in vaccines are factors that contribute to the lack of conclusive 
Figure 21. The single-dose treatment with N1-3-VHH-Fc and N1-7-VHH-Fc rescued mice from a H5N1 
H274Y 1 LD50 challenge, but not with N1-5-VHH-Fc. Twenty-four hours before challenge with 4 LD50 of 
NINRG-14 ma or 1 LD50 H274Y H5N1 virus, groups of 6 Balb/c were given: 84 µg of the N1-3-VHH-Fc, 
N1-5-VHH-Fc, N1-7-VHH-Fc or GP4-Fc. A group of 6 mice was treated with oseltamivir (1 mg/day/kg) as 
positive control. A. In NIGRG-14 ma infected mice, the difference in morbidity of the N1-5-VHH-Fc group 
compared with the N1-3-VHH-Fc, N1-7-VHH-Fc or oseltamivir groups is significant at days: 8 -13 dpi (P 
< 0.001) and 14 dpi (P < 0.01). The difference in morbidity between N1-3-VHH-Fc, N1-7-VHH-Fc or 
oseltamivir groups was not significant, and the maximal peak of weight loss was 9 days post infection. B. 
In NIBRG-14 ma infected mice, the treatment of N1-3-VHH-Fc, N1-5-VHH-Fc and oseltamivir results in a 
highly significant survival of 100%, when compared to PBS and GP4-Fc (***, P < 0.001). The group 
treated with N1-7-VHH-Fc presented a survival of 83.3 %, and is significantly different compared to PBS 
and GP4-Fc (**, P < 0.01). C. In a similar way as in figure 20C, in the H5N1 H274Y infected mice treated 
with N1-3-VHH-Fc and N1-7-VHH-Fc presented severe body weight loss, but a positive gain was seen 
at 10 days post infection in this two groups. The N1-5-VHH-Fc, oseltamivir, GP4-Fc and PBS groups did 
not present any body weight gain. D. In H5N1 H274Y infected mice, the survival of the groups treated 
with N1-3-VHHb and N1-7-VHH-Fc was significant, 100 % (***, P < 0.001) and 66.6 % (*, P < 0.05), 
respectively. The N1-5-VHH-Fc, oseltamivir, GP4-Fc and PBS treatments failed to rescue any H5N1 
H274Y infected mice. 
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evidence in order to determine the amount of NA antigen necessary to elicit a protective 
response. During the last decade, growing evidence of the importance in the NA-dependent 
immune response resulted in the proposal to standardize the NA content in the seasonal 
vaccine formulation (Johansson et al., 1998; Kilbourne et al., 2004; Marcelin et al., 2012). 
Besides the immunogenic and viral protein aggregation, there are other NA roles reported: 
cleavage of decoy receptors of mucins, a process that may be necessary during the initiation of 
infection (Matrosovich et al., 2004a), limitation of IAV superinfections and reassortment (Huang 
et al., 2008), and the possibility of increased IAV infectivity (Goto and Kawaoka, 1998). 
Interestingly, in replicative H5N1 IAVs that are sensitive to NA-inhibitory drugs, a crippled or 
absent NA activity had been observed. For example, introduction of the mutation R156K 
decreased 90% of NA activity in H5N1 IAV, under peramivir pressure. The lack of peramivir 
selective pressure results in the disappearance of this mutant IAV, in culture (Ilyushina et al., 
2012). Other reports have shown that the fitness of mutant IAV virus lacking the NA gene or NA 
activity can be rescued, by decreased HA binding to Sia receptors, due to insertions of 
mutations or glycosylations in the HA, that affect the receptor-binding site  (Gubareva et al., 
2002). The compensatory effect in the HA and NA activities towards fitness had been widely 
reported (Mitnaul et al., 2000; Gubareva et al., 2002; Nedyalkova et al., 2002), demonstrating 
that the NA activity can be compromised, but not necessarily results in a replication-deficient 
IAV. These pieces of evidence highlight the IAV mutants’ complicate escape mechanism, under 
selective pressure. There are also important roles of the NA function that seem not to depend 
on the catalytic site: enhancement of neurovirulence (i.e. the glycan at position 130) (Li, et al. 
1993); enhanced pathogenicity (length of NA stalk), (Yamada et al., 2006; Matsuoka et al., 
2009). Taken together, these data demonstrate the major importance of NA during IAV 
infection, and targeting NA is a rational choice to generate an effective antiviral strategy, 
dependent or independent of the NA-catalytic activity.  
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Our N1-VHHs are not the first inhibitory mAb against a H5N1 NA. Recently, the IgG2bκ mAb 
2B9 derived from A/Vietnam/1203/04 (H5N1), showed H5N1 interclade and oseltamivir- 
resistant mutant inhibition (N294S) in vitro (Shoji et al., 2011). In a MUNANA and NA-Star 
(Applied Biosystems) based NA activity assay in live viruses, the 2B9 mAb inhibited the H5N1 
clade 1 A/Vietnam/1203/04, the clade 2.1 A/Indonesia/05/05 and the oseltamivir-resistant 
double mutant A/Vietnam/HN/30408/05 (H274Y and N294S, N2 numbering) with a 2B9 IC50 
concentration of approximately 1, 8 and 1 µg/ml, respectively to each IAV. In our study, we used 
our panel of inhibitory N1-VHH in their three formats (N1-VHHm, N1-VHHb and N1-VHH-Fc) to 
assess their NA inhibitory and antiviral potential, by NA inhibition assays (using our purified 
N1rec), and also in cell-based plaque reduction assays. Both of our assays cannot be compared 
directly with the NA inhibition assays performed by Shoji and coworkers (2011). Our N1rec 
inhibition assay relies on purified protein, and the NA total protein used in our assays (160 ng) is 
likely to be higher that the NA molecules copies in live virus preparations. In addition, our MDCK 
TMPRSS2-based assay measured the capacity of our N1-VHH formats to inhibit the spreading 
of the H5N1 viruses in a cell monolayer, where other factors than NA inhibition can play a role in 
the virus spreading (i.e. aggregation of viral proteins in the cell membrane). Nevertheless, our 
N1rec inhibition assay results using the N1-3-VHHm and N1-5-VHHm as inhibitors, showed that 
their IC50 of 425 nM (6.3 µg/ml) and 374 nM (5.6 µg/ml), respectively, are increased 2 – 3 log 
fold by the introduction of bivalency, in both bivalent formats (N1-VHHb and N1-VHH-Fc) (Table 
3). In addition, an enhanced but more modest antiviral effect by the bivalent formats was also 
seen in the cell-based assays (Table 3). In NIBRG-14 (NA derived from A/Vietnam/1194/04) 
infected cells, the concentration necessary to inhibit 50% of plaque size (PIC50, table 3) using 
N1-3-VHHm and N1-5-VHHm was 1.8 µM (27.3 µg/ml) or 0.8 µM (12.7 µg/ml), respectively, 
which represents a 30- and 240-fold decrease, respectively when compared with their bivalent 
formats. Interestingly, we also documented in vitro plaque size reduction for the clade 2 H5N1 
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virus NIBRG-23 (NA derived from A/turkey/Turkey/2005, clade 2.2), where N1-3-VHHm and N1-
5-VHHm treatment presented a PIC50 of 4.2 µM (63.6 µg/ml) and 3.4 µM (52.3 µg/ml), 
respectively, resulting in an increase of the inhibitory potential of 130- and 170-fold, respectively 
in both bivalent formats (Table 3). The NAs of NIBRG-14 and NIBRG-23 belong to different 
H5N1 clades but share an homology of 96.7%, and the substitutions in their NA sequences do 
not affect any of the NA catalytic site residues (substrate direct-contact or framework residues). 
These results suggest that the epitope recognized by both N1-3-VHHm and N1-5-VHHm is 
conserved between the H5N1 clades 1 and 2.  
In a murine model, the mAb 2B9 failed to give total protection against the H5N1 
A/Vietnam/1194/2004 challenge. Intravenous administration of 500 μg of 2B9 1 hour before 10 
LD50 of H5N1 IAV, and a daily boost for 5 days, could only protect 50% of mice from mortality, 
and surviving mice displayed a body weight loss peak of ca. 10% on day 9 after infection (Shoji, 
et al. 2011). In our study, we are reporting that a single dose of intranasally administered 60 μg 
of the bacteria–produced N1-3-VHHb or N1-5-VHHb 24 hours before a H5N1 4 LD50 challenge 
can protect 100% of the mice (Figure 18B and D), but a body weight loss peak of 10 – 20% at 9 
days post infection was also observed (Figure 18A and C). The most important difference 
between a conventional mouse mAb and bacteria-produced N1-3-VHHb and N1-5-VHHb is the 
lack of an Fc domain in VHH. Therefore, we also evaluated plant-produced bivalent formats of 
N1-VHH-Fc. For a similar molar amount, N1-VHH-Fc displayed a better protection in H5N1 
challenged mice than the bacteria-produced bivalent N1-VHH. Furthermore, a single dose of 17 
or 3.5 μg of N1-3-VHH-Fc or N1-5-VHH-Fc, respectively, also resulted in 100% of survival in 
mice (Figure 19B and D), and the treatment of N1-5-VHH-Fc decreased significantly or even 
prevented morbidity (Figures 18A and 19C). By comparing the molar ratio necessary to give 
100% survival of H5N1 challenged mice in N1-3-VHH-Fc or N1-5-VHH-Fc treatments 
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(compared to N1-3-VHHb or N1-5-VHHb), we found that approximately 10 or 50 times lower 
amounts of the plant-produced formats are necessary. 
Compared with the 2B9 treatment in order to rescue 100% of H5N1 challenged mice, the single 
dose treatment with our N1-3-VHHb/N1-5-VHHb or N1-3-Fc/N1-5-VHH-Fc requires a 10- or 
150-fold, respectively, lower amount of Ab needed at the beginning of the treatment. Our 
bivalent N1-VHH formats gave 100% survival without any boost, showing better protection 
compared with the 50% survival rate conferred by 2B9 treatment of 500 µg with 5 daily boosts. 
The intravenous administration of 2B9 in the work of Shoji and colleagues (2011) could be an 
important factor that can contribute to the superior protection of our N1-VHH formats, whose 
administration was intranasally. The study of Shoji and colleagues (2011) also evaluated 
protection by mAb 2B9 in the ferret model. The individual viral titers in nasal wash samples of 
H5N1 challenged ferrets treated with 2B9 4 days after infection showed a maximal difference of 
half to one log10 of difference, compared to a PBS treated group. N1-VHH treatment did not 
seem to suppress lung virus titers in our model (Figure 17B and C). This finding is in line with 
the paradigm that NA Abs or NA-inhibitory drugs do not prevent infection and that NA-specific 
immunity is infection permissive.  
The observation that the N1-5-VHHm, N1-5-VHHb and N1-5-VHH-Fc treatments did not have 
any antiviral activity against the oseltamivir-resistant H5N1 H274Y virus in vitro was surprising. 
Not even the highest dilution of any N1-5-VHH format diminished the size or number of the 
plaques (Table 3). In contrast, the N1-3-VHHm treatment presented an antiviral effect in H5N1 
H274Y infected cells, but its PIC50 was approximately 3.5-fold higher when compared to NIBRG-
14 infected cells. The introduction of bivalency in the N1-3-VHH also increased the antiviral 
effect in H5N1 H274Y, by a decrease of 70- to 120-fold in the PIC50 (Table 3). In a H5N1 H274Y 
challenged mice model, we found confirmation of our in vitro results. As previously mentioned, 
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N1-5-VHHb or N1-5-VHH-Fc had a potent antiviral effect and rescued NIBRG-14 ma challenged 
mice (Figure 20A and B, 21A and B), but failed completely to rescue H5N1 H274Y challenged 
mice (Figure 20C and D, 21C and D). The mortality and morbidity presented by these two N1-5-
VHH format treatments during H5N1 H274Y infection was the same as PBS, the irrelevant 
bivalent VHH or oseltamivir groups. In contrast, single dose of N1-3-VHHb or N1-3-VHH-Fc in 
separate treatments, abolished completely mortality but largely failed to control morbidity 
(Figure 20 and 21). An unexpected result was the finding that N1-7-VHH-Fc had in vivo antiviral 
activity. Throughout this project, N1-7-VHH was chosen as an NA-binding but not inhibitory N1-
VHH. Unfortunately, due to cloning difficulties, we did not obtain the bivalent format N1-7-VHHb, 
but the N1-7-VHH-Fc was successfully produced and purified. In our in vitro assays we could 
not observe any antiviral effect of the N1-7-VHHm or N1-7-VHH-Fc. Nevertheless, the N1-7-
VHH-Fc treatment in NIBRG-14 ma or H5N1 H274Y challenged mice gave 83.3% or 66% of 
survival, respectively, even when a NA inhibitory potential is absent in the N1-7-VHH-Fc (Figure 
21B and D). Like the N1-3-VHH-Fc treatment, the N1-7-VHH-Fc treatment was associated with 
severe morbidity (Figure 21A and C). These results suggest that the in vivo antiviral potential of 
the N1-VHH-Fc format is enhanced when the VHH moiety has NA-activity inhibition (like in N1-
3-VHH-Fc and N1-5-VHH-Fc), but does not depend entirely on the NA inhibition potential.  
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ADDITIONAL DATA  
N1-5-VHHb AND N1-5-VHH-Fc PROTECT AGAINST MORBIDITY IN H5N1 CHALLENGED 
FcγRI / FcγRIII K.O. MICE 
Our previous in vivo results indicated that N1-3-VHH-Fc and N1-5-VHH-Fc treatments needed 
lower amounts to give ful protection and decrease morbidity, compared to N1-3-VHHb or N1-5-
VHHb (compare figure 18B and D with Figure 19B and D). These results suggest that bivalent 
format N1-VHH-Fc treatment protection is more potent to rescue H5N1 challenged mice than 
the bivalent N1-VHHb that lacks the Fc moiety. The enhanced protection by the Fc moiety in the 
N1-VHH-Fc can be attributed to the induction of ADCC or CDC, as well as an increased half life 
in the lungs, compared to N1-VHHb formats. On the other hand, the better protection given by 
the treatment of N1-5-VHH-Fc compared to the N1-3-VHH-Fc in H5N1 challenge mice could be 
partially explained by a higher proteolytic stability of the N1-5-VHHm compared to N1-3-VHHm 
(see figure 15D). We therefore decided to choose the N1-5-VHH-Fc over the N1-3-VHH-Fc to 
test the contribution of protection of the Fc moiety, comparing it with N1-5-VHHb. Groups of four 
16-week-old double knockout FcγRI / FcγRIII K.O. mice were treated with 60 μg of N1-5-VHHb, 
or 84 μg of N1-5-VHH-Fc, N1-7-VHH-Fc or GP4-Fc 24 hours before the challenge with 4 LD50 
NIBRG-14 ma, and the weight loss was followed daily. The N1-5-VHH-Fc treatment completely 
abolished morbidity, in contrast with the N1-5-VHHb and N1-7-VHH-Fc, of which the treatment 
reached a peak of 17% and 25% weight loss, respectively, at 8 dpi (Figure 22). The control 
treated groups of GP4-Fc and PBS showed a weight loss close to 30% (Figure 22). The N1-5-
VHH-Fc was able to fully protect mice against morbidity, even with the lack of the FcγRI and 
FcγRIII Fc receptors, suggesting the absence of a major role of these receptors in the rescue by 
the N1-5-VHH-Fc in H5N1 challenged mice. Possibly, the presence of the FcγRIV in these 
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double K.O. mice could partially rescue the Fc moiety contribution to the N1-5-VHH-Fc 
protection. 
 
 
 
 
 
 
 
 
 
N1-5-VHHm ESCAPE MUTANTS 
In order to identify the amino acid residues involved in the N1-3-VHHm or N1-5-VHHm binding 
to H5N1 NA, mutant escape viruses were selected and plaque purified from serial passages of 
NIBRG-14 virus in MDCK cells, in the presence of 10 IC50 of N1-3-VHHm or N1-5-VHHm (Table 
Figure 22. The treatment with N1-5-VHHb and N1-5-VHH-Fc decrease significantly the morbidity in 
H5N1 challenged FcγRI / FcγRIII K.O. mice. Twenty-four hours before challenge with 4 LD50 of NIBRG-
14 ma virus, groups of 4 FcγRI / FcγRIII K.O. mice were given: 60 µg of N1-5-VHHb or 84 µg of the N1-5-
VHH-Fc, N1-7-VHH-Fc or GP4-Fc. The N1-5-VHH-Fc treated group showed no morbidity and was 
statistically different to: the N1-5-VHHb group at 8 dpi (P < 0.01) and 9 dpi (P < 0.05); the N1-7-VHH-Fc 
group at 7- 11 dpi (P < 0.001), 12 dpi (P < 0.01) and 13 dpi (P < 0.05). The morbidity of the N1-5-VHHb 
treated group was statistically different to: GP4-Fc group, at 9 dpi (P < 0.05), 10 dpi (P < 0.01) and 11– 
12 dpi (P < 0.001) and 13 dpi (P < 0.05); PBS group, at 9-10 dpi (P < 0.01), 11 dpi (P < 0.01) and 12 dpi 
(P < 0.05). The morbidity between the N1-5-VHHb and the N1-7-VHH-Fc groups was not statistically 
different. 
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3). Unfortunately, 12 passages in the presence of N1-3-VHHm in NIBRG-14 infected MDCK 
cells did not yield any escape mutant virus. In contrast, after 12 passages, the NA sequences of 
four independently isolated N1-5-VHHm escape mutants revealed four mutations that resulted 
in amino acid residue substitution in the following positions (N2 numbering): one clone with a 
single substitution of tryptophan to arginine at 379 (W379R); one clone with a double 
substitution, glycine to valine at the 324 position (G324V) and threonine to tyrosine at 377 
(T377Y); another clone with the substitutions G324V, W379R and threonine to alanine at 418 
(T418A); and finally another double substitution, W379R and T418A, was found in the last 
clone. All the above substitutions, except G324V, are localized in the NA surface residues.  The 
T377Y and W379R substitutions are close to the 330-loop, which is restrained by a disulfide 
bridge by C336, and has been identified as one N2 NA antigenic site contributing to the binding 
of the mAb NC10 and NC41 by escape mutants and crystal structure analysis (Tulip et al., 
1992; Malby et al., 1994) (Figure 23). On the other hand, the T418A substitution seems to be 
closer to the epitope recognized by the mAb Mem5, which is closer to the NA catalytic site than 
the NC10 epitope (Figure 23). Nevertheless, the substitutions T377Y, W379R and T418A are 
not affecting the substrate-contact or framework residues of the NA catalytic site (Figure 23). 
From the NA surface substitutions, the W379R was the most abundant, presented in three 
independent clones. These results suggest that several substitutions in the surface of the NA 
are favored to be present in N1-5-VHHm escape mutants. 
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Figure 23. Epitope mapping in the A/Vietnam/1194/2004 H5N1 NA (VN04N1) by escape-mutants using 
N1-5-VHHm. NIBRG-14 infected TMPRSS2 MDCK cells were passed 10 – 12 times in the presence of a 
high concentration of N1-5-VHHm (10 IC50, from table 3). Resistant mutants were screened by induction 
of cytopathic effect in infected cells and single plaque purified. The NA gene of the escape mutants was 
subsequently sequenced. The catalytic cleft is depicted in surface and color presentation: residues that 
make direct contact with the Sia substrate (red), catalytic site framework (yellow) and the D149 and R150 
(blue) as part of the “150 loop”. In addition, the epitope loops of the mAb NC10 and Mem5 are depicted in 
orange and purple, respectively (the N2 numbering of the mAb epitopes had been adjusted to fit the N1 
numbering). Three mutations, T401Y, W403R and T436A were identified in the surface of the NA of N1-
5-VHHm escape mutants. These mutations are not in close proximity of the NA catalytic site, and are 
closer to the mAb NC10 epitope rather than the Mem5 epitope. 
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Chapter 4. GENERAL DISCUSSION AND PERSPECTIVES 
DISCUSSION 
The antibody-dependent cell mediated cytotoxicity (ADCC) is a cytolytic effector mechanism of 
anibodies in which the antigen-specific Ab initiates and directs the immune effector cell (typically 
natural killer cells, NKs) in the process of innate immunity by killing antigen-displaying cells. This 
mechanism involves the Fcγ receptors (FcγRs) and the recruitment of immune effector cells in 
an Fc-dependent manner, and destruction of the target cells by exocytosis of cytolytic cytokines 
by NKs. The complement-dependent cytotoxicity (CDC) is like ADCC, a cytolytic cascade 
known as “classical pathway” of the complement system, which is mediated by a series of 
complement proteins (C1-C9), abundantly present in the serum. It is triggered by binding of C1q 
to the Fc domain of immune complexes bound to the cellular surface. The mouse IgG2a-derived 
Fc moiety in the N1-VHH-Fc molecules is able to bind to Fc receptors and triggers Fc-
dependent immune responses (like ADCC or CDC), likely contributing to the protective potential 
of N1-VHH-Fc treatment. We performed a pilot experiment to further explore this hypothesis, 
using FcγRI / FcγRIII double K.O. mice. We chose to compare the protection given by N1-VHH-
Fc treatment (our most protective N1-VHH-Fc against a NIBRG-14 ma challenge) with N1-5-
VHHb and N1-7-VHH-Fc treatments. In NIBRG-14 ma challenged FcγRI / FcγRIII double K.O. 
mice, the N1-5-VHH-Fc treatment was able to protect them completely from morbidity. This N1-
5-VHH-Fc weight loss was significantly different from that of N1-5-VHHb at the 2 peak days of 
body weight loss, and that of N1-7-VHH-Fc at 7 – 13 days post infection, indicating a severe 
morbidity in this last treatment, similar to the negative control PBS or GP4-Fc groups (Figure 
22). Nevertheless, the morbidity presented during the treatment of N1-7-VHH-Fc in NIBRG-14 
ma challenged FcγRI / FcγRIII double K.O. or Balb/c mice is similar in both cases (compare 
Figure 21A with 22). Nevertheless, is necessary to mention that in our experiment the FcγRI / 
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FcγRIII double K.O. mice were substantially older (14 weeks instead of 7 weeks) compared with 
the wild-type Balb/c mice that were used in all the other in vivo experiments reported in this 
PhD. This age difference may explain why only a severe morbidity, but not mortality, was 
observed even in PBS-treated knockout mice that had been challenged with NIBRG-14 ma 
virus. However, their levels of morbidity revealed an interesting tendency of N1-5-VHH-Fc to 
confer higher degrees of protection, even in the absence of FcγRI / FcγRIII receptors. The 
mouse IgG2a is known as one of the most potent Ab isotypes to induce ADCC or CDC, due to a 
high affinity for FcγRIII and especially for FcγRI (KA: 108 - 109 M-1), which binds exclusively to 
IgG2a. Nevertheless, this IgG2a high affinity for FcγRI has a downside: normal serum levels of 
monomeric IgG2a can constantly bind to FcγRI, limiting the access of IgG2a immunocomplexes 
to FcγRI. IgG2a has an intermediate affinity for FcγRIV (KD: 2-3 X 107 M-1), which is one order of 
magnitude higher than its affinity to the inhibitor receptor FcγRIIB (Nimmerjahn and Ravetch, 
2006, 2008). Due to the high conservation and high expression of FcγRIV on neutrophils, 
monocytes, macrophages and dendritic cells, the activation of FcγR effector functions upon Ab 
binding is differentially regulated by the low affinity inhibitory FcγRIIB (Nimmerjahn and Ravetch, 
2006). The IgG2a activation/inhibition ratio (based on individual Fc receptors’ affinities for their 
respective Ab isotypes) of FcγRIII/FcγRIIB is 1.6, in contrast to that of FcγRIV/FcγRIIB which is 
70, indicating a more potent in vivo effector function of the IgG2a than IgG1 or IgG3 
(Nimmerjahn and Ravetch, 2006) (Figure 22). The presence of FcγRIV and the higher 
availability of soluble IgG2a (due the absence of FcγRI) in our double K.O. mouse model 
(Figure 22), could partially rescue a IgG2a activation potential of Fc-dependent effector 
functions in our H5N1 challenged mice model (Figure 22).  
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To our knowledge, our N1-VHH formats are the first VHH in any format reported to target any 
IAV NA. Despite the fact that several IAV NA inhibitory “classical” Abs (light and heavy chain) 
have been reported, their reported NA inhibitory capacity and antiviral effect was variable, 
depending on several factors: the animal model used, route of administration or NA substrate. 
The NA inhibitory mAb NC41, NC10 and Mem5 were able to inhibit the cleavage of 
macromolecular substrates like fetuin, but NC10 failed to prevent the cleavage of the small 
substrate NAL (Chapter 1; table 1). The ability to inhibit NA activity using small substrates like 
NAL or MUNANA seems to characterize Abs that bind close enough to the NA active site 
(Chapter 1; figure 5B), resulting in a possible full occlusion of the NA catalytic site. Given that 
Figure 22. Individual Ab isotypes have different affinities for activating and inhibitory Fc receptors. Red 
arrows indicate preferential interactions of the indicated antibody isotypes with cellular Fc receptors; 
black arrows indicate lower affinity interactions. In the case of IgG2a, the broken red arrow indicates 
that the interaction might be blocked as FcɤR1 is continuously occupied with monomeric IgG2a. The 
table summarizes the actual activation/inhibition ratios based on the affinities of the individual Fc 
receptors for the respective antibody isotypes (taken from (Nimmerjahn and Ravetch, 2006). 
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the VHH CDR3 has been proved to be the major factor responsible in the contact of the VHH 
with its antigen (Desmyter et al., 1996; Desmyter et al., 2002), the N1-3-VHH and N1-5-VHH 
CDR3 sequences of 10 and 12 residues long, respectively, are possibly involved in the direct 
contact with their antigen. In addition, as mentioned before, all NA inhibitory N1-VHHs found in 
this study (N1-1-VHH, N1-3-VHH, N1-5-VHH and N1-6-VHH) presented a predicted 
electronegatively charged protruding paratope that corresponds to their CDR3 (Chapter 3; figure 
11). Nevertheless, the presence of such protruding electronegative CDR3 does not guarantee 
NA inhibition. The N1-4-VHH CDR3 is similar to the inhibitory N1-VHH CDR3 (Chapter 3; figure 
11), but failed to inhibit NA activity. Interestingly, our most potent N1-VHHs, N1-3-VHH and N1-
5-VHH, share similarities in their CDR3. Both of them have a highly electronegative CDR3 
sequence, composed of mainly hydrophobic and electronegative amino acid residues. The 
CDR3 motifs of N1-3-VHH (hGXXhGhGXhX) and N1-5-VHH (hXhXhhXhXh), where h is a 
hydrophobic residue and X is an aspartic or glutamic acid, resulted in a protruding paratope that 
is electronegatively charged, according to the N1-VHH 3D structure simulation (Figure 11). On 
the other hand, even when the N1-5-VHHm escape mutants cannot yield a complete map of the 
epitope, the amino acid residue substitutions observed (Chapter 1; figure 23) can give valuable 
information about the N1-5-VHHm epitope localization. As mentioned in chapter 1, the available 
crystal structures of mAb in complex with NA are all from the group 2 NA, specifically N2 and 
N9. These structures showed that these mAb epitopes rarely include conserved amino acid 
residues from the catalytic site; rather they are targeting amino acids in loops surrounding the 
NA catalytic site (Chapter 1; Table 1, Figure 5), which are described as major antigenic regions 
of the NA. The N1-5-VHHm escape mutants results (Chapter 4) showed that the amino acid 
substitutions T377Y and W379R are found in the NA surface, close to the 330-loop, which is 
part of the NC10 and NC41 epitope. Interestingly, the other surface substitution, T418A, is 
localized closer to the Mem5 than to the NC10 epitope, suggesting that the N1-5-VHHm epitope 
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is overlapping a small part of both mAb epitopes. Although the distance of the T377, W379 or 
T418 residues to the catalytic site is bigger than the residues conforming the Mem5 epitope, it is 
enough to inhibit the catalysis of the small substrate MUNANA. It seems that the N1-5-VHHm 
epitope is, similarly to previously reported mAb (Chapter 1; table 1), in the loops adjacent to the 
NA catalytic cleft.  
It is likely that the epitope recognized by the non-inhibitory N1-7-VHHm is not shared with the 
inhibitory N1-3-VHHm or N1-5-VHHm (Chapter 3; figure 14). In line with this observation, our in 
vivo results showed that N1-7-VHH-Fc was able to rescue mice from NIBRG-14 ma and H5N1 
H274Y challenges (Chapter 3; figure 20 and 21), suggesting that the H274Y mutation (within the 
NA catalytic site) does not affect the N1-7-VHH-Fc antiviral effect, pointing out the possibility of 
a non-shared epitope with N1-3-VHH-Fc or N1-5-VHH-Fc, in line with the SPR analysis.  
Plant-produced Abs have been considered as a promising and powerful alternative for Abs 
production and our N1-VHH-Fc is the first reported plant-produced Ab against the IAV NA. The 
scalability, robustness and speed of production are major advantages, even when the 
glycosylation patterns of the plant-produced Abs (rich in high mannose residues) are different 
than those of the Abs produced in mammalian expression platforms (De Muynck et al., 2010). 
The use of plants for Ab production also presents an interesting approach for less economically-
developed countries: the long-lived storage, relative ease of purification or delivery and the use 
of established agricultural techniques are very attractive. To our knowledge, to date there are 
only four VHH Abs produced in plants: three studies were performed as stably transformed lines 
(Jobling et al., 2003; Ismaili et al., 2007; Winichayakul et al., 2009), but their yield was reported 
very low. The best VHH expression and accumulation was obtained using transient expression 
in tobacco leaves (Teh and Kavanagh, 2010). These reports confirmed that the yield of the 
plant-produced Abs is variable, and depends on several factors: the fusion tag to the 
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recombinant protein, codon optimization and the subcellular compartment targeted. Results 
from our lab demonstrated that the Fc moiety improved significantly the VHH accumulation in 
seeds (compared to the monomeric VHH alone). We observed that in our transformed 
Arabidopsis thaliana seeds, 16% of total seed protein was N1-VHH-Fc (data not published), 
which represents a very good yield for a plant-produced Ab. The VHH technology is widely 
known and praised for the advantages of production, efficacy and versatility for tailor-made 
constructions (Muyldermans S, 2008). This promising technology is currently used and exploited 
by the biotechnological company Ablynx. Previously, the antiviral potential of the VHH has been 
reported in vitro (Hultberg et al., 2011) and in vivo (Ibanez et al., 2011) against IAV, and also 
against another important viral disease, RSV (Schepens et al., 2011). These reports highlight 
the potential of the VHH as antiviral tool. 
Recent significant reports shed light on the complex and concerning situation of HPAIV H5N1 
and pandemic H1N1 epidemiology in humans, situations that highlight the necessity for IAV 
antiviral alternatives. The experimental adaptation of H5N1 virus for airborne transmission in 
ferrets, with mutations in the HA and PB2, warns for the possibility of human-to-human 
transmission of zoonotic HPAIV (Herfst et al., 2012; Imai et al., 2012). Should the HPAIV H5N1 
present human-to-human transmission, the NA targeting could be part of an effective strategy to 
mitigate disease caused by such a virus, which would likely spread globally. Finally an 
interesting prophylactic and therapeutic approach that deserves further validation, is the 
combination of VHH targeting IAV NA, HA or M2 proteins in cocktails or biparatopic bivalent 
constructions, that could diminish the antigenic drift in IAV, and lead to much less selective 
pressure against IAV VHH. 
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PERSPECTIVES 
The in vitro inhibition of other HPAIV H5N1 viruses (i.e. A/Indonesia/05/05) and NIBRG-23 in 
vivo validation are necessary to contribute the elucidation of the inhibitory potential and epitope 
conservation of our inhibitory N1-VHH in H5N1 NA. In addition, in vitro escape virus selection of 
NIBRG-23 virus in the presence of N1-3-VHHm and N1-5-VHHm would be an interesting future 
experiment to perform that would confirm or disprove that an identical epitope in the NA is 
targeted by these N1-VHH.  
The potency of the inhibitory N1-VHHb and N1-VHH-Fc (100 % protection, single dose) and 
broadness of protection (HPAIV clade 2.2, oseltamivir- resistance) should be validated in 
another than the murine model, i.e. natural host for influenza viruses. The chicken model is an 
attractive candidate for the validation of our N1-VHH, not only for the avian origin of the HPAIV, 
but also for the veterinary and economic importance of this avian model. 
It would be interesting to compare the humoral and cellular adaptive immune responses 
following H5N1 infection of mice that had been treated with neutralizing VHH (Ibanez et al., 
2011), N1-VHHb and N1-VHH-Fc. In particular the level of CD8 T cell immunity directed against 
the conserved internal gene products of IAV is considered important in providing a baseline 
level of cross-protection that may be vital during a pandemic outbreak (Schotsaert et al., 2012). 
In addition, a repeat experiment with larger and younger groups of FcγRI/FcγRIII double 
knockout mice (e.g. groups of 7 mice of 7 weeks old) and including age-matched wild-type mice 
in parallel will be required to elucidate the real contribution of the IgG2a-Fc to the N1-VHH-Fc 
protection. Also, a double knockout mice model lacking FcγRIV and FcγRIII could be more 
useful to dissect the exact contribution of the Fc moiety in N1-VHH-Fc protection of H5N1 
challenged mice.  
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Chapter 5. SUMMARY 
The N1-3-VHHm and N1-5-VHHm showed antiviral activity in vitro, which was enhanced by 
bivalency. We observed that the inhibitory potential of N1-3-VHHm and N1-5-VHHm was similar 
to the commercial drug oseltamivir, and resulted in an antiviral effect in cell-based assays 
(Chapter 3; table 3). The high affinity of both N1-3-VHHm and N1-5-VHHm (Chapter 3; table 2) 
likely contributes to their inhibitory potential. In addition, the introduction of avidity in both 
bivalent formats (bacteria and plant-produced) contributed to an increase in their N1rec 
inhibitory and antiviral potential, compared with their monovalent formats in vitro, surpassing the 
oseltamivir inhibitory potential. H5N1 cross-clade inhibition was also found, but only the N1-3-
VHH was able to show antiviral activity against H5N1 H274Y. In addition to their high antiviral 
potential against a clade 1 H5N1 virus, a cross-clade antiviral effect was also observed in the 
three inhibitory N1-VHH formats. The in vitro inhibition of the clade 2 NIBRG-23 and the 
oseltamivir-resistant mutant H5N1 H274Y, illustrates a cross-clade antiviral potential of our N1-
VHH (Chapter 3; table 3). These results suggest that the H274 residue is necessary for the 
binding of N1-5-VHH to the NA. Furthermore, the SPR epitope mapping assay showed that N1-
3-VHH and N1-5-VHH recognized an overlapping epitope, but it is probable that their amino 
acid residues involved in the binding to the NA epitope are not shared between both inhibitory 
N1-VHHs. 
Rescue of H5N1 challenged mice by N1-VHH-Fc was enhanced by the inhibitory capacity of 
N1-VHH, but it is likely that the Fc moiety contributes to the protection (rescue by N1-7-VHH-
Fc). In line with our in vitro results, the bivalent formats of N1-3-VHH were able to protect mice 
against a challenge with H5N1 H274Y. It is possible that morbidity in the H5N1 challenged mice 
can be prevented by a boost of the N1-VHH treatment in future experiments. The treatment with 
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bacteria-produced inhibitory N1-VHHb rescues against H5N1 challenge, but depends on their 
inhibitory potential. It is interesting to point out that the in vitro antiviral potential against the 
HPAIV of the bacteria-produced mono- and bivalent formats, corresponded to the degree of 
protection in HPAIV challenged mice. This is supported by the observation that N1-3-VHHm, 
N1-3-VHHb, N1-5-VHHm and N1-5-VHHb showed antiviral activity in vivo, which was absent in 
N1-7-VHH. In line with the in vitro results, N1-3-VHHb and N1-5-VHHb were more potent than 
the monovalent counterparts in vivo.  
As previously reported with VHH targeting HA HPAIV, selective pressure can give rise to 
escape mutants (Ibanez et al., 2010). The HA mutations present in the escape mutants affected 
the receptor binding site of the HA, possibly impairing the binding to the SA moiety into the 
cellular receptor. As previously described, the H274Y mutation in NA was sufficient to impede 
the antiviral effect of the N1-5-VHH. This mutation occurs in an amino acid that contributes to 
the amino acid framework of the catalytic site of the NA, which is conserved among the NA 
groups 1 and 2. If N1-3-VHH or N15-VHH inhibits the NA activity by occluding the NA catalytic 
cleft, avoiding the substrate docking, it is possible that their binding contacts occur in the amino 
acid framework of the surface exposed NA active site. So then, mutations into or close to the 
framework or substrate-contact amino acids (exposed at the surface of the NA catalytic cleft) 
are likely to impair the binding of N1-3-VHH or N15-VHH to the NA. 
Nowadays, the antiviral strategies for HPAIV human infections rely heavily on antiviral drugs, 
mainly NA inhibitors. There is an increasing concern about the tendency of high dose- 
administration of oseltamivir to patients. The most evident is the emergence of drug resistant 
mutants, i.e. wide use of oseltamivir had been correlated with resistant mutants in several 
countries (de Jong et al., 2005; Lackenby et al., 2008). A possible alternative to the treatment  
of HPAIV infections could be the administration of cocktails of monoclonal Abs mixed with 
antiviral drugs. Both treatments can contribute synergistically to the protection, the Ab inducing 
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an immune response in the host, and the drugs hampering the spreading of the virus by the NA 
inhibition. Our N1-VHHs are excellent candidates for a proof of concept synergistic effect. The 
protective effect of the HA-binding VHH demonstrated by Ibanez and colleagues (2011), and the 
NA-binding reported in this study, raise the interesting concept of the design of heterobivalent 
VHHs against HPAIV. By fusing two different VHHs targeting different IAV proteins, e.g. HA and 
NA, the binding and release of the virion could be inhibited simultaneously, also decreasing the 
probability of the occurrence of escape mutants. In addition, broad protection (cross-clade or 
even cross-subtype) by the VHHS, give them extra attractive and cost effective interests. 
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ADDENDUM 
 
 
PATENT APPLICATION No. EP 12196499.3. 
 
ANTI-INFLUENZA ANTIBODY 
The present invention relates to an antibody that confers protection against influenza. More 
specifically, it relates to an anti-neuraminidase antibody, protecting against highly pathogenic 
H5N1 influenza strains. The invention relates further to the use of the antibody for prophylactic 
and/or therapeutic treatment of influenza virus infections, and to a pharmaceutical composition 
comprising the antibody. 
The zoonotic influenza infections in humans present a persistent and great burden worldwide to 
health, academic and pharmaceutical entities. The possibility of a highly pathogenic influenza 
pandemic in humans had been recognized, which, if present, not only can present a high toll to 
human society, but could also change the importance and perceived danger of infectious 
diseases in the social and cultural context. In less than 10 years, two zoonotic outbreaks had a 
major global impact: the Avian Influenza Virus (IAV) (Tran et al., 2004) and the swine flu (H1N1) 
or “Mexican flu”, confirmed the lack of preparedness against a highly pathogenic pandemic 
(Ilyushina et al., 2010). Among these zoonotic influenza outbreaks, the avian H5N1 influenza 
virus is one of the most concerning because of the vast animal reservoir for this virus 
(domesticated as well as wild water fowl) and the high lethality rate in humans. Indeed, infection 
of humans with highly pathogenic H5N1 (HPAIV H5N1) influenza virus results in a 60% mortality 
rate (Chotpitayasunondh et al., 2005). This high pathogenicity and lethality of the HPAIV H5N1 
in humans can be attributed to a high replication rate and a broad cellular tropism that can lead 
to a systemic spread. During severe infections, a deregulated induction of proinflammatory 
cytokines and chemokines (sometimes called “cytokine storm”) is associated with HPAIV H5N1 
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infections that can result into an excessive immunological response and autoimmune symptoms 
(de Jong et al., 2006). 
The treatments reported and available against HPAIV H5N1 are far from optimal. The currently 
licensed influenza antiviral drugs remain the most used treatment against HPAIV H5N1, even 
though they were developed against seasonal human influenza viruses. These drugs target only 
two viral proteins: the proton ion channel M2 (amantadine and rimantadine) and the sialidase 
Neuraminidase (NA) (oseltamivir, zanamivir and peramivir). The efficacy of these drugs 
depends greatly of the severity of the H5N1 infection, that itself depends on several factors like: 
patient age, activity, previous vaccination and previous exposure to similar Influenza strains. In 
addition, the use of influenza antiviral drugs for hospitalized patients is often characterized by 
long term treatment and high concentrations are used in severe clinical cases. Such treatment 
regimes represent a major concern because they favor selective pressure causing the 
appearance of reported and emerging drug-resistant mutants. Moreover, bacterial secondary 
infections are associated with influenza and complicate the clinical outcome (Hebert et al., 1992; 
Rameix-Welti et al., 2009). On the other hand, the vaccination strategy used against seasonal 
influenza is not efficient in preventing or controlling zoonotic or pandemic Influenza virus 
treatment, due the unpredictability in their occurrence, the antigenic mismatch between such 
vaccines and pandemic viruses and the lack of immunological memory in human. The recent 
reports of experimental adaptation of H5N1 virus for airborne transmission in ferrets, confirm the 
possibility of human to human transmission of zoonotic HPAIV H5N1 (Herfst et al., 2012; Imai et 
al., 2012). Treatment of patients with convalescent plasma from influenza HPAIV H5N1 (Zhou et 
al., 2007) and H1N1 (Hung et al., 2011) survivors patients has been shown to be protective. 
However, those data are based on a limited number of patients, treatment with convalescent 
plasma is certainly not generally accepted as a therapy and there are practical limitations in 
collecting convalescent plasma (Wong et al., 2010). Influenza NA best known function is to 
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prevent aggregation of the newly produced virions by cleaving the sialic acids from the infected 
cell and from the viral glycoproteins. In addition, other functions had been reported for the NA, 
pointing out its relevance in several parts of the replicative cycle of Influenza (Air et al., 2012). 
The immunogenicity of the influenza virion depends mainly of the two major proteins in its 
surface, the Hemagglutinin (HA) and the NA. It has been reported that the HA is 
immunodominant over the NA with respect to T- and B- cell priming (Johansson et al., 1987), 
but their disassociation re-established an equal immunogenic potential of both viral proteins 
(Johansson and Kilbourne 1993). A high immunogenic potential of the NA had been reported, 
and it has been proposed to depend in some degree of defective ribosomal products (DRiP) by 
presenting NA peptides to the MHC class I molecules for T cell activation, enabling rapid 
immunosurveillance (Dolan et al., 2010). Nowadays, the evidence of the importance in the 
immune response dependent of NA, leads to the proposal of standardize the NA content in the 
seasonal vaccine formulation (Johansson et al., 1998) (Kilbourne et al., 2004). In addition, the 
pace with which HA and NA drift in human influenza A viruses is similar, suggesting the 
selection pressure of the human host directed against the two glycoproteins of influenza viruses 
is comparable. Besides the immunogenicity of NA and its receptor destroying activity that avoids 
virion aggregation, there are another NA roles reported: cleavage of decoy receptors in the 
mucins, which is necessary during the initiation of infection (Matrosovich et al., 2004); limitation 
of influenza superinfections and possible reassortment (Huang et al., 2008); possibility of 
increased infectivity (Goto and Kawaoka 1998). Interestingly, Influenza virus sensitive to NA 
inhibitory drugs resulted in a crippled or absence of NA activity (Ilyushina et al., 2012). These 
data confirms that the fitness of these mutant virus can be rescued by decreased HA binding to 
Neu5Ac receptors, which had been reported due to insertions of mutations or glycosylations that 
affect the receptor binding site (Gubareva et al., 2002). Such compensatory effect in the HA and 
NA activities towards fitness had been widely reported (Gubareva et al., 2002; Mitnaul et al., 
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2000; Nedyalkova et al., 2002), demonstrating that the NA activity can be compromised, but not 
necessarily results in a replication deficient virus. These pieces of evidence highlight the 
complexity of the mechanism of Influenza escape mutants under selective pressure. There also 
important roles of the NA function that do not depend of the catalytic site: enhancement of 
neurovirulence (e.g. the glycan at position 130, Li et al., 1993); enhanced pathogenicity (length 
of NA stalk; Matsuoka et al., 2009; Yamada et al., 2006). Taken together, these data 
demonstrate the major importance of the NA in influenza A virus infection, indicating that 
targeting NA may result in a global effective antiviral strategy, dependent or independent of the 
NA catalytic activity. Several authors have disclosed methods for passive immunization using 
monoclonal antibodies. WO2009035420 discloses monoclonal antibodies against H5N1 
hemagglutinin and neuraminidase, and the use of the hemagglutinin antibodies in treatment of 
influenza infection. However, whereas protection using the hemagglutinin antibodies is 
demonstrated, no evidence for protection using the neuraminidase antibodies is shown. Shoji et 
al. (2011) and WO2010037046 describe a humanized neuraminidase antibody, its production in 
plants and the use of this antibody for treatment of influenza virus infection. However, a high 
amount of antibody is needed and even then, the survival after challenge is only 50% in their 
animal model. There is still need for antibodies that can be effectively used in passive 
immunization, resulting in a high protection and survival after lethal challenge. 
Surprisingly we found that high affinity camelid heavy chain antibodies or nanobodies (VHHs) 
can be generated targeting the Influenza NA. The high affinity of these monomeric VHH to bind 
a recombinant N1 (N1rec), results also in highly potent H5N1 inhibitors in vitro. The introduction 
of bivalent formats in the VHH increased the antiviral potential in vitro and rescued H5N1 
lethality challenged mice. Even more surprisingly, bivalent VHHs, either by fusion of the VHH to 
an Fc tail or by linking the VHHs to an IgG2c hinge resulted in an unexpected increase in 
potency of the nanobodies, giving full protection against a lethal challenge in a mouse model, 
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while using low amounts of antibodies. A first aspect of the invention is a variable domain of 
camelid heavy chain antibodies (VHH) specifically binding influenza neuraminidase. Preferably, 
said neuraminidase is an influenza type N1 neuraminidase. Preferably, said VHH is inhibiting 
the neuraminidase activity. Even more preferably, said VHH comprises a CDR1 loop sequence 
selected from the group consisting of SEQ ID N°1 and SEQ ID N° 2, a CDR2 loop sequence 
selected from the group consisting of SEQ ID N° 3 and SEQ ID N° 4 and a CDR3 loop 
sequence consisting of SEQ ID N° 5 and SEQ ID N°6. 
Another aspect of the invention is an influenza neuraminidase binding construct, comprising a 
VHH according to the invention. Preferably, said neuraminidase is a type N1 neuraminidase. 
Said influenza binding construct may be any construct; preferably it is a fusion protein, even 
more preferably it is a bivalent or multivalent construct, comprising more than one influenza 
neuraminidase binding VHHs. In one preferred embodiment, the VHH according to the invention 
is fused to an Fc tail. In another preferred embodiment, two VHHs are linked by an IgG2c hinge. 
Preferably, the construct according to the inventions comprises a sequence; even more 
preferably consist of a sequence selected from the group consisting of SEQ ID N° 7, SEQ ID N° 
8, SEQ ID N° 9 and SEQ ID N° 10. 
 
 
BRIEF DESCRIPTION OF THE FIGURES 
Figure 1. Characterization and production of recombinant H5N1 NA. Soluble recombinant NA 
derived from A/crested eagle/Belgium/01/2004 was produced in Sf9 cells using the Baculovirus 
expression platform. A. Diagram of the expression cassette in the pACMP2 vector: Promoter, 
Baculovirus basic protein promoter; ssHA, secretion signal of Hemagglutinin; tGCN4, 
tetramerizing leucine zipper; H5N1 NA, extracellular domain of the H5N1 NA. B. Sialidase 
activity in crude culture supernatant of infected Sf9 cells. Supernatants of different amounts of 
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Baculovirus N1rec infected cells and mock infected cells were measured in a MUNANA based 
NA activity test. C. Chromatographic elution profile of the fractions of N1rec after superdex 200 
gel filtration. The highest NA activity was localized in the fractions F19 – F26. D. Coomassie 
stained SDS-PAGE and immunoblot against N1rec, of F19 - F26 from D: 18 μl and 9 μl of eluted 
fractions from the gel filtration were loaded on the SDS-PAGE and immunoblot, respectively. 
Figure 2. Characterization of the H5N1 NA-binding VHHs. A. Alignment of the VHH amino acid 
sequence of the 13 VHHs that were isolated by phage-display generated from a N1-rec 
immunized Alpaca. The four framework regions are separated by 3 Complementary 
Determining Regions (CDRs, left-right arrows). The VHH CDR3 is the most variable region in 
the VHH candidates. B. In silico predicted 3D-structure of the VHHs, showing electropositive 
(blue) and electronegative (red) potential. The white ribbon represents the CDR3. Note that N1-
1-VHH, N1-3-VHH, N1-4-VHH, N1-5-VHH and N1-6-VHH CDR3 present an electronegative 
protruding topology. C. Coomassie-blue stained reducing SDS-PAGE of the purified E. coli-
produced N1-VHHm candidates. Twenty μg of SA-VHHm was loaded as control VHH. The VHH 
size ranges from 14 – 15 kDa. Purified BSA standards were loaded for quantification and 
comparison. 
Figure 3. Bivalent formats of the N1-3-VHH and N1-5-VHH, design and production. A. Diagram 
of the expression cassette of the N1-VHHb, which consist of two n1-vhhm moieties in tandem, 
fused by a linker: pelB, signal peptide to the periplasmic compartment; n1-vhhm, n1-3/5-vhhm 
genes; hinge IgG2c, hinge sequence of the llama IgG2c immunoglobulin; his-tag, hexahistidine 
sequence. B. Schematic diagram of the plant produced bivalent format N1-VHH-Fc T-DNA 
region in the binary vector pPhas: 3’ ocs: 3’ end of the octopine synthase gene; npt II, neomycin 
phosphotransferase II open reading frame; Pnos, nophaline synthase gene promoter; Pphas: β-
phaseolin gene promoter; 5’ utr: 5’ UTR of arc5-I gene; SS: signal peptide of the Arabidopsis 
thaliana 2S2 seed storage protein gene; n1-vhh-fc: coding sequence of the N1-3/5/7-VHH-Fc; 
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KDEL: ER retention signal; 3’ arc, 3’ flanking regulatory sequences of the arc5-I gene; RB and 
LB: T-DNA right and left border, respectively. C. PCR amplification of the n1-vhhm (357 bp) and 
the n1-vhhb (763 bp) genes inserted in the pHEN6c vector, resolved in an agarose 1% gel. D. 
BamHI digested empty “E” or n1-vhh-fc gene inserted pPhasGW.arc vector. The 1066 bp band 
indicates an n1-vhh-fc gene insert. E. Cartoon representation of the 2 N1-VHH bivalent formats. 
The bacteria-produced N1-VHHb consists of two moieties in tandem of N1-VHHm linked by a 
llama IgG2c hinge of 17 amino acid residues. The plant-produced bivalent N1-VHH-Fc 
comprises two N1-VHH-Fc moieties, each consist of one N1-VHHm fused to a mouse IgG2a Fc, 
dimerized through a disulphide bond. F. The llama IgG2c-derived hinge is sensitive to trypsin. 
Coomassie stained reducing SDS-PAGE of purified N1-3-VHHm, N1-5-VHHm, N1-3-VHHHb 
and N1-5-VHHb incubated for 37 min at 37 ºC in the presence or absence of 1 μg/ml or 10 
μg/ml trypsin. The N1-VHHb molecules migrate at ca. 32 kDa, and the N1-VHHm and the 
cleavage products of N1-VHHb migrate as bands of ca. 17 kDa (arrows). G. Coomasie stained 
reducing SDS-PAGE of the eluted fractions from a protein G column purification step using seed 
extracts of pPhas transformed A. thaliana T3 plants. The N1-VHH-Fc constructs migrate at ca. 
42 kDa (arrow). A degradation product (*) of ca. 28 kDa corresponds to the Fc moiety only, as 
was confirmed by immunobloting (data not shown). 
Figure 4. Single intranasal administration of N1-3-VHHm, N1-5-VHHm, N1-3-VHHb and N1-5-
VHHb decrease the morbidity during the first four days after challenge with H5N1 virus. A. 
Groups of 6-8 week-old Balb/c mice were given 100 μg of indicated VHH, administered 
intranasally at 4 hours before challenge with 4 LD50 of NIBRG-14ma virus. Thirty μg of 
intranasal administered H5-VHHb and daily oral administration of oseltamivir (45/kg/day, from 4 
hrs before challenge) were included as positive controls. Body weight was monitored daily after 
challenge and expressed as the percentage of initial body weight. The groups of mice treated 
with N1-3-VHHm and N1-5-VHHm displayed significantly less morbidity than the groups treated 
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with PBS (P < 0.001), N1-7-VHHm (P < 0.001) at 72 and 96 hours post infection. B. Mice were 
sacrificed on day 4 after challenge and lung homogenates were prepared. A viral genome 
specific RT-qPCR was used as readout for the viral load. The obtained Ct values for the 
individual mice are plotted and a horizontal line indicates the mean. The Ct value H5-VHHb 
group was significantly different (indicative for lower virus load), compared to all other groups 
(***: P < 0.001). The oseltamivir treated group was only slightly different from the groups treated 
with the N1-3-VHHm, N1-5-VHHm and N1-7-VHHm (*: P <0.05). C. The bivalent format of the 
N1-3-VHH and N1-5-VHH increases the potency to reduce the morbidity in H5N1-challenged 
mice. Four hours before challenge with 4 LD50 of NIBRG-14 ma virus, groups of Balb/c mice 
were treated intranasally with 60 μg of N1-3-VHHb, 60 μg of N1-5-VHHb, 60 μg of BL-VHHb, 84 
μg of N1-3-VHH-Fc, 84 μg of N1-5-VHH-Fc or 84 μg of GP4-Fc. Mice treated with neutralizing 
H5-VHHb (30 μg) or oseltamivir (45 mg/kg/day, daily by gavage) were included as positive 
controls. The groups treated with both bivalent formats of the N1-3-VHH and N1-5-VHH were 
significantly different compared with groups treated with: BL-VHHb and GP4-Fc at 60 hpi (P < 
0.05), 72 and 96 hpi (P < 0.001); PBS, 36 and 60 hpi (P < 0.05), and at 72 and 96 hpi (P < 
0.001).  
Figure 5. The N1-VHH bivalent formats protect against morbidity and mortality in a dose-
dependent way in H5N1-challenged mice. Groups of 4 Balb/c mice were given the indicated 
amount of N1-VHH and administered 24 hours before challenge with 4 LD50 of NIBRG-14 ma 
virus. One group of mice was treated with one dose of oseltamivir (45 mg/day/kg) as positive 
control at 24 hrs before challenge, followed by daily boost from 6-14 days after challenge. A 
boost was given at 6 dpi only to the highest doses of each treatment, including the oseltamivir. 
A. The group of mice treated with 60 μg of N1-3-VHHb presented significant increase in 
morbidity compared to the oseltamivir group at: 10 – 11 dpi (P < 0.001), 12-13 dpi (P < 0.01) 
and 14 dpi (P < 0.05). The difference of the morbidity between the different N1-3-VHHb treated 
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groups was not significant (P > 0.05). B. The survival of the N1-3-VHHb 60 μg group was 100 
%, highly significantly different from the control groups BL-VHHb 60μg and PBS (***, P < 0.001). 
In the group treated with 12 μg N1-3-VHHb survival was 50%, but still significantly different from 
the PBS groups (**, P < 0.01). The survival of the groups treated with N1-3-VHHb 2.5 μg (25 %) 
and 0.5 μg (0 %) was not different to the control groups (P > 0.05). C. The morbidity of the N1-
5-VHHb 60 μg treated group was different from the N1-5-VHHb 12, 2.5 and 0.5 μg groups at 
days 10 – 14 (P < 0.001), but not different from the oseltamivir group (P > 0.05). D. The survival 
and significance of the N1-5-VHHb treated groups was similar to the N1-3-VHHb treatment in C. 
dpi, days post infection. E. Groups of 6 Balb/c mice were treated with different amounts of N1-3-
VHH-Fc, but the difference in morbidity was not significant between them or compared with the 
oseltamivir treated group (P > 0.05). F. The survival and statistical significance of the N1-3-
VHH-Fc treated groups treated with different doses and compared to the control groups PBS 
and GP4-Fc 84 μg: N1-3-VHH-Fc 84 μg and 17 μg, 100% (both ***,P < 0.001); N1-3-VHH-Fc 
3.5 μg, 66.6 % (both, **, P < 0.01); 0.7 μg, 33.3 % (PBS, , P < 0.05, ). G. The morbidity of the 
groups treated with N1-5-VHH-Fc was not significantly different between them, but different 
compared to the oseltamivir treated group. H. The survival of the groups treated with N1-5-VHH-
Fc 84, 17 or 3.5 μg was 100%, being highly significantly different from survival in the groups 
GP4-Fc 84 μg and PBS (***,P < 0.001). The treatment with N1-5-VHH-Fc 0.7 μg resulted in a 
survival of 75 %, significantly different from the groups GP4-Fc 84 μg and PBS (**, P < 0.01). 
Figure 6. Treatment with N1-3-VHHb or N1-3-VHH-Fc, but not with N1-5-VHHb/N1-5-VHH-Fc, 
rescues mice from a H5N1 H274Y 1 LD50 challenge. Twenty-four hours before challenge with 4 
LD50 of NIBRG-14 or 1 LD50 H274Y H5N1 virus, groups of 6 Balb/c were given: 60 μg of N1-3-
VHHb, N1-5-VHHb or BL-VHHb; 84 μg of the N1-3-VHH-Fc, N1-5-VHH-Fc or GP4-Fc. Groups 
of 6 mice were treated with oseltamivir (1 mg/day/kg) as positive control. A. There was no 
significant difference in the morbidity between the groups treated with N1-3-VHHb and N1-5-
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VHHb, or compared to the Oseltamivir group during the NIBRG-14 infection (P > 0.05). B. In 
NIBRG-14 infected mice, the N1-3-VHHb, N1-5-VHHb and oseltamivir treated groups showed a 
survival of 100%, being significantly different from the control groups BL-VHHb and PBS (***, P 
< 0.001). C. The morbidity of H5N1 H274Y infected groups was severe, with all groups close to 
a body weight loss of 70 %, only the N1-3-VHHb treated group showed an increase of body 
weight at 10 dpi. D. The treatment with N1-3-VHHb rescued all the H5N1 H274Y infected mice 
(survival of 100 %), with high statistical significance compared with the rest of the groups (***, P 
< 0.001). The N1-5-VHHb and oseltamivir treatments failed to rescue H274Y infected mice. E. 
In NIGRG-14 infected mice, the difference in morbidity of the N1-5-VHH-Fc group compared 
with the N1-3-VHH-Fc, N1-7-VHH-Fc, GP4-Fc or oseltamivir groups is significant at days: 8-13 
dpi (P < 0.001) and 14 dpi (P < 0.01). F. The treatment of N1-3-VHH-Fc, N1-5-VHH-Fc and 
oseltamivir in NIBRG-14 infected mice results in a highly significant (***, P < 0.001) survival of 
100%. The group treated with N1-7-VHH-Fc presented a survival of 83.3 %, being significantly 
different compared to PBS (**, P < 0.01) and GP4-Fc (P < 0.05). G. In the same way as in C., 
the body weight loss was severe in the H5N1 H274Y infected mice, but the groups treated with 
N1-3-VHH-Fc and N1-7-VHH-Fc presented an increased in the body weight at 10 dpi. H. In 
H5N1 H274Y infected mice, the survival of the groups treated with N1-3-VHHb and N1-7-
VHHFc was significant, 100 % (***, P < 0.001) and 66.6 % (**, P < 0.05), respectively. The N1-
5-VHH-Fc and oseltamivir treatments failed to rescue H5N1 H274Y infected mice. 
Figure 7. The treatment with N1-5-VHHb and N1-5-VHH-Fc decrease significantly the morbidity 
in NIBRG-14 challenged FcγRI / FcγRIII K.O. mice. Twenty-four hours before challenge with 4 
LD50 of NIBRG-14 virus, groups of 4 FcγRI / FcγRIII K.O. mice were given: 60 μg of N1-5-VHHb 
or 84 μg of the N1-5-VHH-Fc/N1-7-VHH-Fc/GP4-Fc. The N1-5-VHH-Fc treated group showed 
no morbidity and was statistically different to: the N1-5-VHHb group at 8 dpi (P < 0.01) and 9 dpi 
(P < 0.05); the N1-7-VHH-Fc group at 7- 11 dpi (P < 0.001), 12 dpi (P < 0.01) and 13 dpi (P < 
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0.05). The morbidity of the N1-5-VHHb treated group was statistically different to: GP4-Fc 
group, at 9 dpi (P < 0.05), 10 dpi (P < 0.01), 11– 12 dpi (P < 0.001) and 13 dpi (P < 0.05); PBS 
group, at 9-10 dpi (P < 0.01), 11 dpi (P < 0.01) and 12 dpi (P < 0.05). The morbidity between the 
N1-5-VHHb and the N1-7-VHH-Fc groups was not statistically different. 
 
EXAMPLES 
Materials and methods to the examples 
H5N1 Influenza Virus 
H5N1 influenza A virus NIBRG-14 and NIBRG-23 were obtained from the UK National Institute 
for Biological Standards and Control, a center of the Health Protection Agency. NIBRG-14 and 
NIBRG-23 are 2:6 reverse genetics–derived reassortant of NA and HA derived from (H5N1) 
A/Vietnam/1194/2004 or A\turkey\Turkey\2005 respectively, and (H1N1) A/PR/8/34 viruses, 
respectively. The H5N1 H274Y is a 1:1:6 reverse genetics-derived reassortant with the NA 
derived from A/crested eagle/Belgium/09/2004 (with the H274Y mutation introduced by site-
specific mutagenesis), the HA from A/Vietnam/1194/2004 and the rest of the influenza genes 
from PR8. All of the HA segments lacks the polybasic cleavage site to allow their use in 
BioSafety level 2 (BSL-2) facilities. The NIBRG-14 and the H5N1 H274Y virus were passaged 7 
times in specific pathogen–free Balb/c mice to obtain a mouse-adapted derivative (NIBRG-14 
ma and H5N1 H274Y ma) and propagated in Madin-Darby canine kidney (MDCK) cells. The HA 
and NA coding region was sequenced and found to be identical in NIBRG-14 and H5N1 H274Y 
and NIBRG-14 ma H5N1 H274Y ma viruses (except the H274Y mutation). The median tissue 
culture infectious dose (TCID50) and median lethal dose (LD50) of NIBRG-14 ma, NIBRG-23 and 
H5N1 H274Y ma virus were determined using the method of Reed and Muench. All 
experiments with the previously described viruses were performed in BSL-2 rooms with 
negative pressure relative to adjoining rooms. 
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Baculovirus production of the N1rec 
The N1rec expression cassette gene (n1rec) consisted of: hemagglutinin type 1 signal 
sequence (ssHA, 16 residues), a tetramerizing leucine zipper derived from transcription factor 
GCN4 (tGCN4, 32 residues) (Harbury et al. 1993), and the extracellular part of the H5N1 NA 
derived from A/crested eagle/Belgium/09/2004 (53–449 amino acid residues) (Van Borm et al. 
2005). This expression cassette was cloned into a pAcMP2 Baculovirus transfer vector (BD 
Biosciences®), resulting in the pAcMP2n1rec vector. The Autografa californica nuclear 
poliedrosis virus (AcNPV) derived BaculoGold Linearized Baculovirus DNA (BD Biosciences®), 
and the pACMp2n1rec were cotransfected in the clonal tissue culture line Sf9 derived from 
Spodoptera frugiperda, by the ESCORT IV Transfection Reagent (Sigma®), resulting in the 
recombinant AcNPVN1rec virus. The transfected Sf9 cells were incubated at 28 ° C in rolling 
tubes for 4 days. Then, 4 X 108 cells Sf9 cells were infected with a multiplicity of infection (moi) 
of 10. After 7 days the supernatant was centrifuged 1 hr at 50000 g, and the NA activity was 
measured. 
Neuraminidase activity assay. 
The Neuraminidase (NA) activity was quantified by the cleavage of the fluorogenic substrate 4-
MUNANA (2’-4-Methylumbelliferyl-α-D-N-acetylneuraminic acid, sodium salt hydrate, 50 mM, 
dissolved in deionized water, Sigma-Aldrich®) into free 4-methylumbelliferone, and measured 
with a excitation at 365 nm and fluorescence emission at 450 nm in a Optima Fluorostar®. The 
NA activity reaction mixture consisted of: 200 mM NaAc, 2 mM CaCl2, 1 % butanol and 1 mM 4-
MUNANA. The amount of NA was measured as NA units: 1 NA unit = 1 nmol of 4- 
methylumbelliferone / min. 
N1rec purification 
Two parts of n-butanol were added to 3 parts of cleared AcNPVN1rec infected Sf9 cells 
supernatant. An aqueous phase, containing the soluble N1rec, was extracted from a lipid phase, 
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and was 2.5 times diluted in 5 mM KH2PO4 pH 6.6 and 0.22 μm filtered. The diluted aqueous 
phase was applied to a HA Ultrogel® Hydroxyapatite Chromatography Sorbent (Pall®) packed 
XK26\70 column (GE Healthcare®), and eluted with a gradient of 5 - 400 mM KH2PO4 pH 6.6, 4 
% butanol to KH2PO4 pH 6.6, 4 % butanol. Eluted fractions that scored positive to NA activity 
were pooled and loaded into a 50 mM MES pH 6.6, 5 % glycerol, 8 mM CaCl2 equilibrated 10 ml 
column packed with Blue Sepharose (Sigma-Aldrich®). A single step elution was done with 50 
mM MES pH 6.6, 5 % glycerol, 8 mM CaCl2, 1.5 NaCl. A desalting step was performed by gel 
filtration in XK70 packed with HiLoad 16/60 Superdex 200 pg (GE Healthcare®) column 
equilibrated with 50 mM MES pH 6.6, 5 % glycerol, 8 mM CaCl2, 150 mM NaCl. All the 
chromatography steps were performed on an Akta purification station (GE Healthcare®). 
Camelid immunization and phage library construction 
An alpaca (Vicugna pacos) was weekly injected subcutaneously with 125 μg of N1rec during 35 
days. On day 39, anticoagulated blood was collected for the preparation of lymphocytes. 
Lymphocytes were isolated using a UNI-SEP density gradient separation kit (NOVAmed®), and 
total RNA was extracted. cDNA was prepared using using oligo (dT) primers, and the VH and 
VHH genes were amplified with: primer call 01 (GTCCTGGCTGCTCTTCTACAAGG) and primer 
call 02 (GGTACGTGCTGTTGAACTGTTCC). The PstI and NotI restriction sites were inserted 
into the amplified sequences using the primers: A6E (GAT GTG CAG CTG CAG GAG TCT 
GGR GGA GG) and 38 (GGA CTA GTG CGG CCG CTG GAG ACG GTG ACC TGG GT). The 
PCR 550 bp product and the vector pHEN4 were PstI and NotI digested and ligated (Arbabi 
Ghahroudi et al. 1997). This ligation was used for the transformation of electrocompetent TGI E. 
coli cells, and was growth in 2xTY (supplemented with 100 μg/ml ampicilin and 1% glucose) into 
the exponential phase, and the helper phage M13K07 was added. The library was subjected to 
4 consecutive rounds of panning, performed in solid-phase coated N1rec (200 μg/ml) to select 
N1rec-binding phages. 
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N1-VHHm production and purification. 
The VHH genes of the selected N1rec binding phages, contained in the pHEN4 phagemid, were 
amplified by PCR amplification with the primers: A6E (GAT GTG CAG CTG CAG GAG TCT 
GGR GGA GG) and 38 (GGA CTA GTG CGG CCG CTG GAG ACG GTG ACC TGG GT). A 
400 bp PCR product and the pHEN6c vector were PstI and BstEII digested and purified with the 
PCR product purification kit (Roche®) and ligated. Competent E. coli WK6 strains were 
transformed with the ligation mix. Positive colonies were screened by PCR amplification for a 
550 bp fragment using the primers: universal reverse primer 
(TCACACAGGAAACAGCTATGAC) and the universal forward primer 
(CGCCAGGGTTTTCCCAGTCACGAC). The VHH gene cloned in the pHEN6c vector contains 
PelB signal sequence at the N-terminus and a hexahistidine tag at the C - terminus. WK6 cells 
transformed with the pHEN6c harboring the VHH genes were growth in TB medium 
supplemented with ampicillin (100 μg/ml), 2 mM CaCl2 and 0.1% glucose. The production of the 
VHH was induced with 1 mM of IPTG. The periplasmic extracts were obtained by osmotic shock 
using TES (0.2 M Tris pH 8.0, 0.5 mM EDTA and 0.5 M sucrose). Periplasmic extracts were 
centrifuged at 8000 rpm at 4 °C and the supernatant was applied to a His Select Nickel Affinity 
gel (Sigma®), washed with PBS and the soluble VHH was eluted with 0.5 Imidazole and 
dialyzed at 4 °C with PBS by ultrafiltration (cutoff 3.5 kDa). Concentration of the monomeric 
VHH (VHHm) was performed in a Vivaspin 5000 MW (Vivascience®). Total protein 
concentration was determined with BCA protein Assay kit (Thermo Scientific®). 
Theorical N1-VHHm structure prediction 
The amino acid sequence of the 13 different candidates VHH directed against NA were loaded 
in the ESyPred3D Web Server 1.0 Molecular Biology Research Unit, The University of Namur, 
Belgium (http://www.fundp.ac.be/sciences/biologie/urbm/bioinfo/esypred/) and retrieved as PDB 
CONFIDENTIAL Page 176 
 
files. The structures of the 13 N1-VHHm were modeled with DeepView/Swiss-PdbViewer 
(http://spdbv.vital-it.ch/). 
VHH Surface Plasmon resonance analysis 
The affinity of the N1-3-VHHm, N1-5-VHHm and N1-7-VHHm elicited against N1rec were 
determined by surface plasmon resonance (SPR) on a Biacore3000. N1rec antigen was first 
immobilized (2000 RU) into a Series S sensor chip CM5 (GE Healthcare®) (coupling was in 10 
mM NaAc, pH 4.5), with regeneration in 0.02% SDS. Subsequently, each N1-VHHm was diluted 
in HBS buffer (0.01 M HEPES, 0.15 M NaCl, 0.005% Tween 20, pH 6.4) to arrive at a 
concentration between 1.95 and 1000 nM and was injected over the CM5 chip to record its 
binding kinetics with the N1rec. Binding sensograms were used to calculate the Kon and Koff 
values with the Biacore T100 evaluation software and to determine the equilibrium dissociation 
constant (KD) and the epitome analysis. 
Construction of the N1-VHH bivalent 
The genes encoding the N1-3-VHHm or the N1-5-VHHm were amplified with primers MH (5′- 
CATGCCATGGGAGCTTTGGGAGCTTTGGAGCTGGGGGTCTTCGCTGTGGTGCGCTGAGG
AGACGGTGACCTGGGT-3′) and A4 short (5′-
CATGCCATGATCCGCGGCCCAGCCGGCCATGGCTGATGTGCAGCTGGTGGAGTCT-3′) to 
introduce a NcoI restriction enzyme site at both extremities of the amplified fragment. The MH 
primer also added the hinge sequence of llama γ2c (AL-His-His-Ser-Glu-Asp-Pro-Ser-Ser-Lys-
Ala-Pro-Lys-Ala-Pro-Met-Ala) (Hmila et al. 2010) to the 3′ end of the VHH. The PCR amplified 
product was then purified with PCR product purification kit (Roche®). The PCR product and the 
pHEN6c plasmid containing the n1-3-vhh or the n1-5-vhh genes were digested for several hours 
with NcoI enzyme and treated with alkaline phosphatase, and then purified. Finally, the pHEN6c 
recombinant plasmid and the PCR fragment were ligated with T4 DNA ligase (Fermentas®). 
The ligated product was used to transform E. coli WK6 electrocompetent cells. Clones were 
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screened by PCR using the universal forward and reverse sequencing primers for the presence 
of the bivalent construct. The amplification products of ca 1000 bp were sequenced to ensure 
the absence of unintended mutations. After expression, the encoded protein was tested for 
binding to N1rec by ELISA. To obtain larger amounts of the tandemly linked bispecific N1-VHH 
construct, the protocols for the expression and purification conditions of the N1-VHHm were 
followed (see above). 
Plant produced N1-VHH-Fc expression cassette 
The n1-vhh-fc expression cassette was designed as follows, from 5’ to 3’: LB (left border of 
TDNA); 3’ ocs (3’ end of the octopine synthase gene); npt II (neomycin phosphotransferase II 
open reading frame); Pnos (nophaline synthase gene promoter); Pphas (β-phaseolin gene 
promoter); 5’ utr (5’ UTR of arc5-I gene); SS (signal peptide of the Arabidopsis thaliana 2S2 
seed storage protein gene); KDEL (ER retention signal); n1-3-vhh (coding sequence of the N1-
3-VHH); 3’ arc (3’ flanking regulatory sequences of the arc5-I gene); n1-3-vhh (coding sequence 
of the N1-3-VHH fused to the mouse CH2 and CH3 IgG2a hinge sequence); RB, DNA right 
border (De Jaeger et al. 2002) (Van Droogenbroeck et al. 2007). This expression cassette was 
synthesized in the commercial vector pUC57 (GenScript®), and cloned into a pPhasGW binary 
T-DNA vector, resulting in the pPhasGWn1-vhh-fc vector. 
Production and purification of soluble N1-VHH-Fc 
The pPhasGWn1-vhh-fc was used for transformation of Agrobacterium C58C1RifR(pMP90). 
This Agrobacterium strain was grown on YEB medium supplemented with rifampicin (100 mg/L), 
gentamycin (40 mg/L), spectinomycin (100 mg/L) and streptomycin (300 mg/L). Arabidopsis 
transformants are obtained via Agrobacterium-mediated floral dip transformation (Clough and 
Bent 1998). Seeds from T1 segregating plants were crushed and total protein was extracted 
with: 50 mM Tris-HCl, pH 8.0, 200 mM NaCl, 5 mM EDTA, 0.1% (v/v) of Tween 20 and 
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Complete® protease inhibitor tablets (Roche®). The seed extracts were applied to a protein G 
sepharose column (GE Healthcare®) and eluted fractions were analyzed. 
Inhibitory immune plaque assay 
Monolayers of MDCK cells were grown in DMEM supplemented with 10% Fetal Bovine Serum, 
1% penicillin/streptomycin, 1% glutamine at 37 °C with 5% CO2. MDCK TMPRRS2 medium was 
supplemented with geneticin (0.3 mg/ml) and puromycin (2 μg/ml) and the expression of 
TMPRSS2 was induced with doxycycline (0.5 μg/ml). At 70% of confluency, the MCDK cells 
were infected with a moi of 10 with the corresponding virus. The antiviral treatment was mixed 
with 0.8% of Avicel RC-591 as an overlay (Matrosovich et al. 2006). After different times of 
incubation, cells were fixed with 4% paraformalfehyde in PBS for 30 min. The cells were 
permeabilized with 20 mM glycine, 0.5% (v/v) Triton X-100. After blocking, the cells were 
incubated for 2 hrs with polyclonal α-NIBRG-14 (1:1000) and α-M2e (mAb 148, 1:5000). After 
washing, α mouse IgG-HRP conjugated was used to visualize plaques using the substrate 
TrueBlue™ Peroxidase Substrate (KPL®). 
Neuraminidase sequences alignment 
The phylogenetic tree and aminoacids substitutions of the aligned sequences of the H5N1 NA 
of: A/crested eagle/Belgium/01/2004 (accession number: ABP52007), A/Vietnam/1194/2004 
(ABA70757) and A/turkey/Turkey/01/2005 (ABQ58915), were obtained by the Clustal W 
method, in the MegAlign software (DNASTAR®). 
Prophylactic Efficacy Studies in Mice 
Specific-pathogen–free female Balb/c mice, 7–9 weeks old, were purchased from Charles River 
(Germany) and used for all experiments. Mice were housed in cages individually ventilated with 
high-efficiency particulate air filters in temperature-controlled, air-conditioned facilities with food 
and water ad libitum. Mice were anesthetized by intraperitoneal injection of xylazine (10 μg/g) 
and ketamine (100 μg/g) before intranasal administration of N1-VHH or challenge virus (50 μl, 
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divided equally between the nostrils). The N1-VHH in any format were diluted in endotoxin-free 
phosphate-buffered saline (PBS) with 1% (weight/volume) bovine serum albumin and 
administered as a single dose, ranging from 100 to 0.5 μg per mouse (5–0.25 mg/kg). To 
determine the effect of intranasal N1-VHH delivery on lung virus titer production, mice were 
challenged with 4 LD50 of NIBRG-14ma virus. Lung homogenates were prepared in PBS, 
cleared by centrifugation at 4°C, and used for virus titration. Monolayers of MDCK cells were 
infected with 50 μl of serial 1:10 dilutions of the lung homogenates, in a 96-well plate in serum-
free Dulbecco's modified Eagle medium (Invitrogen®) supplemented with penicillin and 
streptomycin. After 1 h, the inoculum was replaced by medium containing 2 μg/ml of L- 
(tosylamido-2-phenyl) ethyl chloromethyl ketone–treated trypsin (Sigma®). End-point virus titers 
were determined by hemagglutination of chicken red blood cells and expressed as TCID50 per 
milliliter. Influenza RNA levels were determined with quantitative polymerase chain reaction 
(PCR). RNA was isolated from 150 μl of cleared lung homogenate using the Nucleospin RNA 
virus kit (Machery-Nagel®). The relative amount of NIBRG-14 ma genomic RNA was 
determined by preparing viral cDNA and performing quantitative PCR with M-genomic segment 
primers 5'TCGAAAGGAACAGCAGAGTG3' and 5'CCAGCTCTATGCTGACAAAATG3' and 
probe 5'GGATGCTG3' (probe no. 89; Universal ProbeLibrary, Roche) and the LightCycler 480 
Real-Time PCR System (Roche®). To determine the degree of protection against mortality, 
mice were challenged with 4 LD50 of NIBRG-14 ma virus and subsequently monitored for 14 
days. A 30% loss in body weight drop was the end point at which moribund mice were 
euthanized. All animal procedures were approved by the Institutional Ethics Committee on 
Experimental Animals. 
Statistical Analysis 
Graphpad (Graphpad Prism®, version 5) was used for statistical analysis. Differences between 
groups were tested using the 2-way ANOVA. When this test demonstrated a significant 
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difference between groups (P < .05), t tests were used to compare 2 groups. Kaplan-Meier 
survival curves were plotted and evaluated. 
Example 1: Production of recombinant tetrameric Neuraminidase 
A Baculovirus Expression Vector System was used to produce a recombinant H5N1 NA derived 
from A/crested eagle/Belgium/09/2004. The N1rec expression cassette gene (n1rec) (Figure 
1A) was cloned into a pAcMP2 expression vector (pAcMP2n1rec), under the control of the 
AcNPV basic protein promoter, an infectious cycle late phase promoter preferred for the 
production of proteins with post-translational modifications (BD Biosciences®). Infection of 
Spodoptera frugiperda (Sf9) cells with a recombinant baculovirus containing the N1rec 
expression cassette resulted in sialidase activity in the cell supernatant suggesting that the 
N1rec product was soluble and enzymatically active tetrameric NA (Figure 1B). The N1rec in the 
culture supernatant was purified from the culture supernatant. Following a final size exclusion 
chromatography step, we obtained 90% pure N1rec (Figure 1C). The theoretical molecular 
weight of N1rec is 49.5 kDa. The relative electrophoretic mobility in SDS-PAGE suggested a 
size of approximately 60 kDa (Figure 1D), presumably due to the presence of glycosylations; 
there are predicted 3 N-glycosylation and 2 O-glycosylation sites in the N1rec. The purified 
protein had a specific activity of 56850.9 NA units/mg of total protein. 
 
Example 2: Immunization and VHH phage library construction 
N1rec was next used as an immunogen for the generation and selection of NA-specific VHH. An 
alpaca (Vicunia pacos) was immunized at day 0 with 125 μg of N1rec, followed by 6 weekly 
boosts. One week after the last immunization, blood was collected and peripheral blood 
lymphocytes were isolated. From the lymphocytes, total RNA was extracted and used as 
template for cDNA synthesis. The VH and VHH genes were amplified by PCR, and the VHH 
genes were isolated and cloned into the phagemid vector pHEN4 (Arbabi Ghahroudi et al. 
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1997). We obtained a VHH phage library of 2 X 108 independent transformants. Fifty seven % of 
these transformants harbored a pHEN4 with a VHH cDNA insert of the correct size (550 bp). 
The VHH phage display library was then subjected to four consecutive rounds of panning, 
performed on solid-phase coated N1rec antigen. From the panning, 78 positive clones were 
retained. Subsequent Restriction fragment Length Polyphormism analysis narrowed down the 
N1rec-specific VHH candidates to 24 colonies, encoding 13 different VHHs. Sequences analysis 
of these 13 VHHs allowed classifying them into 9 clonally related groups, with differences 
mainly in the CDR3 domain sequence (Figure 2A). We named these N1rec-binding VHHs N1-
(1-13)-VHH. The in silico predicted topology of the 13 N1-VHH, suggested that they covered a 
diverse range of CDR3 structures (Figure 2B). Some of the N1-VHH structures showed a 
protruding electronegatively charged CDR3 (e.g. N1-3-VHHm, Figure 2B). 
Example 3: Production and characterization of soluble N1-VHHm 
The coding information for each of the 13 N1-VHH candidates was transferred into the bacterial 
expression vector pHEN6 under the control of a lac operon, for expression and purifications 
purposes (Kang et al., 1991). The transformation of amber suppressor E. coli strain WK6 with 
the pHEN6n1-vhh produced a monomeric N1-VHH (N1-VHHm) that is targeted to the periplasm 
and C-terminally tagged with hexahistidine. Following osmotic shock, periplasmic extracts were 
prepared and loaded onto a nickel sepharose column, to purify a set of 13 N1-VHH proteins 
(Figure 2C). The binding of each of the 13 N1-VHHm to the NA part of N1rec, but not to the 
tGCN4 moiety, was confirmed by ELISA (data not shown). We next assessed the capacity of 
our monovalent N1-VHHm candidates to inhibit the enzymatic activity of N1rec. For this, we 
used a small substrate-based fluorogenic assay to evaluate the potential inhibitory activity of our 
N1-VHHm. Interestingly, 4 candidates; N1-1-VHHm, N1-3-VHHm, N1-5-VHHm and N1-6-VHHm 
could inhibit the N1rec catalytic activity. The N1-3-VHHm and the N1-5-VHHm were the most 
potent inhibitors of the N1rec catalytic activity (data not shown), and together with N1-7-VHHm, 
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were analyzed by surface plasmon resonance using immobilized N1rec. The N1-7-VHHm was 
included in this analysis as a binding but non-inhibitory N1-VHHm control. Both N1-3-VHHm and 
N1-5-VHHm presented a high affinity for N1rec, with an equilibrium dissociation constant (KD) in 
the low nanomolar (N1-5-VHHm) to picomolar (N1-3-VHHm) range. N1-7-VHHm showed an 
approximately 10- to 100-fold lower affinity KD than N1-5-VHHm and N1-3-VHHm, respectively 
(data not shown). These binding affinities of N1-3-VHHm and N1-5-VHHm for N1rec are 
comparable to the maximal affinities reported for a monomeric VHH (De Genst et al., 2006). 
Competitive surface plasmon resonance analysis also showed that prior binding of N1-3-VHHm 
to N1rec abolished subsequent binding of N1-5-VHHm and vice versa. On the other hand, N1-7-
VHHm binding to N1rec was not affected by prior binding of N1-3-VHHm or N1-5-VHHm to 
N1rec (data not shown). This observation suggests that N1-3-VHHm and N1-5-VHHm bind an 
overlapping epitope in N1rec, while the N1-7-VHHm targets a different epitope. 
We next analyzed the antiviral potential of the N1rec inhibitory VHHs, N1-3-VHHm and N1-5-
VHHm. A/crested eagle/Belgium/09/2004 is a highly pathogenic H5N1 virus that we could not 
handle in our BLS-2 facilities. Therefore, we used the laboratory strain NIBRG-14 virus, 
generated by reverse genetics and containing NA and HA (lacking the polybasic maturation 
sequence) segments derived from A/Vietnam/1194/2004. The NA sequences of these two 
H5N1 viruses are highly homologous with only 13 amino acid sequence differences. In the 
presence of N1-3-VHHm or N1-5-VHHm the size and number of NIBRG-14 plaques in 
monolayers of infected MDCK cells were reduced in a concentration dependent manner (data 
not shown). In contrast, the N1-7-VHHm did not affect the size or number of NIBRG-14 plaques 
in this assay (data not shown). These results suggest that the in vitro antiviral potential of the 
N1-3-VHHm and N1-5-VHHm depends of their NA-inhibitory activity. 
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Example 4: A bivalent format of the N1-VHH enhances their NA-inhibitory and antiviral 
activity 
It has been reported that multivalent formats of VHHs increases their affinity, by introducing 
avidity, for their target antigen and often also their functional activity (Hultberg et al., 2011) 
(Ibanez et al., 2011) (Schepens et al., 2011). For example, the introduction of avidity drastically 
decreased the dissociation constant (Koff) of the VHH molecules directed against lysozyme, and 
significantly improved their enzyme inhibitory activity as compared to their monovalent 
counterpart formats (Els Conrath et al. 2001) (Hmila et al. 2010). To increase the avidity of the 
N1-VHHm, two different bivalent formats were produced. As a first approach to obtain bivalent 
VHH, we used the llama IgG2c hinge (17 amino acid residues) as flexible linker to fuse 2 
identical inhibitory N1-VHHm in a tandem configuration resulting in N1-3-VHHb and N1-5-VHHb 
(Figure 3C). N1-3-VHHb and N1-5-VHHb were expressed and purified from E. coli and their in 
vitro NA inhibitory and antiviral activities were compared with those of their monovalent 
counterparts. We found that N1-3-VHHb and N1-5-VHHb displayed a 500-2000 fold enhanced 
N1rec inhibition activity as compared with the corresponding monovalent N1-3-VHHm and N1-5-
VHHm format. Surprisingly, in a plaque assay using NIBRG-14 virus infected MDCK cells, both 
N1-3-VHHb and N1-5-VHHb had an antiviral activity that was comparable to the levels of their 
monovalent counterparts (data not shown). We reasoned that the integrity of the bivalent format 
is necessary to present an enhanced antiviral potency in both N1-VHHb. However, in the plaque 
assay with H5N1 infected MDCK cells, exogenous trypsin is used to facilitate maturation of HA 
in newly produced virions to allow multicycle replication of the recombinant NIBRG-14 virus. We 
found that the dimerizing llama IgG2c hinge linker in the N1-VHHb was sensitive to trypsin 
cleavage (Figure 3F). Therefore, in the presence of relatively low amounts of trypsin N1-3-VHHb 
and N1-5-VHHb were effectively severed into monovalent VHH. To circumvent the use of 
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exogenously added trypsin we took advantage of the TMPRSS2 MDCK cells, which are stably 
transformed with the doxycycline inducible serine protease TMPRSS2 and allow multicycle 
replication of influenza A viruses in the absence of trypsin (Bottcher et al., 2009). Using 
monolayers of TMPRSS2 MDCK cells for infection with NIBRG-14, the antiviral effect of N1-3-
VHHb and N1-5-VHHb was 240 and 58 fold increased, respectively, compared with their 
monovalent format (data not shown). These results obtained with N1-VHHb indicate that (i) 
there is a significantly enhanced NA-inhibitory and antiviral activity of both N1-VHHb compared 
with the N1-VHHm format and (ii) the 10-fold difference between the increase of the N1rec 
inhibition compared to the plaque assay, suggests than there are other factors that account for 
the in vitro antiviral effect of the N1-VHHb than just their inhibitory potential. 
Example 5: Transgenic plant produced bivalent N1-VHH (N1-VHH-Fc) 
The previously described N1-VHH monovalent or bivalent molecules are relatively simply 
molecules that are stable and small sized, feasible for production in prokaryotic and yeast 
systems. For more complex protein molecules, other production platforms are available and 
have to be considered. We used a plant-based approach, with reported high-end yield results 
for recombinant antibodies (Van Droogenbroeck et al., 2007). In particular, targeting the protein 
of interest as a seed storage protein, we were able to produce a second bivalent N1-VHH 
format. For this, the n1-3-vhh, n1-5-vhh and the n1-7-vhh genes were fused to the sequence 
encoding the hinge and Fc tail of a mouse IgG2a (n1-vhh-fc). The resulting N1-VHH-Fc consists 
of two identical N1-VHH-Fc moieties linked by a disulphide bridge (Figure 3B). These n1-vhh-fc 
constructs were cloned into the binary vector pPhas as a T-DNA expression cassette (Figure 
3E). Subsequently, transgenic Arabidopsis thaliana plants were generated by Agrobacterium-
mediated floral dip transformation. Seed extract of segregating T3 Arabidopsis clones were 
used for screening to identify the highest expressers of the recombinant dimeric protein N1-
VHH-Fc (data not shown). Coomassie stained, reducing SDS-PAGE analysis showed that the 
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N1-VHH-Fc monomers migrated at ca. 42 kDa band (Figure 3F). We also found a good 
correlation between the expression level of the N1-VHH-Fc and the NA inhibitory activity in 
crude seed extracts from different T3 transformants (data not shown). The N1-3-VHH-Fc, N1-
5VHH-Fc and N1-7-VHH-Fc were purified from seed extracts by protein G affinity 
chromatography (Figure 3G). We found stronger N1rec inhibition and in vitro antiviral activity by 
N1-3-VHH-Fc and N1-5-VHH-Fc compared with the monovalent N1-3-VHHm and N1-5-VHHm 
(data not shown). Nevertheless, the N1-3-VHHb and N1-5-VHHb still proved to be 2 to 8 times 
more potent in NA inhibition compared with N1-3-VHH-Fc and N1-5-VHH-Fc. In addition, 
inhibition of replication of NIBRG-14 virus by either N1-3-VHH-Fc or N1-5-VHH-Fc was 80- and 
30-fold stronger, respectively, compared with their monovalent counterparts. We conclude that 
the in vitro NA inhibition and antiviral activity against NIBRG-14 virus is strongly enhanced by 
bivalent N1-VHH formats with the highest improvement observed for tandemly linked copies of 
VHH molecules. 
Example 6: In vitro antiviral activity of N1-VHH against clade 2.2 and oseltamivir-resistant 
H5N1 virus 
The NA derived from A/crested eagle/Belgium/01/2004 belongs to the clade 1 of the H5N1 NAs, 
which also includes NA of the NIBRG-14 (derived from A/Vietnam/1194/2004).H5N1 NA derived 
from A/turkey/Turkey/01/2005 belongs to the clade 2.2. These 3 different NAs shared a high 
homology between them (> 95%) and were used as targets in the present study. Although the 
number of laboratory confirmed human cases of H5N1 virus infection remain limited, it appears 
that clade 2 H5N1 viruses comprise a majority of these zoonotic infections with highly 
pathogenic avian influenza viruses. We therefore evaluated the antiviral potential of N1-3-VHH 
and N1-5-VHH in the three formats available (i.e. monovalent, bivalent without and with Fc) 
against the clade 2.2 virus NIBRG-23. Monovalent N1-3-VHHm and N1-5-VHHm reduced in 
vitro growth of NIBRG-23 virus on MDCK with an IC50 in the low micromolar range. Both 
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bivalent formats of these NA-inhibitory VHH, (N1-3-VHHb, N1-5-VHHb, N1-3-VHH-Fc and N1-5-
VHH-Fc) displayed an approximately 150-fold higher in vitro antiviral activity against this clade 2 
virus as judged by a plaque size reduction assay, compared with their monovalent counterparts. 
Based on these findings, we conclude that the two NA-inhibitory VHH can inhibit H5N1 viruses, 
representative for clade 1 and clade 2 with a comparable efficiency in vitro, suggesting that they 
target an epitope that is shared in the NA of these viruses. Oseltamivir-resistant influenza 
viruses frequently emerge and spread in the human population. Several mutations had been 
reported to contribute to oseltamivir resistance but among these the mutation H274Y (N2 
numbering) is the most commonly found in oseltamivir resistant viruses (Wang et al., 2002). 
Therefore, we wanted to determine if our N1-3-VHHb, N1-5-VHHHb, N1-3-5 VHH-Fc and N1-5-
VHH-Fc would be active against an oseltamivir-resistant H5N1 virus that carries this mutation. 
We used a reverse genetics method (Hoffmann et al., 2000) to generate a clade 1 H5N1 virus 
(harboring the H274Y mutation in NA derived from A/crested eagle/Belgium/09/2004, the HA 
segment from NIBRG-14 and the remaining 6 segments from PR/8), resulting in the H5N1 
H274Y virus used in this study. Given that all of our formats of N1-3-VHH and N1-5-VHH 
performed similar in biochemical and in vitro antiviral activity assays, we were surprised to 
observe that only the N1-3-VHH in monovalent and both bivalent formats, but not any format of 
N1-5-VHH, reduced growth of oseltamivir-resistant H5N1 H274Y virus (data not shown). 
Compared to NIBRG-14 as a target, the H5N1 H274Y IC50 values were 3 to 7-fold higher, but 
still in the low nM range. Even though the competitive surface Plasmon resonance experiment 
suggested that the epitope in NA is shared for both N1-3-VHHm and N1-5-VHHm, the contact 
residues necessary for their binding are not the same. The H274Y mutation seems to be 
sufficient to abolish the in vitro antiviral effect of the N1-5-VHH formats during the infection with 
the H5N1 H274Y mutant virus used here. We conclude that NA-specific VHH, such as N1-3-
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VHHm, N1-3-VHHb and N1-3-VHH-Fc can inhibit growth of H5N1 viruses in vitro, even if such 
viruses are oseltamivir resistant. 
Example 7: The treatment with N1-3-VHHm and N1-5-VHHm reduces morbidity in H5N1-
challenged mice 
We next evaluated the in vivo antiviral effect of the NA-specific VHH. In a first experiment we 
administered intranasally 100 μg of N1-3-VHHm, N1-5-VHHm, and N1-7-VHHm to Balb/c mice 
at 4 hours before challenge with 4 LD50 of mouse-adapted NIBRG-14 virus (NIBRG-14ma). As 
positive controls we included a group of mice that received 30 μg of H5-VHHb, a bivalent 
NIBRG-14ma-neutralizing VHH (Ibanez et al., 2011) as well as daily oral administration of 
oseltamivir, at a high dose (45 mg/kg/day). The body weight was followed daily, and the groups 
treated with the inhibitory N1-3-VHHm or N1-5-VHHm showed a significant difference in 
morbidity at 72 and 96 hours after infection, compared with the groups treated with the N1-7-
VHHm and PBS (P < 0.001) (Figure 4A). Four days after infection, the mice were sacrificed to 
determine lung virus titers. Assessment of the lung virus load by endpoint dilution in a TCID50 
assay, revealed that all mice had a high and comparable virus load between -4.75 to -6.48 
TCID50/ml in the lung homogenates (including the oseltamivir treated group)(data not shown). 
We therefore decided to quantify the amount of viral RNA in the lung homogenates using a 
genome strand-specific RT-qPCR method. Except for the samples derived from the H5-VHHb 
treated mice, all the N1-VHH treated groups showed high viral RNA levels at 96 h after 
infection, comparable to those in the PBS-treated group, even so for the high oseltamivir dose 
treated mice, which difference with the rest of the groups was significant (P < 0.05) (Figure 4B). 
We conclude that intranasal administration of monovalent N1-3-VHHm and N1-5-VHHm 
prevents body weight loss after challenge with NIBR-14 ma virus during the early stage of 
infection. 
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Example 8: Bivalent formats of N1-VHHb protect against H5N1 challenge 
The in vitro results indicated that the bivalent formats of the NA-inhibitory VHH increased their 
potency against the tested H5N1 viruses at least 30-fold compared to the monovalent ones 
(Table 3). We therefore assessed if this increased antiviral effect would also be reflected in an in 
vivo challenge experiment. We first determined the protective potential during the early stages 
of viral infection. Four hours prior to challenge with 4 LD50 of NIBRG-14 groups of Balb/c mice 
were intranasally given 60 μg of N1-3-VHHb, 60 μg of N1-5-VHHb, 60 μg of BL-VHHb (a 
bivalent VHH directed against the irrelevant bacterial target β-lactamase), 84 μg of N1-3-VHH-
Fc, 84 μg of N1-5-VHH-Fc or 84 μg of GP4-Fc (a plant-produced Coronavirus-Fc fusion protein 
with an IgG2a Fc moiety, used here as an irrelevant control). Treatment with N1-3-VHHb or with 
N1-3-VHH-Fc significantly improved morbidity at 72 and 96 h after infection compared with the 
negative control groups GP4-Fc and PBS (P < 0.001). This protection against weight loss was 
comparable to that observed with the positive controls (H5-VHHb and oseltamivir) (Figure 4C). 
On the other hand, treatment with the bivalent formats of N1-5-VHH resulted in a decrease in 
morbidity that was significant at 60, 72 and 96 hpi compared with the negative controls (P <  
0.001) (Figure 4C). Determination of the lung virus load on day 4 after challenge by a TCID50-
based assay using lung homogenates from sacrificed mice, revealed that all challenged groups, 
except the H5-VHHb-treated mice (no virus detectable), had a comparable lung virus load (data 
not shown). Taken together, both bivalent formats (tandem repeats and Fc-mediated) of N1-
inhibitory N1-3-VHH and N1-5-VHH improve protection during the first four days following 
NIBRG-14 challenge. 
Example 9: Bivalent NA inhibitory VHH protection against a lethal challenge with H5N1 
virus is dose-dependent 
In order to probe if mice that have been challenged with 4 LD50 of NIBRG-14ma virus can be 
rescued by prior administration of N1-3-VHHb, N1-3-VHH-Fc, N1-5-VHHb or N1-5-VHH-Fc we 
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followed the morbidity and mortality over a 2-week period. For this, we focused on the bivalent 
formats and first assessed their protective efficacy in a dose-response experiment. Groups of 
four Balb/c mice were treated intranasally with 60, 12, 2.5 or 0.5 μg of N1-3-VHHb or N1-5-
VHHb. In parallel a group was treated by oral administration of oseltamivir (45 mg/kg/day), and 
boost of oseltamivir were given at 6 – 14 days after challenged. In addition, one group of mice 
was treated with 60 μg of BL-VHHb or with PBS prior to challenge. In this experiment mice that 
had received 60 μg of N1-3-VHHb, N1-5-VHHb or BL-VHHb prior to challenge received a 
second intranasal dose with 60 μg of the same bivalent VHH at day 6 after challenge. All mice 
from the PBS and BL-VHHb treatment groups succumbed after challenge at 9 -10 days after 
challenged. In contrast, oseltamivir and high dose (60 μg) intranasal treatment with N1-3-VHHb 
or N1-5-VHHb displayed clear body weight loss following challenge (Figure 5A and C), but 
protected the mice against lethality (Figure 5B and D). Surviving N1-3-VHHb 60 μg treated 
group, but not the N1-5-VHHb 60 μg treated group, displayed a significant delay in recovery 
from weight loss after challenge compared with the oseltamivir treated group (Figure 5A and C). 
A single intranasal dose of 12 μg or 2.5 μg of either N1-3-VHHb or N1-5-VHHb provided partial 
protection against mortality but failed to reduce morbidity (Figure 5A-D). We next evaluated 
protection against a potentially lethal NIBRG-14 ma challenge by prior single intranasal 
administration of the plant-produced N1-3-VHH-Fc and N1-5-VHH-Fc formats. Eighty four and 
17 μg of N1-3-VHH-Fc as well as oseltamivir treatment provided full protection against NIBRG-
14 challenge but the survival of the mice treated with 3.5 and 0.7 μg was dose-dependent 
(Figure 5F and H). Nevertheless this protection was associated with significant body weight loss 
in all dosing used, including the oseltamivir group (Figure 5E and G). All PBS and GP4-Fc 
treated animals died after challenge by day 9 after challenge. On the other hand, the body 
weight loss was less severe in the treatment with all N1-5-VHH-Fc treated groups, and only the 
group treated with 0.7 μg failed to show a survival of 100% (Figure 5G and H). Finally, when 
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comparing the protective efficacy of the two bivalent formats of N1-3-VHH and N1-5-VHH, it 
appears that the Fc moiety in the N1-VHH-Fc formats provides an extra protective effect against 
morbidity and mortality following NIBRG-14ma challenge. This increased protective potential 
correlates with the somewhat higher NA inhibitory activity in a biochemical assay using purified 
N1rec but is not reflected in the plaque number/size reduction assay (data not shown). Taken 
together, we conclude that bivalent formats of N1-3-VHH and N1-5-VHH can protect mice 
against a potentially lethal challenge with an H5N1 virus, although this protection does not 
eliminate completely morbidity following challenge. 
Example 10: N1-3-VHHb and N1-3-VHH-Fc protect against challenge with an oseltamivir-
resistant 
H5N1 virus 
In vitro analysis demonstrated that N1-3-VHH but not N1-5-VHH in monovalent or bivalent 
format could reduce growth of oseltamivir-resistant H5N1 H274Y virus. Groups of 6 Balb/c mice 
received 30 μg of N1-3-VHHb, N1-5-VHHb or BL-VHHb by intranasal administration 24 hours 
before challenge with 4 LD50 of either NIBRG-14 ma or H5N1 H274Y virus. A PBS-recipient 
group was included as negative control. In parallel, a group was treated by daily oral 
administration of oseltamivir (1 mg/kg/day), a dose that has been reported to protect laboratory 
mice against challenge with an H5N1 virus (Govorkova et al., 2001). All N1-3-VHHb, N1-5-
VHHb and oseltamivir treated mice survived challenge with NIBRG-14 ma virus whereas PBS 
and BL-VHHb recipient mice succumbed after challenge (Figure 6A and B). This result 
demonstrates that a single intranasal administration of N1-3-VHHb of N1-5- VHHb is sufficient 
to protect against a subsequent (24 h later) potentially lethal challenge with an H5N1 virus that 
has an antigenically matching NA. Again all surviving mice suffered from substantial but 
transient weight loss after challenge (Figure 6B). From the mice that had been similarly treated 
as above but challenged with H5N1 H274Y virus, only those that had received N1-3-VHHb prior 
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to challenge survived. All other groups, including those that had been treated with an oseltamivir 
dose that fully protected against NIBRG14 ma challenge, died following challenge with H5N1 
H274Y virus (Figure 6C and D). Finally, we evaluated the effect of prior intranasal instillation of 
bivalent Fc formatted N1-3-VHH-Fc, N1-5-VHH-Fc and now also N1-7-VHH-Fc in our lethal 
challenge model. We again included PBS and oseltamivir treatment groups as well as GP4-Fc 
recipients. Following challenge with 4 LD50 of NIBRG-14 ma, all mice except 1 mouse in the 
PBS and 1 mouse in the GP4-Fc group died. In the N1-7-VHH-Fc group, only 1 of 6 mice died 
after challenge. In contrast, all mice in the N1-3-VHH-Fc, N1-5-VHH-Fc and oseltamivir groups 
survived this challenge and all displayed significant body weight loss, except for the mice that 
had received N1-5-VHH-Fc that appeared to be fully protected from morbidity following NIBRG-
14 ma challenge (Figure 6E and F). Challenge with H5N1 H274Y virus proved lethal to all mice 
except for those that had been treated in advance with N1-3-VHH-Fc (all mice survived) or N1-
7-VHH-Fc (4 out of 6 mice survived) although all animal suffered from substantial body weight 
loss after challenge (Figure 6G and H). We conclude that bivalent NA-specific VHH can protect 
against a potentially lethal challenge with oseltamivir-resistant H5N1 virus. 
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CLAIMS 
1. A VHH specifically binding influenza neuraminidase. 
2. The VHH according to claim 1, comprising a CDR1 loop sequence selected from the group 
consisting of SEQ ID N°1 and SEQ ID N° 2, a CDR2 loop sequence selected from the group 
consisting of SEQ ID N° 3 and SEQ ID N° 4 and a CDR3 loop sequence consisting of SEQ ID 
N° 5 and SEQ ID N°6 
3. An influenza neuraminidase binding construct comprising a VHH according to claim 1 or 2. 
4. The neuraminidase binding construct according to claim 3, wherein said construct is bivalent. 
5. The neuraminidase binding construct according to claim 4, wherein said VHH is fused to an 
Fc tail. 
6. The neuraminidase binding construct according to claim 4, wherein said VHHs are linked by 
an IgG2c hinge. 
7. The neuraminidase binding construct according to claim 5 or 6, wherein said construct 
comprises a sequence selected from the group consisting of SEQ ID N°7, SEQ ID N° 8, SEQ ID 
N° 9 and SEQ ID N° 10. 
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ANTI-INFLUENZA ANTIBODY 
ABSTRACT 
The present invention relates to an antibody that confers protection against influenza virus 
infection. More specifically, it relates to an anti-neuraminidase antibody, protecting against 
highly pathogenic H5N1 influenza strains. The invention relates further to the use of the 
antibody for prophylactic and/or therapeutic treatment of influenza virus infections, and to a 
pharmaceutical composition comprising the antibody. 
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1. Introduction 
 
1.1 Conventional Antibodies 
Recombinant antibodies are widely regarded as one of the main, if not the most promising tools against cancer and 
auto-immune, inflammatory, neurodegenerative and infectious diseases (Stiehm et al., 2008). Conventional 
antibodies (Abs) are complex molecules consisting of pairs of heavy and light chains, whose N- terminal domain is 
more variable than the rest of the protein sequence. The antibody heavy chain consists of three constant domains 
(CH1, CH2 and CH3) and a variable domain (VH). The light chain has only two domains, the constant light (CL) and 
the variable light (VL). Important Glycosylations on the CH2 domain are necessary for antibody effector functions, 
such as Antibody-Dependent Cellular Cytotoxicity (ADCC) and Complement–Dependent Cytolysis (CDC), and for 
regulating antibody half time in serum (Fig. 1, A). Antigen-binding is determined by the three hypervariable 
Complementary Determining Regions (CDR1, CDR2 and CDR3) present in both the VH and VL domains. These 
regions are located in juxtaposed loops, creating a continuous surface of ~ 1000 Å2 that specifically binds to the 
epitope in an antigen. Although all CDRs can potentially make contact with the antigen, CDR3 contacts with the 
epitope are generally more extensive. The structural diversity of the antigen-binding sites of a conventional antibody 
depends on the size of the CDR3 in the VH and the conjunction with the VL at different angles and distances. These 
are grouped in three different classes, according to the size and type of an antigen: cavities (fitting haptens), grooves 
(fitting peptides) and planar sites (fitting surface patches of proteins) (Johnson et al., 2010). 
1.2 The Single variable domain of the heavy chain antibodies 
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In 1993 a surprising observation was made in members of the Artiodactyl Tylopoda family (camelids). Next to 
conventional IgG antibodies, camelids also naturally produce Heavy Chain antibodies (HCAbs) that lack the light 
chain (Hamers-Casterman et al., 1993). Two years later, similar single chain antibodies were discovered in 
cartilaginous fish (sharks) (Greenberg et al., 1995). Although the CH2 and CH3 of the HCAbs and the conventional 
antibodies are highly homologous, there is no CH1 domain in the camelid HCAbs. The single variable domain, called 
VHH, is the only domain of HCAbs that makes contact with the antigen. Surprisingly, although the VHH have only 
three CDR regions, their affinity for antigens reaches the low nanomolar to even picomolar range, matching the best 
affinities of classical antibodies. When expressed as single domains (often referred to as nanobodies, Nb), the VHHs 
retain their strong epitope specificity and affinity, a feature that might be explained by the VHH architecture (Fig. 1, 
B). Just like the VHs of conventional antibodies, the amino acid (AA) sequence of VHHs is organised in three 
hypervariable regions (CDR1, CDR2 and CDR3) separated by four Framework regions (FR1-FR4) (Muyldermans et 
al., 1994). As the AA sequence of the VHH FRs is highly similar to those of conventional VHs it was not surprising 
that the overall architecture of VHHs closely resembles that of VHs (Muyldermans et al., 1994). Both VHH and VH 
domains fold  into two β-sheets with the three CDRs that link these two sheets at one end of the barrel (or domain) 
(Desmyter et al., 1996; De Genst et al., 2006) (Fig. 1, C,E).  However, there are striking structural differences between 
VHHs and conventional VH. Evidently, VHHs lack an interacting VL domain. Associated with this lack, the 
hydrophobic amino acids present at the VH surface that is normally interacting with the VL, are substituted by 
hydrophilic AA (Fig.1, D). This enhances the solubility of VHH single domain proteins have an enhanced solubility 
compared to engineered VH single domain proteins.  
The absence of the additional CDRs in VHHs is likely compensated by structural features. First, the CDR3 regions of 
camelid VHHs are generally longer (13-17 amino acids) than the CDR3 regions of mouse and human VHs (9-12 and 
9-17 AA respectively) (Wu et al., 1993). In contrast to conventional Abs, in which the antigen binding surface is often 
a flat surface, a cavity or a groove, the long CDR3 loop may extend from the antigen binding surface (Desmyter et al., 
1996). This enlarges the paratope surface and hence the potential affinity and repertoire of camelid HcAbs. In 
addition, especially in dromedaries, the CDR1 and CDR3 regions contain a cysteine, which allows formation of a 
second disulfide bridge next to the single disulfide bridge in conventional VHs (Muyldermans et al., 1994). This extra 
bridge likely stabilizes the CDR loops, thereby reducing their flexibility. This probably also contributes to the affinity 
(less entropy is lost upon antigen binding) and structural diversity of VHHs.  Long extending CDR3 loops that are 
stabilized by an extra disulfide bridge can explain the tendency of VHHs to bind to clefts and concaves surfaces more 
readily than conventional antibodies do (Fig.  1, F) (De Genst et al., 2006). Indeed comparison of multiple structures 
of hen egg white lysozyme interacting with either several conventional human antibodies or several camelid VHHs 
clearly illustrated that VHHs tends to bind to the concave substrate-binding pocket, whereas conventional antibodies 
favor epitopes on the “flat” surface of the antigen (Fig. 1, C). In addition, whereas each of the three CDRs of 
conventional VHs contributes considerably to the interaction with antigen, VHHs depended mainly on the CDR 3 
loop for this interaction. Other antigens that are hard to target by conventional antibodies, but can be targeted by 
cameloid VHHs are ion channels, GPCRs, haptens and enzymatic sites (Lauwereys et al., 1998) (Rasmussen et al., 
2011). 
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Next to an extended CDR3, the AA sequence of the H1 loop that precedes and comprises CDR1 appears to be 
particularly more variable in camelid VHHs than in conventional VHs. This might be interpreted as an extension of 
the VHH CDR1 (Vu et al., 1997). Associated with this high variability in camelid VHHs, CH1 loops adopt 
conformations that deviate from the canonical H1 structures of conventional VHs (Barre et al., 1994); (Decanniere et 
al., 1999; Decanniere et al., 2000). Camelid VHH CH1 loops appear to fold into a more diverse repertoire of 
structures. The high variability in the AA sequence and conformations of the CH1 loop contribute to the VHH 
paratope size (850-1150 Å2), which approaches that of conventional antibodies (VH + VL) (Desmyter et al., 2002). 
Clearly, different biochemical and structural features of camelid VHHs compensate for the lack of a VL domain and 
allowing a broad repertoire of specific high affinity antigen interactions. In addition, due to their small size and 
typical extruding CDR3 regions, camelid VHH tend to bind in cavities that are not readily accessible for conventional 
antibodies. Next to these particular features, VHH single domain protein is exceptionally stable and soluble, even in 
stringent conditions. As VHH are small and naturally monomeric, they can be easily formatted. In addition, the small 
size of VHHs allows them penetrate deeper into tissue (e.g. tumor tissue) and to occasionally cross the blood-brain 
barrier. On the down side, the small size of single domain VHH contributes to their rapid clearance from circulation. 
Using display technologies, it is possible to select VHHs from large, synthetic or naive libraries (Verheesen et al., 
2006). Nevertheless, the phage display generated from an immune VHH repertoire is the most widely and powerful 
technique used nowadays to rapidly select VHHs with the desired specificity (Arbabi Ghahroudi et al., 1997). VHH 
are easily produced in bacterial or yeast systems in miligram quantities per liter of culture. Their stability, solubility, 
ease of production and small size make them excellent candidates for multivalent formatting. Tailor-made 
constructions using VHHs as building blocks enhance the avidity of the molecule even in a 3 log scale, and several 
constructions are being tested in clinical trials (Els Conrath et al., 2001; Hmila et al., 2010). Their high potential as 
therapeutics had prompted the creation in Belgium of the company Ablynx in 2001. Because of the publicity 
surrounding nanotechnology and the small size of the VHH, Ablynx named the VHH as “Nanobody (Nb)”, and 
retains full intellectual property rights of the use of Nbs in therapeutics and diagnosis. The combined features of 
VHHs potential tools for many applications. In this chapter, we focus on the development and use of VHHs for anti-
viral therapy. It is interesting to point that in the field of therapy, only one monoclonal antibody is used today 
(Synagis) against infectious disease (Groothuis and Simoes, 1993). 
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Figure 1. Representative diagrams of a conventional antibody, an HCAb, and a VHH. (A) A conventional antibody is 
a dimeric molecule, and each monomer comprising a heavy chain and a light chain. The heavy chain consists of the 
constant domains (CH1, CH2 and CH3) and the variable domain (VH). The light chain has only one conserved 
domain (CL) and a variable domain (VL). Important glycosylation sites (orange stars) are present in CH2, which is 
responsible for effector functions and the flexibility of the molecule. (B) The HCAb devoid of the light chain and CH1 
is the paratope (yellow box) present only in the single variable domain (VHH). (C) The VHH can be expressed as a 
prolate-shaped, soluble molecule of ~15 kDa, with. The yellow square shows the antigen binding site. (D) The VHH 
sequence is made of four Framework Regions (FR1, light gray; FR2, cyan; FR3, magenta and FR4, yellow), and three 
Complementary Determining Regions (CDR1, green; CDR2, blue and CDR3, red). Residues F37, E44, G47and R45 
(orange) are located in the FR2 and mask a hydrophobic patch. C, C- terminal; N, N-terminal. The dotted red line 
represents a disulfide bond between the FR2 and the CDR3; this bond stabilizes the molecule and is present in 
dromedaries. (E) A three-dimensional structure of an anti lysozyme VHH, showing the Ig folding of β sheets, five 
strands in the front (roman numerals: I – V) and four strands in the back (VI – IX). The enlarged yellow square shows 
the antigen binding site, formed by juxtaposition of three CDRs. (F) The VHH shown in (F) is drawn in complex with 
lysozyme (light blue). A protruding paratope consisting mainly of CDR3 (red) recognizes and binds the catalytic cleft 
of lysozyme, inhibiting its activity. 
 
2. Influenza virus 
Nowadays, the main prophylactic measure against Influenza is vaccination. Therapeutic options for influenza are 
small molecule drugs targeting the viral proteins Neuraminidase (NA) or matrix protein 2 (M2). Influenza virus 
poses a great and continuous threat to humans and zoonotic infections also pose a dangerous challenge to human. In 
the last six years, two important viruses have risen as pandemic or potential pandemic outbreaks: the recent 
pandemic outbreak in the 2009 by the swine-derived H1N1 influenza virus (also called the Mexican Flu) and Highly 
Pathogenic Avian Influenza (HPAV) viruses of the H5N1 subtype, mainly in Asiatic countries. The 2009 H1N1 
pandemic presents an interesting case. It was a zoonotic infection that could be transmitted between humans, but had 
a low mortality rate. On the other hand, the HPAV H5N1 virus infections present a high replication efficiency, 
broader cell tropism and possible systemic spread in patients. Fulminant pneumonia, multi-organ failure caused by a 
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high viral load and an intense inflammatory response (cytokine storm) are responsible of a mortality rate of 60 % (de 
Jong et al., 2006).  Vaccines to prevent HPAV infection are not available, but NA inhibitors (oseltamivir) are used as 
antiviral drugs. A combination of antiviral drugs and immunomodulators was used to control infection by HPAV 
H5N1 in patients, but its use was considered as a risk. On the other hand, passive immunization has been a 
successful alternative. Immunoglobulins in immune sera derived from animals or humans exposed to a homologous 
virus had been used to treat HPAV-infected humans (Luke and Subbarao, 2006; Zhou et al., 2007).  In addition, the 
genetic shift and drift of the influenza virus underline the need for new antiviral approaches. In addition, the 
emergence of drug resistant strains poses an extra concern. The Tamiflu Resistant strain (conferred mainly by the 
H274Y mutation, (Wang et al., 2002a) is evidence of the urgent need of new anti-influenza tools. It is also urgent to 
develop new and better antiviral tools against the zoonotic Influenza virus, including HPAV. The characteristics of 
Nbs mentioned above makes them a potentially effective antiviral approach. Several attempts have been made to 
target conserved epitopes of proteins in the capsid of Influenza viruses. The main antigenic target in Influenza virus 
is the HA protein. However, the genetic shift of this viral protein, especially in its antigenic regions and including the 
binding site, complicates this approach. Even though this strategy has been successful in current seasonal vaccines, it 
is a costly and far from optimal: it is not suitable for emerging pandemic viruses, as has been proven not suitable by 
the Mexican flu in 2009.  
 
2.1 Targeting Influenza HA: the Nb approach 
The work of Hultberg and colleagues (Hultberg et al., 2011) is the first report of the use of Nb technology as an 
antiviral tool against influenza. That study proved the binding of the Nb to an Influenza protein and the 
neutralization of the binding of the virion to its cellular receptor in human transformed mammalian cells. These 
results are the proof of principle of the use of Nbs as antivirals. We discuss the most relevant results in scope of the 
potential further use of Nbs. To obtain Nanobodies directed against H5N1 viruses, llamas were immunized with 
recombinant H5N1 Hemagglutinin (H5, A/Vietnam/1203/2004). The nanobody repertoire of the hyperimmune 
animals was cloned into a phage display library, and two promising HA-binding Nbs were isolated. The VHH of the 
HCab or Nb was cloned, produced as monovalent molecules, purified and screened for specific binding to the 
antigen, using as competitor the HA surrogate receptor fetuin. Two of the specific binders (B12 and C8) had high 
affinity to HA (KD = 9.91 and 30.1 nM) as determined by surface plasmon resonance. In addition, in a MLV (H5) 
pseudotyped neutralization assay both Nbs neutralized the parental virus A/Vietnam/1203/04 and also another 
clade 1 virus (A/Vietnam/1194/04) with a minimal inhibition concentration (IC50) of 75 nM. The possibility of cross 
reactivity among different H5N1 clades was also tested. The Nbs efficiency in neutralizing other clades of Influenza 
virus decreased proportionally with the antigenic distance from the virus A/Vietnam/1203/04. Three viruses from 
clade 2.2 were inhibited by the monovalent Nbs in a similar range as clade 1 (IC50 = 50–150 nM). On the other hand, 
one virus of clade 2.3.4 and one virus from clade 2.5 showed little or no inhibition. As mentioned above, Nbs are 
potentially good building blocks for multivalent molecules due their small size, high affinity, and efficacy as a 
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production platform. Based on Nbs C-8, bivalent and trivalent constructs were made, using Gly4/Ser linkers (GS) of 
different lengths. As expected, the neutralization potential of the bivalent and trivalent constructions was greatly 
enhanced against the A/Vietnam/1194/04 virus (IC50 ≤ 1 pM). Inhibition of this clade 1 virus was confirmed by a 
micronetralization assay in NIBRG-14 infected cells. NIBRG-14 is an engineered recombinant virus whose HA and 
NA are derived from the A/Vietnam/1194/04 virus. Surprisingly, the IC50 in the bivalent and trivalent Nbs 
neutralization activity (9 and 3 pM, respectively) decrease by more than 3 logs compared to the monovalent Nb. 
These results show that NIBRG-14 outperforms a previously developed monoclonal antibody CR 261 (Throsby et al., 
2008). These results were also confirmed in a hemagglutination inhibition assay, which showed an IC50 of 2 nM for 
the bivalent and trivalent construction, compared to 156 nm of the monovalent. 
The multivalency format also resulted in the potential for neutralization of Influenza virus of different clades. For 
three clade 2.2 viruses, two bivalent constructions of the Nb C-8 (9GS and 15 GS) did not show any decrease in the 
IC50. On the other hand, the 10 GS linker trivalent molecule showed a 10 - 40 fold increase in the neutralization 
potential, but the 20 GS linker trivalent showed only two fold decrease in the IC50, or none at all.  Nevertheless, using 
the monovalent Nb the neutralization of virus from clades 2.3.4 or 2.5 was in the high nM range or absent, 
respectively. This result confirms the previous result showing that both bivalent and one trivalent (10GS) 
constructions decrease the IC50 to a low nM range. It is worth mentioning that the retroviral pseudovirus 
A/Vietnam/1194/04 and the Influenza virus NIBRG-14 share the same HA, but different results were obtained using 
the MLV pseudotyped neutralization assay and the infected cells microneutralization. Using the microneutralization, 
the reported IC50 of the monovalent; bivalent and trivalent molecules was reduced by ten-fold compared to the IC50 
obtained by the pseudotyped neutralization. The difference in sensitivity of the assays emphasize the need to confirm 
the results of the different influenza clades by NBs by using infected cells based assays. The validation of the anti HA 
Nbs in an in vivo model was performed in a mouse model by Ibañez (Ibanez et al., 2011). 
To confirm the efficacy of the Nbs in vivo, Ibañez et al. used an H5N1 NIBRG-14 mouse adapted (NIBRG-14 ma) virus 
strain. It is important to point out that the Nbs were administered intranasally in all mouse experiments, in order to 
enhance penetration in the respiratory tract. Initially, to evaluate the antiviral potential using the bivalent Nb (C-8, 15 
GS) in vivo, a dose of 5 mg/kg (100 µg) was used in mice. This dose completely prevented loss of body weight at 4, 24 
and 48 h before a challenge of 1 LD50 of NIBRG-14 ma, compared to the controls after 4 days of monitoring. Using the 
same set up, on day 4 after challenge, any detectable lung virus titers were observed at 4 and 24 hrs before challenge, 
and at 48 hrs the titer was 50-fold lower than in controls. These results suggested that the bivalent Nbs provide 
strong protection against 1 LD50, but it is important to consider the half life of the molecule. In previous in vitro 
results, the bivalent Nb neutralization activity was even 3 logs higher than that of the monovalent Nb, but in vivo also 
there was a significant improvement using the bivalent. The difference in the virus neutralization capacity between 
the monovalent and bivalent Nbs and the minimal protective dose was assessed by administration of different doses 
of Nbs 24 h before challenge with 1 LD50 NIBRG-14. The doses of Nb ranged from 3 to 0.025 mg/kg, and complete 
neutralization was confirmed for the highest doses of both constructions. In addition, administration of the highest 
dose (60 µg, 3 mg/kg) of bivalent Nb 24 h before challenge with 4 LD50 also resulted in complete protection. The 
monovalent neutralization activity was dependent on the amount of Nb, but it was statistically also for doses of 6 or 
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1.2 µg of Nb per mouse. Remarkably, very low or any lung virus titer was detected in mice treated with the bivalent 
Nb, even for the lowest doses used (2.5–0.5 µg). These results strongly confirmed the neutralization efficacy of the 
bivalent Nb when used as prophylactic tool against a NIBRG-14 ma, a highly pathogenic Influenza virus model. 
In addition, the therapeutic efficacy of the bivalent Nb was also tested in the same model. The administration of 60 µg 
of bivalent Nb prevented the drop in body weight and showed a reduction in the lung viral titers when administered 
4, 24 and 48 h after 1 LD50 challenge. On the other hand, 72 h after challenge, the drop in body weight was similar to 
that of the controls, but statistically significant reduction in lung viral titers was observed. The decrease in viral titers 
was also confirmed by measuring the amount of viral RNA by RT-PCR. In addition, 48 h after challenge of mice 
(treated with this dose of bivalent Nb) with 4 LD50 of NIBRG-14 ma, weight loss was observed and also a delay in 
mortality compared with the controls.  
The antigenic site of the HA was mapped by escape mutants in presence of the monovalent or bivalent Nbs. Three 
escape mutants were  selected in the presence of monovalent Nb, K189E/N and N154D/S mutations were found, 
they are contiguous in the antigenic B site of the HA (Wiley et al., 1981; Yamada et al., 2006). It is noteworthy to 
mention that N154D/S remove an N glycosylation site, a possible adaptation to mask an antigenic site (Fig.2). The 
escape mutants selected in presence of the bivalent Nb presented not only the K189E/N mutation, but an additional 
D145N mutation located in the stalk of HA, 40 residues upstream of the membrane anchor. The results of the 
hemagglutination assays and microneutralization experiments suggest that mutation K189N/E is necessary and 
sufficient to abolish binding to the Nb in a monovalent or bivalent conformation, indicating a close proximity 
between the antigenic B site and the receptor binding domain. Those results are the first one reported of the potential 
antiviral activity of a Nb against the Influenza virus.  
The Nb viral neutralization activity against a trimeric HA molecule (HA) was greatly enhanced when presented as 
bivalent and trimeric molecule, but the dynamics and details of the binding are not clear. It has been demonstrated 
that in intramolecular binding, a multivalent molecule has greater avidity than its monovalent counterpart. But a 
very interesting question is whether intermolecular binding occurs during Nb binding to the HA. In recent reports, 
the existence of intermolecular binding was proved to enhance an antiviral effect (Wang and Yang, 2010). 
Intermolecular binding could explain the increase in the neutralization activity:  steric, the hindrance of the HA for its 
cellular receptor is enhanced, and the flexibility of the HA is decreased.  
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Figure 2. Ribbon representation of the H5N1 HA trimeric protein. Two mutations in the head of the trimer confer 
resistance to the monovalent and bivalent VHH C-8. The mutation K189N/E was necessary and sufficient to prevent 
binding of both mono and bivalent proteins. (PDB : 2IBX) 
 
3. RSV virus 
Respiratory Syncytial Virus (RSV) infections are the leading cause of acute lower respiratory tract infections (ALRI) in 
children and associated hospitalizations world wide (Falsey et al., 2005; Nair et al., 2010). There is no specific antiviral 
therapy for RSV infection available. Each year 66, 000 – 199,000 children die worldwide due to RSV ALRI. Most 
pediatric cases of fatal RSV infections occur in developing countries. As RSV infections do not evoke protective 
immunity, infections occur throughout life, causing severe morbidity in young infants, the elderly, and immune-
comprised adults (Boyce et al., 2000; Falsey et al., 2005).  
Although high levels of RSV neutralizing antibodies correlate with lower frequencies of RSV-associated ALRI, no 
RSV vaccine is available (Glezen et al., 1981). However, monthly administration of large amounts of a humanized 
RSV neutralizing antibody, palivizumab (Synagis), reduces RSV-associated hospitalization of high risk infants by 
about 78-39% (Groothuis and Simoes, 1993). Palivizumab is currently the sole monoclonal antibody that is approved 
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for preventing viral infection. Palivizumab blocks fusion of the RSV membrane with the membrane of the target cell 
by binding to the RSV fusion protein (F) (Huang et al., 2010). However, due to the high cost of Palivizumab, there is 
an urgent need for new anti-virals that can prevent or treat RSV infections. RSV neutralizing Nbs have been 
developed as an alternative to antibodies (Hultberg et al., 2011). 
 
3.1 RSV binding VHHs antiviral effect: comparison with Synagis Mab. 
To investigate if Nbs could be used for antiviral therapy, Nbs that bind to the palivizumab epitope were developed. 
For this purpose, two lamas were immunized with recombinant RSV A F protein (RSV FTM-) lacking the 
transmembrane region (Hultberg et al., 2011). This protein folds into trimers that resemble the native RSV F protein 
in its post-fusion conformation (Ruiz-Arguello et al., 2004). Remarkably, RSV FTM- proteins can be readily recognized 
by RSV F neutralizing antibodies that, just like palivizumab, bind to the antigenic site II (McLellan et al., 2011; 
Swanson et al., 2011). In this way, RSV FTM- immunization can potentially induce RSV F antigenic site II specific 
camelid HCabs. HcAbs that specifically bind to the RSV F antigenic region II were enriched by biopanning using RSV 
FTM- protein and competitive elution in the presence of excess of palivizumab antibody. From these HCAbs, VHHs 
were produced and tested for binding to the RSV FTM- protein. Twelve VHHs that bound to the RSV F protein were 
tested for neutralization of RSV Long strain (RSV A subtype) virus in a micro-neutralization assay. Two VHHs (RSV-
C4 and the RSV-D3) could neutralize RSV in the high nanomolar range (IC50: 640 nM and 300 nM, respectively), 
which is similar to the neutralization activity than the Synagis Fab (IC50: 549.2 nM) and about 100-fold less effective as 
the Synagis Mab (IC50: 3.02 nM). However, in contrast to palivizumab, neither RSV-C4 nor RSV-D3 VHHs could 
neutralize RSV B subtype virus in vitro. On the contrary, another VHH (RSV-E4) could neutralize RSV B infection to 
some extent.  
The epitopes of different VHHs were determined by antibody competition assays and diverse antibody escape RSV 
mutants.  Whereas RSV-C4 and RSV-D3 VHHs readily competed with palivizumab for binding to recombinant RSV 
FTM- or inactivated RSV virions, RSV-E4 competed with 101 Fab, which is known to bind to the antigenic region IV-VI 
(Wu et al., 2007). These data are in line with the observation that AA substitutions within antigenic regions II and IV-
VI, respectively, affected the binding of both RSV-D4 and RSV-C3 VHHs and RSV-E4 VHH. These data strongly 
suggest that both RSV-C3 and RSV-D4 bind to antigenic region II (palivizumab epitope) (Crowe et al., 1998) whereas 
RSV-E4 VHH binds to antigenic region IV-VI, explaining the observed differences in neutralization.  
The affinity of the three VHHs, Synagis Mab and Synagis Fab was determined by Surface Plasmon Resonance using 
recombinant RSV F TM- as bait. The KD of RSV-D3, RSV-E4 and RSV-E4 were in the low nanomolar range: 9.24 nM, 
1.78 nM and 0.45 nM, respectively. Although RSV-D3 was more effective than RSV-C4 at neutralizing RSV A, it had a 
lower affinity for FTM- than RSV-C4.  Moreover, the efficient binding of RSV-E4 VHH to a neutralizing epitope 
(antigenic region IV-VI) was not associated with neutralization of RSV A. This suggests that the affinity of VHHs for 
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the recombinant RSV FTM-, which likely represents the F protein in its post-fusion conformation, does not correlate 
directly with neutralization of living RSV (Table 1.) 
It has been reported before that the avidity of a binding molecule can be increased in a multivalent format (Rudge et 
al., 2007; Wang and Yang, 2010). In order to increase its antiviral potential, the RSV-D3 was selected and formatted in 
a bivalent molecule, by a flexible linker of Gly4/Ser (GS). Surprisingly, bivalent RSV-D3 VHH’s with GC linkers of 
different size neutralized RSV A Long virus between 2421 and 4181 times more efficient than monovalent RSV-D3 
VHH’s, reaching picomolar range (190 - 110 pM). In contrast, Synagis Mab was only 200 times (IC50: 6.5 nM) more 
efficient in neutralizing RSV A virus than its corresponding Fab fragment. In this way bivalent RSV F specific VHHs 
outperform the Synagis antibody in RSV neutralization. Moreover, in contrast to its monovalent format, bivalent 
RSV-D3 could also neutralize RSV B1 strain virus.  Also linking two different VHHs, RSV-D3 and RSV-E4 targeting 
two different epitopes, notably boosted neutralization of both RSV A and B virus subtypes. Likely the profound 
enhancement in activity by linking two VHHs is enabled by the flexibility of the linker. Experiments aiming to 
characterize the binding dynamics of the RSV-D3 to the F protein are necessary for characterize an intra- or 
intermolecular binding. 
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The RSV protein F is responsible of the fusion of the viral lipid membrane with the host membrane, but also 
participates in the attachment of the RSV virions to target cells. Moreover it was recently demonstrated that RSV F 
protein can bind to nucleolin expressed at the surface of target cells and that this interaction is crucial for RSV 
infection in vitro and in vivo (Tayyari et al., 2011).  After viral attachment, the RSV F protein mediates fusion of the 
viral membrane with the plasma membrane of the target cell, thereby releasing the viral genome into the cytoplasm 
of the host cell. This process involves a series of conformational changes of the F protein from a metastable pre-fusion 
to a stable post-fusion conformation. We recently demonstrated that bivalent RSV-D3 VHHs can prevent RSV 
infection both before and after viral attachment, can inhibit syncytia formation but cannot hamper RSV attachment 
(Schepens et al., 2011). Together observations constantly indicate that in a similar mechanism that palivizumab, 
bivalent RSV-D3 VHHs prevent RSV infection by blocking fusion. Although the conformations of the RSV F antigenic 
regions II and IV-VI are maintained in the post-fusion form, it is more plausible that the RSV VHHs block viral fusion 
and syncytia formation by binding to the RSV F protein in either its pre-fusion or intermediate conformations (Fig. 3). 
Possibly, binding of the VHHs to the antigenic region II interferes with the conformational changes of the F protein 
that are required for fusion. 
Immune compromised (cyclophosphamide treatment) Balb/c mice were used to test whether bivalent RSV-D3 VHHs 
could protect against RSV infection in vivo (Schepens et al., 2011). As VHHs are known to remain active in the 
respiratory tract after nebulisation, bivalent RSV-D3 and control VHHs were administered intranasally (patent 
application WO 2009/147248). Prophylactic treatment of mice with 5mg/kg bivalent RSV-D3 VHH or palivizumab 
reduced RSV pulmonary titers below the detection limit of the RSV plaque assay. This strong reduction was 
confirmed by quantitative PCR analysis. Remarkably, as low as 0.6 mg/kg bivalent RSV-D3 could either prevent or 
strongly reduce (at least 100-fold) pulmonary RSV replication. In comparison, monovalent RSV-D3 VHH could 
protect against pulmonary RSV replication about 25 times less efficient than their bivalent counterpart. In order to be 
valuable, even an easy to administer prophylactic treatment should have a long-lasting effect. We could demonstrate 
that intranasal administration of bivalent RSV-D3 VHHs can protect at least for 48 hours against RSV infection. 
Although prophylactic treatment with palivizumab in high risk infants reduces RSV associated hospitalization, there 
is currently no effective therapeutic treatment available. Therefore RSV-D3 VHHs were also evaluated as therapeutic 
treatment. Intranasal administration of RSV-D3 VHHs 4 or 24 hours after infection strongly reduced (at least 100-
fold) pulmonary RSV replication. Plaque assays also indicated that administration of bivalent RSV-D3 VHHs 72 
hours after RSV treatment can reduce pulmonary RSV replication. However, as lung homogenates used to quantify 
the pulmonary RSV titer in mice (treated 72 hours after infection) still contained neutralizing RSV VHHs, it is not 
clear to which extend treatment at this time point reduced RSV replication in vivo. The potential of bivalent VHHs to 
prevent morbidity and pulmonary inflammation upon RSV infection was assessed in a non immunocompromised 
mice model. Prophylactic administration of bivalent RSV-D3 VHHs (1 mg/kg) could completely prevent body 
weight loss and pulmonary cell infiltration that was observed in mice treated with control VHHs. Therapeutic 
treatment with bivalent RSV-D3 VHHs 24 hours after infection partially reduced body weight loss and pulmonary 
cell infiltration. These observations confirm the in vivo antiviral potential of neutralizing VHHs.  
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Figure 3. Ribbon representation of the RSV F protein trimer structure, in the post-fusion form. In this recombinant 
protein the head and stalk are depicted of the protein, and lacking the fusion peptide, the transmembrane region and 
the cytoplasmic domain,. The immunogenic epitopes recognized by the 101F Mab (site II) and the palimuzab (site IV-
VI) are shown in red and blue respectively, the rest of the F protein in green. The RSV-D3 and RSV-C4 resistant 
escape mutants are shown in yellow. The mutations I432T, K433T and S436F localized in the site II disrupt the 
binding of the RSV-C4. The K262Y, N268I and K272E in the site IV-IV, resulting in loss of binding of the RSV-D3 
molecule. (PDB: 3RKI). 
 
Currently Ablynx is preparing a phase I clinical trial to evaluate the safety of a trivalent RSV neutralizing VHH 
format which consists of 3 identical VHHs. Preclinical evaluation of this lead candidate illustrated its potential to 
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readily neutralize a broad spectrum of clinical RSV A and RSV B subtype viruses, more efficiently than Synagis 
(abstract, 7th international RSV symposium). In vivo studies demonstrated that both prophylactic and therapeutic 
treatment with this RSV neutralizing VHH can readily reduce RSV replication in the upper and lower respiratory 
tract of cotton rats (abstract, 7th international RSV symposium).  
In summary, neutralizing RSV VHHs are exiting new candidates for anti-RSV therapeutics for different reasons. First, 
VHHs allow versatile formatting including the creation of multivalent formats by the use of flexible linkers. This 
feature enabled the creation of bivalent and trivalent VHH which can neutralize RSV at picomolar range, more than 
1000 fold more efficient than their monovalent counterpart. Second, by linking two different VHHs which neutralize 
different virus strains (such as the RSV A versus the RSV B subtype strains) cross-reactive VHH constructs can be 
obtained. Moreover, as a result of avidity effects, cross linking VHH with different specificity can considerably 
improve the neutralizing activity. Third, the VHHs small sizeand protruding paratopes can contribute to its 
neutralizing activity. As structural models and electron microscopic analysis indicate that the antigenic region II is 
located at the side of the RSV F protein trimer, at the dense surface of RSV virions this region is reasonably more 
accessible for small and flexible VHH formats rather than for large more rigid antibodies (Ruiz-Arguello et al., 2004; 
McLellan et al., 2011) (Fig. 3). Fourth, due to their high stability at stringent conditions, VHHs can be administered 
via nebulisation, which allows a rapid accumulation of high amounts of neutralizing VHH at the site of respiratory 
viral infections. In addition, due to the high stability of VHHs and the ease of intranasal or pulmonary 
administration, VHH therapy could be applied more generally, even in developing countries. 
 
4. Rabies Virus 
Rabies virus (RV) is a single stranded RNA virus, from the Rhabdoviridae family, genus Lyssavirus. The infection with 
RV in humans causes acute encephalitis, with a mortality rate of almost 100 %. It is transmitted to humans by bite 
from a carnivore or quiroptera vector and the majority of cases occur in Asia or Africa. The long incubation period 
following infection by RV presents a paradigm, because of the absence or very weak immune response (Johnson et 
al., 2010). The small amount of virus inoculated after infection and the neurotropism of RV have been considered as 
factors that contribute to the lack of effective antibodies in the patient. After the bite, wound cleaning it is a highly 
and low cost means to lower the chances of a productive infection in human. Passive immunization and vaccination 
promptly after exposure remains the only efficient therapeutic tool nowadays. Modern vaccines are inactivated virus 
produced from continuous cell lines, like the human –diploid –cell vaccine by Aventis Pasteur. Nevertheless, in 
underdeveloped countries, the high cost of established RV therapy (attenuated virus, Mab anti RV) represents a non 
affordable approach for the majority of the population. The RV has a genome of 12 kDa coding for 5 proteins: the 
nucleoprotein, phosphoprotein, matrix, a RNA-dependent RNA polymerase and the Glycoprotein (RVG). In the 
virus particle, the RVG is the only viral protein exposed as a trimeric spike, responsible of: i) recognition of cellular 
receptors; ii) the determination of the virulence; iii) antigenicity.  
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4. 1 Nbs present a broad protection against Rabies Virus 
 
For more than 25 years, two well-defined antigenic sites in the RVG had been characterized by Mabs, the antigenic 
site II and III (Lafon et al., 1990). Other epitopes are also been characterized, but their contribution to the antigenicity 
is minor. The antigenic site III extends from 330 to 340 amino acids and is linear (Seif et al., 1985). The mutations in 
this site affect the virulence and the host range of the virus. On the contrary, the antigenic site II is conformational 
and discontinuous, determined by two regions, amino acids 34 -42 and 198-200. This site is responsible of 
approximately 70 % of the known MAbs against RVG (Benmansour et al., 1991). 
The RGV is an interesting target for the Nb platform, because of the need of alternative cost effective antirabies tools. 
In a similar approach as those previously discussed for the Influenza and RSV, a llama was immunized with 
recombinant RVG and 5 VHHs were obtained (Rab – E8, H7, F8, E6 and C12). Those VHHs were validated in their 
neutralizing activity against 10 Rabies genotype 1 viruses: 3 laboratory strains (CVS-11 as prototype, ERA, CB-1) and 
7 field isolates. Also one rabies genotype 5 virus (EBL-V1) was included to validate broad cross neutralization. The 
data of the virus neutralization relies on one cell based assay, the Rapid Fluorescent Focus Inhibition Test (RFFIT) 
(Vene et al., 1998). This assay has been internationally recognized as the in vitro standard for virus neutralizing 
antibodies. The Mab 8-32, which recognizes the RVG protein antigenic site II, was also included as positive control 
(Montano-Hirose et al., 1993). The VHHs F8, E6, H7 and C12 neutralized the genotype 1 strains: CB-1 and ERA, with 
an IC50 in the low nanomolar range; the CVS-11 strain from the low to high nanomolar range. Also they were able to 
neutralize several field isolates. On the other hand, the E8 was efficient in the neutralization only of the CB-1 and 
CVS-11, in the low and high nanomolar range, respectively. When compared with MAb 8-2, the C12 and E6 
presented better neutralization activity, against the strains ERA and CB-1. Using the same reasoning of the previous 
sections, the authors also use the bivalent approach against the Rabies genotype 1 CVS -11 and the genotype 5 EBLV-
1. Bivalent monoparatopic VHHs (12, H7, E8 and F8) were constructed using a Gly4/Ser linker. The neutralization 
IC50 of these constructions was reduced from a 2 fold – 180 fold, compared with the monovalent protein, indicating 
the previously seen enhancement of the neutralization. Nevertheless, the best results were obtained when biparatopic 
molecules were used. The E6/H7 and the H7/F8 molecules increase the neutralization potency by a 2 log factor, 
while the E8/H7 reach an increase of 3 log fold, compared with the monovalents. The E8/H7 even outperformed the 
Mab 8 -2 against the CVS-11. On the contrary, in the case of the genotype 5 strain EBLV-1, the monovalent molecules 
showed no or modest neutralization potency. But confirming the tendency shown above, the biparatopic molecule 
E8/C12 presented an increase in the neutralization potential of 147 fold (IC50 = 3.76 nM) compared with the 
monovalent moiety, but not as low as Mab 8 – 2 (IC50 = 0.12 nM). The results of competition assays of the 5 VHHs 
against the Mab 8- 2 shown that the E6, E8, F8 and H7 compete for the same epitope. On the other hand, the C12 did 
not compete with the Mab 8-2, which indicates the recognition of a different epitope. The difference in epitope 
recognition can be one of the causes of the high and broad effect of biparatopic molecules, specially the E8/C12, 
which recognize different epitopes in the RVG. Experiments using those VHHs with Rabies mutant virus, carrying 
substitutions in the known residues in the antigenic site II, could define the exact place of binding of these new 
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antibodies. For example it is reported that the substitution K198E of the glycoprotein abolish the binding of the Mab 8 
– 2 (Montano-Hirose et al., 1993). Unfortunately, the crystallographic structure of the RVG protein has not been 
reported. For modelling of the RVG structure, the vesicular stomatitis virus glycoprotein is often using as template 
and surrogate (Cibulski et al., 2009; Tomar et al., 2010). We are using the alignment of this protein with the RVG as 
reference, to show the possible structure representation of the antigenic site II (Fig. 4). The purpose of this estimate is 
to show the tendency of the VHHs to recognize conformational epitopes, over linear epitopes. In line with the results 
of the neutralizing VHHs against Influenza and RSV, the results of the broadness and the high potency against both 
RV genotypes indicate these RV neutralizing VHHs as a promising tool. Nevertheless, in contrast with the previous 
cases of the Influenza and RSV VHHs, there is not in vivo validation of the RV neutralizing VHHs available. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Schematic representation of the trimeric vesicular stomatitis vescicular virus protein G trimer. This protein 
is taken as reference to depict the amino acids corresponding with the antigenic site II of the Rabies Virus 
glycoprotein (residues 34-42, and 198-200, in blue). The localization of the K198E mutation that prevents the binding 
of the Mab 8-2 is shown in red. The VHHs E8, F8, E6 and H7 compete with the MAb 8- 2 for the binding, mapping 
their possible epitope within the antigenic site II. (PDB: 2CMZ) 
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5. Conclusion  
 
The Nb platform as an antiviral agent is a new and promising antiviral tool. The ease to produce Nbs in bacterial and 
lower eukaryotic cells and the possibility to produce tailor made construction makes them an attractive and cost 
effective alternatives compared to established antiviral means. This approach may be useful for the treatment of 
infectious orphan diseases (including viral) and in developing countries, where the “standard” prophylaxis or 
therapy is prohibitively expensive or not available. In this work we discussed the data of recently developed 
Nanobodies directed against 3 human viruses:  the generation and in vitro validation of the VHHs against Influenza 
H5N1, RSV and RV (Hultberg et al., 2011); the in vivo validation of the Influenza HA binding VHH (Ibanez et al., 
2011) and RSV (Schepens et al., 2011). In the case of protection against Influenza infection the bivalent format of the 
Nbs proved superior in vitro and in vivo.  But, as indicated by the successful in vivo validation of one of the H5N1 
strains, it is imperative to extend this validation to the others Influenza strains. Furthermore, it would be very 
interesting to isolate and characterize Nbs that recognize conserved domains in HA, such as the stalk. In line with the 
Influenza results, the RSV and RVG neutralizing Nbs activity was significantly higher in the bivalent compared to the 
monovalent format, increasing both the cross neutralization activity and potency. Those results manifest the 
advantages of using a multimeric format against multimeric viral targets. As stated before, the increase in avidity and 
the intra or inter molecular binding can be part of the explanation of the enhancement in the antiviral potential. 
Experiments to assess this could lead to a better design of multivalent antiviral antibodies. The surprising results 
confirm two important points: the high potential of the Nbs as prophylactic and therapeutic tools, and the 
development of Nbs directed against other infectious diseases. The similarity among the three proteins used as 
antigens (HA, RSVF and RVG) besides their trimeric architecture and antigenicity, is limited. The functionally similar 
HA and the RVG proteins are involved in the cellular receptor binding, whereas RSVF participates in virion binding 
to the receptor, it s main function is in membrane fusion. In all three cases Nbs with the capacity to neutralize the 
viral target by blocking binding or hampering necessary conformational changes indicates the great versatility and 
efficiency of the antiviral Nbs here discussed.  In competition assays, the recognition of non – conventional epitopes 
by these antiviral Nbs was not observed, but could be focused on in the future. In the three cases, the Nbs recognized 
well known antigenic sites that are also targeted by Mabs. The described viral proteins are not enzymes, and lack 
extensive antigenic clefts. This could be one reason why recognition of the Nbs of “classical” epitopes in the viral 
proteins appeared to be preferred. If the presence of antigenic clefts could lead to recognition of none “classical” 
epitopes in the viral proteins, targeting viral enzymes could be an interesting approach. Enzymes like the Influenza 
Neuraminidase could be an interesting target. This viral sialidase presents a catalytic cleft, in which framework and 
substrate contact residues are conserved in most of the Influenza strains. The coming years will probably bring 
potent novel anti-viral Nbs directed against different viruses and it is likely that some of these Nbs will reach clinical 
trials.  
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This corrigendum should be considered as a replacement for paragraph “N1-5-VHHm 
ESCAPE MUTANTS” on pages 132-134 and Figure 23 in said PhD thesis. This Figure 23 
and the accompanying text were based on preliminary data and, in hindsight, ambiguous 
sequence data. The text and corrected figure shown below, are based on additional 
experiments and sequencing results, performed after the PhD thesis was submitted and 
successfully defended. These additional data and the resulting figure, have been published: 
“Single domain antibodies targeting neuraminidase protect against an H5N1 influenza
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On pages 132 – 134, the text regarding N1-5-VHHm escape mutants and Fig.23 should be 
as following: 
N1-5-VHHm escape mutants 
To identify the amino acid residues involved in the binding of N1-3HHm and N1-5-VHHm to 
H5N1 NA, escape viruses were selected and plaque purified after serial passage of NIBRG-
14 ma virus in MDCK cells, in the presence of 10 IC50 of N1-3-VHHm or N1-5-VHHm, 
essentially as described before (1). After nine passages, candidate escape mutants were 
plaque purified and the NA sequences of four (N1-5-VHHm selection) and three (N1-3-
VHHm selection) isolated escape viruses were determined. One of the escape viruses that 
was selected with N1-5-VHHm contained a mutation in the NA coding region that resulted in 
a change from isoleucine to threonine at position 437 in the deduced amino acid sequence 
(Fig 8C). This substitution is located on the NA surface, relatively close to the active site (Fig. 
8A). A conserved NA epitope that is recognized by HCA-2 under denaturing conditions (2, 3) 
and localized within the NA catalytic site, and the amino acids necessary for binding a 
recently reported set of mAbs that recognize H1N1 and H5N1 NA (4) do not overlap with this 
N1-5-VHHm escape mutations (Fig. 8A). Sequence alignment of a set of representative N1 
influenza A viruses, including human H1N1, other H5N1 viruses and an avian H6N1 virus 
showed that I437 is conserved in these NA sequences (Fig. 8B).  


Figure 8. Epitope mapping of N1-5-VHHm escape mutants in NIBRG-14 ma NA. MDCK cells 
were infected with NIBRG-14 ma in the presence of 3.7 µM N1-5-VHHm. Evidence for 
resistant viruses was based on cytopathic effect in infected cell culture and was followed by 
plaque purification of candidate escape viruses. The NA coding sequence of the resultant 
escape viruses was amplified by RT-PCR and sequenced. One selected escape virus carried 
an Ile to Thr change at position 437. The deduced amino acid sequence in NA was modeled 
with with PyMol (Delano Scientific, http://www.pymol.org) using the H5N1 NA structure 
derived from A/Vietnam/1194/2004 (PDB code 2HTY). A. Top (left) and later view (right) of 


surface exposed amino acid residues of the NA dimer. The I437T amino acid substitution of 
the NA of N1-5-VHHm escape mutant is surface exposed and marked in yellow. Residues 
that form the catalytic site framework are depicted in red. The N1 “150 loop” is shown in 
green. For comparison, residues involved in mAb HCA-2 binding are shown in dark blue 
(residues 222–230) and those in mAb 3H10 binding in orange (N272, V339 and T340). B. 
Sequence alignment of relevant N1 NAs. The I437T change in one of the N1-5-VHHm 
escape viruses is highlighted in yellow. The residues highlighted in red are important for mAb 
3H10 binding. C. Fluorogram showing the T to C substitution in the cloned cDNA of the N1-5-
VHHm escape virus. 
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